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Introduction 
Congenital heart defects 
Birth defects are fairly common with an overall reported prevalence of 3-5% of all live births 
(1). Congenital heart defects (CHD) account for approximately one third of all birth defects, 
with a reported prevalence in Europe of 7.2 per 1000 births (2). Advances in prenatal detection 
and early treatment of CHD have increased survival of these children. However, surgical 
intervention in patients with CHD is needed within the first year of life in 58% or in the first 
three years of life in 67% (3). 
Congenital cardiac surgery and influence of cardiopulmonary bypass and cell saver system 
on routinely used drugs 
Cardiopulmonary bypass 
Congenital cardiac surgery is often performed with use of the cardiopulmonary bypass (CPB). 
The CPB is connected to the patient during surgery to replace the function of the heart and 
lungs during surgery. The venous cannulas of the CPB is generally inserted in either the upper 
and lower caval vein, of the right atrium. The arterial canula is inserted in the ascending aorta. 
The blood from the patient is collected via the venous drainage line into the venous reservoir. 
The blood is transported by a pump through an, oxygenator and filter. The CPB has a 
continuous flow of blood from the patient, to the CPB and back to the patient. Different sizes 
of CPB systems are available, depending on the weight of the patient. Figure 1 givens a 
schematic interpretation of the blood flow in an adult CPB system.  
Use of the CPB may have a profound effect on distribution and effects of drugs in the patient, 
therefore altering the pharmacokinetic (PK) parameters of drugs (4). There are several reasons 
for altered drug PK when using the CPB. First, there are hemodynamic changes due to change 
from pulsatile to non-pulsatile flow. This affects organ perfusion, and therefore organ 
function, with subsequent effects on organ drug metabolism. Second, at onset of the CPB, 
addition of CPB prime fluid to the patients’ blood volume causes hemodilution. 
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Figure 1: schematic overview of blood flow in a CPB system.  
Especially in neonates, the total circulating volume may be doubled at onset of CPB. The 
impact of this effect is determined by drug properties in terms of protein binding, lipophilicity 
and volume of distribution. Blood pressure and blood flow rate are decreased during CPB, 
leading to decreased renal and hepatic perfusion and decreased clearance (Cl) of drugs from 
the patient. Hypothermia during surgery also decreases drug elimination, due to temperature 
dependence of metabolic enzyme function (5, 6). The use of CPB also stimulates a systemic 
inflammatory response by both the complex humoral and cellular reactions, leading to the 
“systemic inflammatory response syndrome” (SIRS). SIRS can vary from very mild to severe, 
mainly depending on duration of CPB (7). Finally, sequestration of drugs in the CPB system 
occurs, with mainly lipophilic drugs adhering to the tubing and oxygenator (8, 9). Also, the 
type of surgery may influence the PK of drugs, since this correlates with CPB run time, 
hemodynamic instability and SIRS. All summarized potential alterations in drug PK during 
cardiac surgery are investigated in adults. Almost no literature is available for routinely used 
drugs and CPB systems in neonates and children (4). This could lead to suboptimal treatment 
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inflammatory response by both the complex humoral and cellular reactions, leading to the 
“systemic inflammatory response syndrome” (SIRS). SIRS can vary from very mild to severe, 
mainly depending on duration of CPB (7). Finally, sequestration of drugs in the CPB system 
occurs, with mainly lipophilic drugs adhering to the tubing and oxygenator (8, 9). Also, the 
type of surgery may influence the PK of drugs, since this correlates with CPB run time, 
hemodynamic instability and SIRS. All summarized potential alterations in drug PK during 
cardiac surgery are investigated in adults. Almost no literature is available for routinely used 
drugs and CPB systems in neonates and children (4). This could lead to suboptimal treatment 
of children undergoing cardiac surgery with use of CPB. Influence of CPB on drug PK may be 
more profound in neonates and children, since they have a lower bodyweight and circulating 
volume and are thus more vulnerable to the above described changes. To gain more insight 
on potential drug alterations, we aimed to investigate the influence of CPB on PK of routinely 
used drugs in neonates and children, aged 0-18, undergoing cardiac surgery. Since alteration 
on PK parameters are both patient and CPB dependent we also investigated different types of 
CPB systems in vitro. These in vitro studies ought to eliminate the variability within the 
patients and give more specific insight in the CPB systems used at least in our clinic and serve 
as a model for other institutions.  
Cell saver 
Allogenic donor blood is used in a majority of pediatric patients undergoing cardiac surgery 
with use of the CPB. Prime fluid in the CPB consists in part of donor blood to minimize the 
extent of hemodilution at onset of CPB. However, the use of allogenic donor blood increases 
the risk of postoperative morbidity, mainly infections (10). In order to minimize the need for 
allogenic donor blood during the operation an auto-transfusion devise is used, commonly 
known as a cell saver. The cell saver system collects blood from the operation site in a 
reservoir, after which it is processed, passed through a lipophilic filter and returned to the 
patient. Influence of the cell saver on removal of drugs per-operatively or on re-dosing drugs 
through the autotransfused blood is not known. However, this is of interest since cell saver 
blood is often returned to the patient on the Pediatric Intensive Care Unit (PICU). A clinically 
relevant drug dose of strong opioids or sedatives may lead to complications in this different 
setting. Also, gaining knowledge on influence of volume of distribution (Vd) and Cl of drugs by 
the cell saver adds to the sparse PK data that is available on routinely used drugs during 
pediatric cardiac surgery. To investigate the loss of drugs peri-operatively and the potential 
return of a clinically relevant drug dose postoperatively, we measured several commonly used 
drugs in various stages of the cell saver procedure.  
Antibiotic prophylaxis in adult cardiac surgery 
In the Netherlands all patients, adults and children, undergoing cardiac surgery receive 
antibiotic prophylaxis with cefazolin, a first-generation cephalosporin. Administration of 
cefazolin should prevent the development of postoperative deep sternal wound infections 
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(DSWI). DSWI have an incidence of approximately 2-3% and can lead to increased 
postoperative morbidity, such as prolonged hospital stay, subsequent reoperation and 
mortality (11). In adults, a national guideline from the Dutch Antibiotic Taskforce (Stichting 
Werkgroep Antibiotica Beleid, SWAB) is in place, advising on the optimal dosing and timing of 
cefazolin (12). Evidence for this guideline is limited, however this seems compensated by the 
liberal dosing regimen ensuring a cefazolin concentration above the Minimal Inhibitory 
Concentration (MIC). Upon reviewing the guideline in 2018, the recommended cefazolin dose 
is drastically decreased, for both peri-operative and postoperative administration. This new 
regimen is backed-up by evidence from non-cardiac surgery (13). Due to differences in PK 
parameters in patients undergoing cardiac surgery compared to non-cardiac surgery these 
new dosing recommendations may not obtain cefazolin concentrations above the MIC. We 
argue that more evidence should be available to ensure adequate cefazolin prophylaxis in 
adult cardiac surgery to optimally prevent the occurrence of DSWI. To investigate the new 
Dutch dosing guideline, cefazolin concentration during and after surgery was measured in 40 
adult patients.  
Pain treatment in children after cardiac surgery 
Current guidelines 
After the landmark paper by Anand and Aynsley-Green, adequate pain treatment in neonates 
and infants became an important focus in postoperative care using the concept of pre-
emptive analgesia (14). In the average PICU population, postoperative pain has a mixed 
etiology, with different treatment approaches. Worldwide, opioids are the drug of first choice 
for pain treatment after cardiac surgery. Since the publication by Lynn et al., determining the 
adequate opioid dose after cardiac surgery based on respiratory adverse effects, limited 
research has been done to improve analgesic use in children after cardiac surgery (15). PK 
parameters of analgesic drugs are often not reported in studies, even though this is expected 
to be different in these children after cardiac surgery. A recent publication concluded that in 
children after cardiac surgery the Vd is increased and Cl decreased (16, 17). Perhaps due to 
this scarcity of data, specific international and national guidelines on optimal pain treatment 
in children after cardiac surgery are lacking. This is also reflected by the guideline from the 
Association of Pediatric Anaesthesists of Great Britain and Ireland published in 2012, that 
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adult patients.  
Pain treatment in children after cardiac surgery 
Current guidelines 
After the landmark paper by Anand and Aynsley-Green, adequate pain treatment in neonates 
and infants became an important focus in postoperative care using the concept of pre-
emptive analgesia (14). In the average PICU population, postoperative pain has a mixed 
etiology, with different treatment approaches. Worldwide, opioids are the drug of first choice 
for pain treatment after cardiac surgery. Since the publication by Lynn et al., determining the 
adequate opioid dose after cardiac surgery based on respiratory adverse effects, limited 
research has been done to improve analgesic use in children after cardiac surgery (15). PK 
parameters of analgesic drugs are often not reported in studies, even though this is expected 
to be different in these children after cardiac surgery. A recent publication concluded that in 
children after cardiac surgery the Vd is increased and Cl decreased (16, 17). Perhaps due to 
this scarcity of data, specific international and national guidelines on optimal pain treatment 
in children after cardiac surgery are lacking. This is also reflected by the guideline from the 
Association of Pediatric Anaesthesists of Great Britain and Ireland published in 2012, that 
recommends opioids, but does not provide dosing or PK specific information (18). To assess 
the clinical effect of the pain treatment, pharmacodynamic (PD) endpoints need to be 
considered. Several validated PD assessment tools are available for use in children, such as 
the COMFORT-Behavioral (COMFORT-B scale) score (19, 20), the Numeric Rating Scale (NRS), 
or the Nurses Interpretation of Sedation Scale (NISS). PD scores that take vital parameters, 
such as heart rate, into account cannot be used in children after cardiac surgery, because of 
the inevitable need for inotropes directly postoperative. Presumably the lack of uniform 
guidelines could results in a large variability in analgesic regimen per hospital. We aimed to 
clarify differences in local practice and preferences on use of analgesics and PD assessment 
tools by means of an international survey.  
Morphine 
Morphine is the opioid of first choice for pain treatment in children after cardiac surgery. 
Morphine elimination is mainly through glucuronidation by urine diphosphate 
glucuronosyltransferase (UGT) 2B7. Both morphine metabolites, morphine-3-glucuronide 
(M3G) and morphine-6-glucuronide (M6G) are cleared through renal elimination. Decreased 
renal function could lead to accumulation of these active metabolites, and subsequent 
clinically important effects. Renal function is often decreased during and after cardiac surgery, 
and also the use of inotropes implies an impaired cardiovascular function. Also, morphine 
clearance has been shown to be significantly slower in children who need inotropic support 
after cardiac surgery (21).  
A major concern about the use of morphine in neonates and infants are the potential negative 
effects of morphine on neurological development (22). In animal models and human fetal cells 
these negative neurological effects seem to be dose and duration dependent (23). 
Fortunately, but not necessarily reassuring, in our own institution follow-up studies in children 
who were born preterm and received morphine after birth, showed no negative long term 
effects (24, 25). A very small sample of the NEOPAIN study suggested that prematurity, opioid 
exposure and neonatal pain was significantly associated with brain volume, but not with major 
impairment in neuropsychological functioning (26). Other adverse drug reactions of morphine 
include hypotension and respiratory depression, which is a particular problem in 
hemodynamically unstable children after cardiac surgery (27). Recently several advances have 
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been made to reduce the morphine consumption in children. Population PK based studies of 
morphine dosing in neonates, infants and children have resulted in a dose reduction in 
children after non-cardiac surgery (28, 29). Replacement of morphine by a non-opioid 
analgesic after cardiac surgery could result in equally optimal analgesic effect and reduce 
adverse effects.  
Paracetamol 
The most preferable non-opioid analgesic to replace morphine is paracetamol, since NSAIDs 
are not used in children after cardiac surgery due to increased risk of bleeding and impaired 
renal function. Paracetamol is the world most frequent used analgesic, with additional 
antipyretic and weak anti-inflammatory effects. The working mechanism is not yet fully 
understood, but it is likely due to inhibition of prostaglandin synthesis in the central nervous 
system and in peripheral tissue, and interaction with the serotonergic system (30, 31). 
Paracetamol metabolism and PK has been described for children including newborns (32, 33). 
Paracetamol is metabolized by glucuronidation (50-60%), sulfation (25-44%), that both form 
inactive metabolites excreted by the kidney, and oxidation (2-10%). N-acetyl-p-benzo-quinone 
imine (NAPQI) is one of the end products of the oxidation pathway. NAPQI is toxic and 
interference in the conjugation of NAPQI could lead to an overdose causing mitochondrial 
dysfunction and centrilobular necrosis in the liver (34). However, when used in therapeutic 
doses in children without liver dysfunction, the safety profile of paracetamol is excellent (32).  
The study by van der Marel et al. showed that rectal paracetamol does not reduce morphine 
consumption in young infants after major non-cardiac surgery (35). One of the main problems 
with rectal administration is the inadequate plasma concentration of paracetamol in 50% of 
patients. When comparing intravenous (IV) paracetamol to morphine as primary analgesic 
after major non-cardiac surgery in children aged 0-1 year, IV paracetamol proved to be 
equipotent to morphine (36). Also in the implementation of this regimen in another 100 
patients this was proven, rendering IV paracetamol as the drug of first choice (37). Decreasing 
the postoperative morphine consumption resulted in less morphine related adverse effect. 
This may be especially preferable in children after cardiac surgery, who can be 
hemodynamically unstable and may be more prone to morphine related adverse effects. We 
investigated the equipotency of IV paracetamol and morphine in children after cardiac 
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consumption in young infants after major non-cardiac surgery (35). One of the main problems 
with rectal administration is the inadequate plasma concentration of paracetamol in 50% of 
patients. When comparing intravenous (IV) paracetamol to morphine as primary analgesic 
after major non-cardiac surgery in children aged 0-1 year, IV paracetamol proved to be 
equipotent to morphine (36). Also in the implementation of this regimen in another 100 
patients this was proven, rendering IV paracetamol as the drug of first choice (37). Decreasing 
the postoperative morphine consumption resulted in less morphine related adverse effect. 
This may be especially preferable in children after cardiac surgery, who can be 
hemodynamically unstable and may be more prone to morphine related adverse effects. We 
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randomized controlled trial are reported to offer advice to others who would want to engage 
in such an endeavor.  
 
Aims and outline of this thesis 
The aims of this thesis are: 
- To study the influence of the CPB and the cell saver system on routinely used drugs in 
neonates and children undergoing cardiac surgery. 
- To study the evidence for dose adjustments in cefazolin prophylaxis in adults 
undergoing cardiac surgery with the use of CPB. 
- To study the use of IV paracetamol as primary analgesic after cardiac surgery in 
neonates and children aged 0-3 years, aimed to reduce postoperative morphine 
consumption.  
Chapter 2 gives an introduction into treatment regimens and pharmacokinetic considerations 
for patients receiving analgesia in the PICU. Chapter 3 describes the potential influence of the 
cell saver system on drug concentration in auto-transfused blood. In vitro CPB systems spiked 
with routinely used drugs are studied in Chapter 4 and Chapter 5 to further understand the 
influence of the CPB system on Vd and drug absorption. Chapter 6 describes cefazolin time 
and concentration above the MIC before and after implementation of a new peri-operative 
protocol for cefazolin prophylaxis. An international survey on postoperative analgesia is 
reported in Chapter 7. Chapter 8 describes the study protocol investigating morphine versus 
IV paracetamol as primary analgesic after cardiac surgery in children aged 0-3 years (PACS 
study). The challenges concerning the design and implementation of the PACS study are 
discussed in Chapter 9.  
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Abstract  
Introduction 
Adequate postoperative analgesia in pediatric patients in the intensive care unit (ICU) matters, 
since untreated pain is associated with negative outcomes. Compared to routine 
postoperative patients, children undergoing hypothermia (HT) or extracorporeal membrane 
oxygenation (ECMO), or recovering after cardiac surgery likely display non-maturational 
differences in pharmacokinetics (PK) and pharmacodynamics (PD). These differences warrant 
additional dosing recommendations to optimize pain treatment.  
Areas covered 
Specific populations within the ICU will be discussed with respect to expected variations in PK 
and PD for various analgesics. We hereby move beyond maturational changes and focus on 
why PK/PD may be different in children undergoing HT, ECMO or cardiac surgery. We provide 
a stepwise manner to develop PK-based dosing regimens using population PK approaches in 
these populations.  
Expert opinion 
A one-dose to size-fits-all for analgesia is suboptimal, but for several commonly used 
analgesics the impact of HT, ECMO or cardiac surgery on average PK parameters in children is 
not yet sufficiently known. Parameters considering both maturational and non-maturational 
covariates are important to develop population PK-based dosing advices as part of a strategy 
to optimizing pain treatment.  
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Abstract  
Introduction 
Adequate postoperative analgesia in pediatric patients in the intensive care unit (ICU) matters, 
since untreated pain is associated with negative outcomes. Compared to routine 
postoperative patients, children undergoing hypothermia (HT) or extracorporeal membrane 
oxygenation (ECMO), or recovering after cardiac surgery likely display non-maturational 
differences in pharmacokinetics (PK) and pharmacodynamics (PD). These differences warrant 
additional dosing recommendations to optimize pain treatment.  
Areas covered 
Specific populations within the ICU will be discussed with respect to expected variations in PK 
and PD for various analgesics. We hereby move beyond maturational changes and focus on 
why PK/PD may be different in children undergoing HT, ECMO or cardiac surgery. We provide 
a stepwise manner to develop PK-based dosing regimens using population PK approaches in 
these populations.  
Expert opinion 
A one-dose to size-fits-all for analgesia is suboptimal, but for several commonly used 
analgesics the impact of HT, ECMO or cardiac surgery on average PK parameters in children is 
not yet sufficiently known. Parameters considering both maturational and non-maturational 
covariates are important to develop population PK-based dosing advices as part of a strategy 
to optimizing pain treatment.  
  
Introduction 
The importance of postoperative pain relief in neonates and infants became apparent after 
the landmark publication by Anand and Aynsley-Green (1). While untreated pain results in 
prolonged Pediatric Intensive Care Unit (ICU) stay and increases the children’s stress 
responses (2, 3), overtreatment may result in prolonged artificial ventilation. Repetitive 
painful stimuli may induce hypersensitivity to pain and negative behavioral consequences in 
later life; longitudinal data on this issue in humans are limited (4-7). 
 The World Health Organization (WHO) has published guidelines on the pharmacological 
treatment of pain in children (2012) (8, 9). These general guidelines are also often applied to 
children admitted to specialized PICUs. Currently, approximately 50% of the current patient 
case mix in many PICUs concerns postoperative patients of various surgical specialties, 
including those admitted for surveillance of vital functions and/or undergoing hypothermia. 
Postoperative pain is hereby defined as pain within the first 48 hours after surgery. Standard 
systemic pharmacotherapy for mild postoperative pain consists of acetaminophen 
(paracetamol) and non-steroidal anti-inflammatory drugs (NSAIDS). For moderate and severe 
pain, opioids are recommended as part of multimodal analgesia (10-12). Although these WHO 
guidelines provide a framework with specific emphasis on the two-stage, multimodal 
approach (non-opioids to opioids) and on dosing suggestions for different analgesics, they still 
fail to catch the full spectrum of variability and heterogeneity, sticking to the concept of a one-
dose to size or age-fits-all for analgesia (8, 9). Particularly, children undergoing hypothermia 
(HT); extracorporeal membrane oxygenation (ECMO) or after cardiac surgery) may benefit 
from fine tuning that takes into account the pharmacokinetics (PK), pharmacodynamics (PD), 
but also pharmacogenetics (PG) and disease characteristics (SIRS,HT, ECMO or cardiac surgery 
or renal impairment) to reach an optimal dosing regimen for postoperative pain relief. PK 
parameters such as volume of distribution (Vd) and clearance (CL) are expected to differ in 
maturational (e.g. size, weight, age) and non-maturational (HT, ECMO, cardiac surgery, 
disease severity, including renal impairment) variables. Validated PD assessment tools have 
been developed to assess the clinical effects of pain treatment (13, 14), but incorporating the 
endpoints in a dosing model remains challenging, while the assessment results may also be 
affected by the disease characteristics. While knowledge on PG is available for several genetic 
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polymorphisms involved in drug PK or PD, it is not yet routinely applied in clinical practice (15, 
16). 
Critically ill pediatric patients tend to display a large variability in PK and PD compared to the 
average pediatric ICU population or compared to patients after less extensive surgery. To 
illustrate this, due to mechanisms underlying cold-induced pain, the pain expression of 
children undergoing HT setting differs from that in children not exposed to HT (different cry, 
facial response, no shivering, no muscles tremor and decreased muscle contractions ) (17, 18). 
Several studies have recently been undertaken to provide insight in the changes in PK in these 
specific patients groups (19, 20). Similarly, ECMO or cardiac surgery likely affects the PK (larger 
Vd, decreased CL) of several analgesics.  
In this review, we aim to integrate both maturational (e.g. size, weight, age) and non-
maturational characteristics that affect intra- and inter-patient variability in PK/PD, and to 
identify patient groups that are expected to differ in PK and PD compared to the general 
pediatric ICU population. We will first describe the general aspects of PK, focusing on drug 
absorption, distribution, metabolism and excretion (ADME) and PD of analgesics in neonates, 
infants and children (21). We will then focus on the earlier mentioned non-maturational 
characteristics and the expected variation in PK and PD. The magnitudes and effects of specific 
patient and disease characteristics on PK and PD parameters are described. However, a 
direction or magnitude of effect cannot always be given, since the direction may go both ways 
depending on covariates. Also the magnitude may vary depending on the patient and clinical 
circumstances.. Subsequently we explore the consequences of these variations, working 
towards a PK and PD based dosing recommendation for these specific patients. In the expert 
opinion section, we focus on tools for future research to close the current knowledge gap, 
including suggestions to integrate this knowledge in population PK/PD modelling.  
Maturational and non-maturational related changes  
Pharmacokinetics 
In clinical pharmacology, drug-related effects are predicted from compound- and population-
specific PK and PD. The general PK principles of drugs hereby apply, irrespective of population-
specific characteristics. The absorption, distribution, metabolism and elimination (ADME) of 
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polymorphisms involved in drug PK or PD, it is not yet routinely applied in clinical practice (15, 
16). 
Critically ill pediatric patients tend to display a large variability in PK and PD compared to the 
average pediatric ICU population or compared to patients after less extensive surgery. To 
illustrate this, due to mechanisms underlying cold-induced pain, the pain expression of 
children undergoing HT setting differs from that in children not exposed to HT (different cry, 
facial response, no shivering, no muscles tremor and decreased muscle contractions ) (17, 18). 
Several studies have recently been undertaken to provide insight in the changes in PK in these 
specific patients groups (19, 20). Similarly, ECMO or cardiac surgery likely affects the PK (larger 
Vd, decreased CL) of several analgesics.  
In this review, we aim to integrate both maturational (e.g. size, weight, age) and non-
maturational characteristics that affect intra- and inter-patient variability in PK/PD, and to 
identify patient groups that are expected to differ in PK and PD compared to the general 
pediatric ICU population. We will first describe the general aspects of PK, focusing on drug 
absorption, distribution, metabolism and excretion (ADME) and PD of analgesics in neonates, 
infants and children (21). We will then focus on the earlier mentioned non-maturational 
characteristics and the expected variation in PK and PD. The magnitudes and effects of specific 
patient and disease characteristics on PK and PD parameters are described. However, a 
direction or magnitude of effect cannot always be given, since the direction may go both ways 
depending on covariates. Also the magnitude may vary depending on the patient and clinical 
circumstances.. Subsequently we explore the consequences of these variations, working 
towards a PK and PD based dosing recommendation for these specific patients. In the expert 
opinion section, we focus on tools for future research to close the current knowledge gap, 
including suggestions to integrate this knowledge in population PK/PD modelling.  
Maturational and non-maturational related changes  
Pharmacokinetics 
In clinical pharmacology, drug-related effects are predicted from compound- and population-
specific PK and PD. The general PK principles of drugs hereby apply, irrespective of population-
specific characteristics. The absorption, distribution, metabolism and elimination (ADME) of 
analgesic drugs in neonates, young infants and children are illustrated in Table 1. Absorption 
is described by the absorption rate constant (Ka), the time to reach the maximum (peak) 
plasma concentration (Tmax) and drug bioavailability (F). F is the fraction of an administered 
dose of unchanged drug that reaches the systemic circulation and is typically 100% upon 
intravenous administration (22). Absorption can be affected by maturational and non-
maturational changes (Table 1). Distribution is represented by the Vd of a central 
compartment and in some cases by the Vd of one or more peripheral compartments that are 
in equilibrium with the central compartment. For example, a peripheral compartment that is 
used as PK sample site for the central nervous system is the cerebrospinal fluid (CSF), which is 
in close equilibrium with the neurons in the brain, where the effect of opioids are expected to 
occur (23). More lipophilic opioids will diffuse faster across the blood-brain barrier – with 
faster onset of analgesia (24). Also, distribution can be affected by maturational and non-
maturational changes (Table 1).  
Table 1: General aspects of ADME of analgesic drugs on PK in neonates, young infants and 
children  
PK covariates Absorption Distribution Elimination 
(Metabolism/Excretion) 
Maturation ↑ or ↓ Variable or ↓↑ Variable or ↓↑ 
Asphyxia ↓or variable Variable NS or ↓↑ Variable or ↓↑ 
Sepsis (SIRS) No data Variable or ↓↑ Variable or↓↑ 
Hypothermia Decreased ↓ Decreased↓ Decreased↓ 
ECMO No data Increased↑ Decreased↓ 
Abbreviation: NS, not significant. Updated and used with permission from P. Pokorna, 2015 
(59). 
 
Metabolic or primary renal elimination is commonly expressed as clearance (CL), while the 
elimination half-life (t1/2) represents the time it takes to reduce by half the drug concentration. 
By definition, in a one-compartment model, the elimination half-life is influenced by both Vd 
and CL, since CL = k.Vd with t1/2=0.693/k, with k = elimination rate constant) (25). 
Chapter 2
26
Simple extrapolation of PK or PD estimates from adults to pediatric patients is obsolete. Both 
PK and PD processes change with a child’s growth and development, but these factors are 
collinear. Growth relates to the increases in weight, length and size with proportional or 
disproportional changes in body proportions, body composition and organ weights, and 
associated changes in activity or function (e.g. barrier functions, renal clearance, or hepatic 
drug metabolism) as reflected in the maturational changes in the ADME patterns. This is 
predominantly observed in infancy, and most notably in prematurely born children (26). Thus, 
within the pediatric-age range the inter-individual variability in PK and PD for almost all drugs 
is higher than that in adults (27, 28). Age, not weight, is key in the ontogeny of hepatic and 
intestinal drug transporters, with increases or decreases of specific transporters depending on 
age (29). These transporters are important to both drug absorption and elimination of drugs. 
Even when we only focus on PK, variability between and within a specific population occurs 
up to the level of clinical relevance, as ignoring the variability may result in concentrations 
below or above the therapeutic range. This variability is explored with the use of covariates, 
subdivided in maturational (size, weight, age) and non-maturational characteristics (disease 
and/or treatment dependent), together with pharmacogenetic (PG) characteristics (Figure 1). 
For these ADME related processes, maturational covariates have been reported, as 
summarized below. 
Absorption: Following oral administration, absorption displays extensive maturation because 
of gastro-enteral maturation (e.g. anatomy, motility, drug metabolism or transporters). Also 
non-enteral routes (e.g. cutaneous, muscular size, inhalation and circulation) display age-
related changes. Distribution: Although a ‘theoretical volume’, distribution volume depends 
on physical (e.g. extra- and intracellular water, lipophilic or water soluble compound, 
ionization and protein binding) and physiologic (protein binding, tissue uptake, permeation to 
deep compartments) processes. Consequently, the distribution volume is also driven by 
maturational changes and disease characteristics.  
Metabolism: The drug metabolizing maturational activity of the different iso-enzymes is 
enzyme specific and determined by age (postnatal age, postmenstrual age) or size. The 
expression and activity of cytochrome p450 (CYP) iso-enzymes – proteins that catalyze phase 
I metabolism of many drugs – change dramatically from fetal life through adolescence. At 
birth, the overall CYP content and activity is 30-60% of adult activity when expressed per gram 
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Simple extrapolation of PK or PD estimates from adults to pediatric patients is obsolete. Both 
PK and PD processes change with a child’s growth and development, but these factors are 
collinear. Growth relates to the increases in weight, length and size with proportional or 
disproportional changes in body proportions, body composition and organ weights, and 
associated changes in activity or function (e.g. barrier functions, renal clearance, or hepatic 
drug metabolism) as reflected in the maturational changes in the ADME patterns. This is 
predominantly observed in infancy, and most notably in prematurely born children (26). Thus, 
within the pediatric-age range the inter-individual variability in PK and PD for almost all drugs 
is higher than that in adults (27, 28). Age, not weight, is key in the ontogeny of hepatic and 
intestinal drug transporters, with increases or decreases of specific transporters depending on 
age (29). These transporters are important to both drug absorption and elimination of drugs. 
Even when we only focus on PK, variability between and within a specific population occurs 
up to the level of clinical relevance, as ignoring the variability may result in concentrations 
below or above the therapeutic range. This variability is explored with the use of covariates, 
subdivided in maturational (size, weight, age) and non-maturational characteristics (disease 
and/or treatment dependent), together with pharmacogenetic (PG) characteristics (Figure 1). 
For these ADME related processes, maturational covariates have been reported, as 
summarized below. 
Absorption: Following oral administration, absorption displays extensive maturation because 
of gastro-enteral maturation (e.g. anatomy, motility, drug metabolism or transporters). Also 
non-enteral routes (e.g. cutaneous, muscular size, inhalation and circulation) display age-
related changes. Distribution: Although a ‘theoretical volume’, distribution volume depends 
on physical (e.g. extra- and intracellular water, lipophilic or water soluble compound, 
ionization and protein binding) and physiologic (protein binding, tissue uptake, permeation to 
deep compartments) processes. Consequently, the distribution volume is also driven by 
maturational changes and disease characteristics.  
Metabolism: The drug metabolizing maturational activity of the different iso-enzymes is 
enzyme specific and determined by age (postnatal age, postmenstrual age) or size. The 
expression and activity of cytochrome p450 (CYP) iso-enzymes – proteins that catalyze phase 
I metabolism of many drugs – change dramatically from fetal life through adolescence. At 
birth, the overall CYP content and activity is 30-60% of adult activity when expressed per gram 
of liver (30). With advancing age, CYP-related metabolism increases, but the different 
isoenzymes of the P450 family show different developmental patterns (30). In addition to 
phase I metabolism, phase II metabolic pathways such as glucuronidation and sulfation also 
display maturational changes.  
Excretion: the most relevant route is the renal route, both through glomerular filtration and 
renal tubular transport. These processes do not mature simultaneously and also relate to both 
postnatal age and weight. We refer the reader to some recent reviews on the maturational 
aspects of drug disposition throughout childhood s (26, 31, 32).  
Obviously, these maturational changes have an important impact on drug disposition of 
analgesics, resulting in changes in PK parameters, as illustrated for acetaminophen, but this 
exercise can also be performed for opioids. Changes in acetaminophen absorption (gastric 
emptying) and Vd (body composition) have been quantified across neonates and adults (33). 
In addition, CL increases with age and/or size (27, 28, 34). The complex influence of these 
maturational covariates has also been illustrated for acetaminophen: Wang et al. documented 
that acetaminophen CL changes nonlinearly with bodyweight (33). Interestingly, the authors 
provided dosing guidelines for the age range from preterm neonates to adolescents, resulting 
in similar exposure across these age range (33). These changes in the clearance reflect both 
maturational changes in hepatic metabolism and subsequent renal elimination (35). 
In addition to these maturational changes, non-maturational changes such as disease-
dependent (asphyxia, sepsis, renal impairment, systemic inflammatory response syndrome 
(SIRS)) (36, 37), and multiple organ dysfunction syndrome (MODS) or treatment modalities 
(HT, ECMO) (38) can further influence PK parameters, leading to additional variability between 
and within patients. (Table 1 and Figure 1). Acute kidney injury in critically ill neonates 
receiving ECMO warrants dosage adjustment or even avoidance of nephrotoxic drugs (39). At 
present, the numbers of evidence based observations and estimates on the impact of these 
covariates are limited. Moreover, the distinction between maturational and non-maturational 
covariates cannot always be made, as in the case of genetic polymorphisms or renal 
impairment.  
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Figure 1: concentrations-time profiles of individual patients (blue, purple, yellow) (a), 
concentration-time profile of population; including the variability (residual errors, intra- and 
inter-individual variability (b), individual profiles related to population concentration-time 
profile(c). 
 
Genetic polymorphisms cannot simply be considered non-maturation related changes. The 
impact of polymorphisms in e.g. cytochrome-P-450 (CYP) enzyme activity can change 
throughout the childhood age range(maturational), as has been documented for CYP2D6 or 
CYP2C19 (40). Therefore, PG should be considered a potential covariate in individualized pain 
management in children of different ages. At present, dosing in clinical practice is not based 
on the information on PG differences amongst children explaining inter-patient variability is 
not yet taken into account for dosing in clinical practice (15, 41). However, it has been 
reported that PG can have an impact on outcome – including serious adverse reactions due to 
drug toxicity – (42, 43). 
The frequency of genetic polymorphisms varies between racial and ethnic populations, with 
differences in allele functionality between European Caucasians, Asians and African-
Americans of all ages (16). Polymorphisms in neonates receiving tramadol in a postoperative 
setting have been extensively described for CYP2D6 and organic cation transporter1 (OCT1). 
Implementation of a CYP2D6 activity score showed that inter-individual variability in 
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Genetic polymorphisms cannot simply be considered non-maturation related changes. The 
impact of polymorphisms in e.g. cytochrome-P-450 (CYP) enzyme activity can change 
throughout the childhood age range(maturational), as has been documented for CYP2D6 or 
CYP2C19 (40). Therefore, PG should be considered a potential covariate in individualized pain 
management in children of different ages. At present, dosing in clinical practice is not based 
on the information on PG differences amongst children explaining inter-patient variability is 
not yet taken into account for dosing in clinical practice (15, 41). However, it has been 
reported that PG can have an impact on outcome – including serious adverse reactions due to 
drug toxicity – (42, 43). 
The frequency of genetic polymorphisms varies between racial and ethnic populations, with 
differences in allele functionality between European Caucasians, Asians and African-
Americans of all ages (16). Polymorphisms in neonates receiving tramadol in a postoperative 
setting have been extensively described for CYP2D6 and organic cation transporter1 (OCT1). 
Implementation of a CYP2D6 activity score showed that inter-individual variability in 
metabolism of tramadol to the tramadol metabolite CL could partly be explained by CYP2D6 
polymorphism (15, 41). Furthermore, polymorphism in OCT1 (reuptake transporter in the 
hepatocyte) has demonstrated that the ratio metabolite/tramadol is higher with <2 functional 
copies. Tramadol also illustrates the impact of maturational and non-maturational changes in 
renal elimination clearance. The plasma tramadol metabolite concentrations will not only 
depend on their formation, but also on its subsequent renal elimination. This means that 
metabolite accumulation is more likely to occur in early infancy (renal elimination matures 
slower than hepatic metabolism) or in the context of renal impairment (41). A similar pattern 
has been described for morphine during HT, with accumulation of morphine metabolites (44).  
Exploring the impact of covariates on the inter- and intra-individual variability in PK is relevant 
as these covariates can subsequently be used to develop PK-based dosing regimens for the 
subpopulations or even individual patients.  
Pharmacodynamics 
The clinical efficacy of any intervention should be established using validated PD endpoints 
(45). As with PK, there is a large inter and intra-variability in PD, with different PD endpoints 
being used, while a clear correlation between plasma concentration and for instance pain 
scores is often lacking (46).  
Although integrated PK/PD studies have been published, PK data are usually reported 
separately or without integration with validated PD endpoints. PKPD modeling incorporating 
PD endpoints in a model is difficult and currently PKPD modeling studies are scarce for 
children. Moreover, validated PD assessment tools are highly tailored to specific age groups 
and circumstances as reflected by a mission statement paper from the European Society for 
Pediatric and Neonatal Intensive Care (ESPNIC) (45). For instance, the COMFORT-B scale is a 
validated postoperative pain instrument for children 0-3 years, including pre-verbal neonates 
and infants. It detects meaningful effects of pain treatment, but cannot be used during 
muscular relaxation (13, 14). The same holds true for the Face, Legs, Activity, Cry and 
Consolability (FLACC) scale. Another scale, the CRIES, consists of the following items: Crying; 
Requires increased oxygen administration; Increased vital signs; Expression; Sleeplessness, 
and was specifically developed for postoperative infants (47, 48).  
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Interestingly, the observed variability in PD can also in part be explained by polymorphisms. 
For polymorphisms are not limited to PK, but can also affect PD related outcome variables. 
This was illustrated for the link between combined opioid mu-receptor (OPRM1, opioid 
receptor) and Catechol-0-methyltransferase (COMT, intracellular signaling) polymorphisms 
and the need for rescue morphine in mechanically ventilated newborns (49, 50). To date the 
role of PG is still limited, but should at least be considered when an abnormal drug response 
is observed following surgery. 
Considerations to treat postoperative pain in neonates, young 
infants and children: from one dose to size-fits-all towards patient 
tailored treatment 
Pain treatment is warranted in case of operative procedures, for specific neonatal anomalies, 
underlying critical disease (51) and specific conditions (52). Optimal postoperative analgesia 
decreases stress and improves recovery and clinical outcome (53). However, associations 
between neuro-apoptosis, neurological outcome and exposure to analgesics have been 
observed in animal models, while the clinical implications for adults and children are still hard 
to interpret. The American Society of Anesthesiologists' 2012 Practice Guidelines for Acute 
Pain Management in the Perioperative Setting provided guidance on the prevention and 
treatment on pain. Designing a care plan tailored to the individual and the surgical procedure 
involved is recommended – with an emphasis on multimodal regimens and regular pain 
assessment (54). In children within the ICU setting, this commonly translates to intravenous 
administration of opioids and non-opioid analgesics.  
Acetaminophen, morphine and fentanyl are the most widely used analgesic drugs. Multimodal 
analgesia in postoperative children (average age 4 year), acetaminophen combined with 
morphine, resulted in an opioid sparing effect (55). The PK data hereby resulted in the use of 
loading doses with patient-tailored maintenance dosages for IV morphine or acetaminophen 
(56), subsequently guided by validated assessment (PD) tools. This concept is strongly 
supported in the WHO guidelines on treatment of pain although the evidence for the use of 
multimodal analgesia in children is still limited (WHO guidelines 2012) (9). For other 
analgesics, the available data are even more limited (57, 58). Tramadol (59), nalbuphine (60) 
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Interestingly, the observed variability in PD can also in part be explained by polymorphisms. 
For polymorphisms are not limited to PK, but can also affect PD related outcome variables. 
This was illustrated for the link between combined opioid mu-receptor (OPRM1, opioid 
receptor) and Catechol-0-methyltransferase (COMT, intracellular signaling) polymorphisms 
and the need for rescue morphine in mechanically ventilated newborns (49, 50). To date the 
role of PG is still limited, but should at least be considered when an abnormal drug response 
is observed following surgery. 
Considerations to treat postoperative pain in neonates, young 
infants and children: from one dose to size-fits-all towards patient 
tailored treatment 
Pain treatment is warranted in case of operative procedures, for specific neonatal anomalies, 
underlying critical disease (51) and specific conditions (52). Optimal postoperative analgesia 
decreases stress and improves recovery and clinical outcome (53). However, associations 
between neuro-apoptosis, neurological outcome and exposure to analgesics have been 
observed in animal models, while the clinical implications for adults and children are still hard 
to interpret. The American Society of Anesthesiologists' 2012 Practice Guidelines for Acute 
Pain Management in the Perioperative Setting provided guidance on the prevention and 
treatment on pain. Designing a care plan tailored to the individual and the surgical procedure 
involved is recommended – with an emphasis on multimodal regimens and regular pain 
assessment (54). In children within the ICU setting, this commonly translates to intravenous 
administration of opioids and non-opioid analgesics.  
Acetaminophen, morphine and fentanyl are the most widely used analgesic drugs. Multimodal 
analgesia in postoperative children (average age 4 year), acetaminophen combined with 
morphine, resulted in an opioid sparing effect (55). The PK data hereby resulted in the use of 
loading doses with patient-tailored maintenance dosages for IV morphine or acetaminophen 
(56), subsequently guided by validated assessment (PD) tools. This concept is strongly 
supported in the WHO guidelines on treatment of pain although the evidence for the use of 
multimodal analgesia in children is still limited (WHO guidelines 2012) (9). For other 
analgesics, the available data are even more limited (57, 58). Tramadol (59), nalbuphine (60) 
and ketorolac (61) seem to be promising and safe alternative drugs for postoperative care, 
although pain relief was considered to be less effective for nalbuphine compared to other 
opioids. Sufentanil may be another alternative, but this has been hardly studied in children 
(62, 63) and neonates (64). The variability in PK of analgesics in neonates, young infants and 
children is further illustrated in Table 2. As discussed earlier, special conditions like HT, ECMO 
or cardiac surgery are likely to further affect PK, and likely also PD.  
Table 2: Clinical studies on PK of selected analgesic drugs –opioids and NSAIDs (IV) in 
neonates, young infants and children 
Drug Volume of distribution Clearance 
Alfentanil (112) Neonates: Vdbeta 1L/kg   
Children: 0.163-0.48 L/kg  
Neonates: 2.2±2.4 ml/kg/min 
Infants and children: 5.9-11.1 
ml/kg/min 
Ketorolac (55) 4-8 years: 0.19 – 0.44 L/kg  
 
2-18 months: 
S-enantiomer 4.4-5 ml/kg/min  
R-enantiomer 1-1.04 ml/kg/min 
Morphine (19) Vcentral : 46-81.2 L/70kg 
Vperipheral: 128 L/70kg 
1.62 L/min/70kg 
Acetaminophen (27) 0.179 - 17.2929 L (BW 0.5-50 kg) 0.047-13.422 L/h (BW 0.5-50 kg) 
Sufentanil (57) 2.9 L/kg 30.5 (8.8) ml/kg/min 
Remifentanil  
(77, 78) 
0-2 years: 0.452(0.144) L/kg   
2-6 years: 0.240 L/kg 
7-12 years: 0.249 L/kg 
0-2 years: 90.5 (36.8) ml/kg/min  
adolescents: 57.2 (21.2) 
ml/kg/min  
Nalbuphine (54) Vcentral: 210 L/70 kg  
Vperipheral: 151 L/70 kg 
130 L/ h/ 70 kg,  
inter-compartment clearance 
75.6 L/ h/ 70 kg 
Tramadol (36, 53)  Neonates: fixed metabolite 
224 L/70 kg  
0-2 years: 0.2-0.3 L/kg  
2-12 years: 2.5-3.0 L/kg  
0-2 years: 90 ml/kg/min  
2-12 years: 60 ml/kg/min  
 
* Mean (SD) PK parameters reported from different studies in these populations. 
Abbreviation: BW: body weight, L: liter, h: hour, min: minutes, kg: kilogram 
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Hypothermia 
Evidence-based guidelines on pain management for neonates and children who undergo HT 
are still lacking. However, analgesics (e.g. opioids, mainly morphine) are commonly combined 
with sedatives (e.g. midazolam) in term neonates exposed to HT after perinatal asphyxia (65, 
66). Evidence based data on PK of drugs in neonates and children who underwent HT have 
been reviewed by van den Broek et al. 2010 (66) and Pokorna et al. 2015 (65), but only few 
data are available on PK of analgesics or on PK in cases when perinatal asphyxia indicated HT. 
PK changes in neonates and children who underwent HT are known in terms of reduction in 
absorption (due to low splanchnic flow) for non-parenteral administered drugs (for oral or 
rectal route of administered acetaminophen), changes in distribution (decreased Vd of 
lipophilic drugs) or in CL. The impact of HT on morphine (PK) in neonates undergoing HT on 
indication of perinatal asphyxia has been quantified as a 23% decrease in morphine CL (44). 
The PHARMACOOL study illustrates how a pragmatic study design with opportunistic sampling 
can provide more insight in the effect of HT on the PK of frequently used drugs in these 
neonates. We therefore suggest to focus on short-acting and rapid-onset opioids (e.g. 
alfentanil, nalbuphine, remifentanil) or intermediate-acting drugs (tramadol) guided by 
validated PD scores. Once the PK aspects have been elucidated, we can explore PD related 
aspects since HT also affects pain expression by mechanisms related to cold-induced pain (17, 
18) while thermal stimuli are initiated via thermoreceptors and the nociception may be 
sensitized under HT (17). In general, a surgical procedure will not be performed under 
hypothermia if the procedure is not considered lifesaving. The patient will be rewarmed first, 
undergo neurological evaluation, and surgery is considered once the neurological condition 
has stabilized. 
Extracorporeal membrane oxygenation 
ECMO provides temporary respiratory and cardiac support to critically ill neonates and 
children with Multiple Organ Dysfunction (MODS) if conventional treatment has failed. 
Optimal analgesia is essential during the ECMO run and during cannulation and decannulation 
(67). Similar to HT, the effects of ECMO superimpose on the underlying disease and thereby 
further affect the maturational and non-maturational PK changes of analgesics (68, 69). 
Compound specific drug losses in the ECMO circuit have been quantified in different in vitro 
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Hypothermia 
Evidence-based guidelines on pain management for neonates and children who undergo HT 
are still lacking. However, analgesics (e.g. opioids, mainly morphine) are commonly combined 
with sedatives (e.g. midazolam) in term neonates exposed to HT after perinatal asphyxia (65, 
66). Evidence based data on PK of drugs in neonates and children who underwent HT have 
been reviewed by van den Broek et al. 2010 (66) and Pokorna et al. 2015 (65), but only few 
data are available on PK of analgesics or on PK in cases when perinatal asphyxia indicated HT. 
PK changes in neonates and children who underwent HT are known in terms of reduction in 
absorption (due to low splanchnic flow) for non-parenteral administered drugs (for oral or 
rectal route of administered acetaminophen), changes in distribution (decreased Vd of 
lipophilic drugs) or in CL. The impact of HT on morphine (PK) in neonates undergoing HT on 
indication of perinatal asphyxia has been quantified as a 23% decrease in morphine CL (44). 
The PHARMACOOL study illustrates how a pragmatic study design with opportunistic sampling 
can provide more insight in the effect of HT on the PK of frequently used drugs in these 
neonates. We therefore suggest to focus on short-acting and rapid-onset opioids (e.g. 
alfentanil, nalbuphine, remifentanil) or intermediate-acting drugs (tramadol) guided by 
validated PD scores. Once the PK aspects have been elucidated, we can explore PD related 
aspects since HT also affects pain expression by mechanisms related to cold-induced pain (17, 
18) while thermal stimuli are initiated via thermoreceptors and the nociception may be 
sensitized under HT (17). In general, a surgical procedure will not be performed under 
hypothermia if the procedure is not considered lifesaving. The patient will be rewarmed first, 
undergo neurological evaluation, and surgery is considered once the neurological condition 
has stabilized. 
Extracorporeal membrane oxygenation 
ECMO provides temporary respiratory and cardiac support to critically ill neonates and 
children with Multiple Organ Dysfunction (MODS) if conventional treatment has failed. 
Optimal analgesia is essential during the ECMO run and during cannulation and decannulation 
(67). Similar to HT, the effects of ECMO superimpose on the underlying disease and thereby 
further affect the maturational and non-maturational PK changes of analgesics (68, 69). 
Compound specific drug losses in the ECMO circuit have been quantified in different in vitro 
studies (68, 70). PK of analgesic drugs is hereby also affected by drug-dependent 
characteristics (drug lipophilicity, protein binding capacity and drug sequestration). In vivo, 
the final observed phenotypic disposition covers both maturational, disease related and 
equipment related aspects. For high lipophilic drugs like fentanyl or sufentanil (70), ECMO 
leads to an increased Vd and decreased CL. ECMO flow was found to have a small effect on 
M3G metabolite clearance. An increase in ECMO blood flow was associated with decreased 
clearance, possibly reflecting illness severity. Dopamine dose reflected decreased renal CL (71, 
72).  
Pain treatment after cardiac surgery  
Current guidelines on pain treatment after cardiac surgery in children are not yet based on 
population tailored PK or PD. The main guidelines on this issue were provided by the 
association of Paediatric Anaesthetists of Great Britain and Ireland in 2012 but are based on 
small, non-randomized trials (73). Morphine is recommended as the analgesic of first choice, 
but very little PK and PD data on this drug are presented in this guideline, despite the fact that 
PK and PD based dosing guidelines have been established for non-cardiac surgery in children 
(19). Routinely used analgesics and sedatives in cardiac critical care are discussed in the recent 
consensus statement by Lucas et al. (74).  
Several studies show differences in morphine serum concentration in children after cardiac 
surgery and children after non-cardiac surgery. Dagan et al. found that the use of inotropic 
support, e.g. epinephrine, dopamine or dobutamine, at more than 10 mcg/kg/min after 
surgery significantly decreased morphine CL from 1.5 ± 0.41 to 0.73 ± 0.3 L/kg/h. This is most 
likely due to changes in cardiovascular status, and a 50% reduction in morphine dosage was 
recommended for these children (75). Lynn et al. also found decreased morphine CL in 
children after cardiac surgery as compared to age-matched peers after non-cardiac surgery, 
but attributed this to slower maturation in the cardiac surgery patients (76). In contrast, 
Elkomy et al. more recently were unable to find differences of morphine CL in children after 
cardiac surgery and children after non-cardiac surgery (77). Morphine serum levels seemed to 
be dependent on age and renal function, with renal function being often impaired after 
cardiac surgery (78). Alternatively, Valkenburg et al. showed an increased Vd and a decreased 
morphine CL in children after cardiac surgery compared to non-cardiac surgery (79).  
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PK parameters in children after cardiac surgery have been reported for remifentanil, clonidine 
and dexmedetomidine. Two studies on remifentanil have been published in the last decade, 
both reporting maturational and non-maturational changes in children after cardiac surgery 
compared to non-cardiac surgery (80, 81). Due to an 2.4 times increase in Vd during CPB and 
post-CPB compared to pre-CPB values, a supplemental bolus dose of remifentanil of 25 
microgram is proposed at the start of CPB to achieve the target concentration of 14 ng/ml in 
50% of patients (81). While clonidine was initially used as a sedative, it is currently also used 
as an analgesic for its favorable hemodynamic profile and mild analgesic effects (82, 83). For 
intravenous clonidine administration, the Vd (central volume 123%, peripheral volume 126%) 
but not CL, was increased in neonates and children after cardiac surgery (84). The dosing 
recommendation for clonidine was only driven by maturational changes in neonates and 
infants, unrelated to cardiac surgery. , Su et al. recently published a PK-based dosing advice 
for dexmedetomidine in neonates and children after cardiac surgery (85). Both maturational 
(weight and age), and non-maturational (presence of intra-cardiac shunt and total bypass 
time) affected CL. Due to decreased CL during the first two weeks of life, a 30-40% dose 
reduction is required in neonates to achieve similar steady state plasma concentration when 
compared to infants. Alternatively, CL is increased by 24% in the presence of a right-to-left 
intra-cardiac shunt.  
The PK in children after cardiac surgery can be expected to differ from that in children after 
non-cardiac surgery. This can be mainly ascribed to the perioperative use of CPB, which has 
profound effects on the PK because of 1) hemodynamic changes, 2) hemodilution, 3) HT, 4) 
SIRS, 5) sequestration of drugs in the CPB system. These effects change constantly during CPB 
and continue to have effects after weaning from CPB (78, 86).  
1) Hemodynamic changes during CPB are due to a decrease in blood pressure and the 
related changes in blood flow. These changes can arise because of non-pulsatile flow, 
a decrease in peripheral vascular resistance and the use of inotropes in 
hemodynamically unstable patients (75, 87).  
2) At the onset of CPB, priming fluid dilutes the patient’s blood, to sometimes doubling 
of the circulating volume. Due to low protein concentration in the prime fluid, a shift 
in bound and unbound drug concentration may occur. Subsequent redistribution of 
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PK parameters in children after cardiac surgery have been reported for remifentanil, clonidine 
and dexmedetomidine. Two studies on remifentanil have been published in the last decade, 
both reporting maturational and non-maturational changes in children after cardiac surgery 
compared to non-cardiac surgery (80, 81). Due to an 2.4 times increase in Vd during CPB and 
post-CPB compared to pre-CPB values, a supplemental bolus dose of remifentanil of 25 
microgram is proposed at the start of CPB to achieve the target concentration of 14 ng/ml in 
50% of patients (81). While clonidine was initially used as a sedative, it is currently also used 
as an analgesic for its favorable hemodynamic profile and mild analgesic effects (82, 83). For 
intravenous clonidine administration, the Vd (central volume 123%, peripheral volume 126%) 
but not CL, was increased in neonates and children after cardiac surgery (84). The dosing 
recommendation for clonidine was only driven by maturational changes in neonates and 
infants, unrelated to cardiac surgery. , Su et al. recently published a PK-based dosing advice 
for dexmedetomidine in neonates and children after cardiac surgery (85). Both maturational 
(weight and age), and non-maturational (presence of intra-cardiac shunt and total bypass 
time) affected CL. Due to decreased CL during the first two weeks of life, a 30-40% dose 
reduction is required in neonates to achieve similar steady state plasma concentration when 
compared to infants. Alternatively, CL is increased by 24% in the presence of a right-to-left 
intra-cardiac shunt.  
The PK in children after cardiac surgery can be expected to differ from that in children after 
non-cardiac surgery. This can be mainly ascribed to the perioperative use of CPB, which has 
profound effects on the PK because of 1) hemodynamic changes, 2) hemodilution, 3) HT, 4) 
SIRS, 5) sequestration of drugs in the CPB system. These effects change constantly during CPB 
and continue to have effects after weaning from CPB (78, 86).  
1) Hemodynamic changes during CPB are due to a decrease in blood pressure and the 
related changes in blood flow. These changes can arise because of non-pulsatile flow, 
a decrease in peripheral vascular resistance and the use of inotropes in 
hemodynamically unstable patients (75, 87).  
2) At the onset of CPB, priming fluid dilutes the patient’s blood, to sometimes doubling 
of the circulating volume. Due to low protein concentration in the prime fluid, a shift 
in bound and unbound drug concentration may occur. Subsequent redistribution of 
drugs from the peripheral to the central compartments depends on protein binding, 
lipophilicity and Vd. 
3) HT induces changes in metabolism and organ perfusion. Decreased hepatic flow causes 
subsequent changes in drug metabolism such as CYP2D6, which lead to impaired CL 
and drug accumulation with increased risk of toxicity (66). This also potentially changes 
the child’s response to the administered drug, thus the PD.  
4) SIRS occurs in one third of patients during the use of CPB. Main risk factors are the 
duration of CPB and the amount of fresh frozen plasma used. SIRS is associated with 
organ dysfunction and prolonged stay at the intensive care unit (86, 88). Inflammation 
and organ dysfunction reduce CL of CYP3A-mediated drugs, such as midazolam (89). 
Therefore children may be at risk of increased plasma concentrations and associated 
toxicity.  
5) Sequestration of drugs in the CPB system is a problem mainly for lipophilic drugs. The 
oxygenator has been identified as the main binding site of drugs. Coating of CPB tubing 
with heparin or biocompatible coating does not prevent absorption of drugs. 
Depending on the type of drug, up to 90% can be absorbed in the CPB circuit only 
minutes after administration (90, 91). 
Based on what has been discussed until now, it seems essential to explore the PK and PD 
related differences in these specific subpopulations, and population PK modelling or PK/PD 
modelling is likely the ideal tool.  
Tolerance, drug dependency and withdrawal 
All three patient groups described above are at risk for tolerance, drug dependency and 
withdrawal after prolonged use of analgesics and sedatives. Tolerance is the decreased effect 
of a drug after prolonged exposure (92). Several subcategories are described, such as innate 
(genetic) and pharmacokinetic tolerance. However, pharmacodynamic tolerance is the most 
appropriate definition since it refers to alterations at the distal end of the receptor (93). The 
primary mechanisms of tolerance are receptor desensitization and upregulation of the cAMP 
pathway by various causes (92). Different types of opioids have different effects on these 
mechanisms, leading to a variable potential to cause tolerance. The risk of developing 
tolerance is higher with prolonged duration of therapy, early developmental stage of the 
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patient, male gender and the use of synthetic or short-acting opioids (92). Tolerance and 
withdrawal symptoms can occur after five days of continuous infusion of opioids or 
benzodiazepines. Validated PD tools to assess withdrawal are the Withdrawal Assessment 
Tool-1 (WAT-1) and the Sophia Observation withdrawal Symptoms score (SOS) (34, 45).  
The clinical management of opioid tolerance and subsequent withdrawal is multimodal. 
Gradual weaning of opioids and replacing intravenous short-acting opioids with non-IV 
administered long-acting opioids is the recommended pharmacological therapy. Tolerance 
and withdrawal may be prevented or delayed by using daily interruption of sedation, nurse-
controlled analgesia, or sequential rotation of analgesics (45, 92). Vet et al. showed that daily 
interruption of sedation in critically ill children decreased withdrawal symptoms, but did not 
improve clinical outcome (94). The influence of pharmacogenetics on the cellular changes that 
lead to tolerance is not yet clear (92).  
Towards model-based dosing regimens using population 
pharmacokinetic modelling 
Population pharmacokinetic modelling 
Population PK modelling paves the way to estimate PK parameters such as CL and Vd (based 
on concentration-time profiles) and to translate them in model-based dosing regimens, which 
should take into account information on (before, during and after) ECMO, cooling and 
CPB. The development of such dosing regimens using PK data is illustrated in figure 2 and 
consists of a multi-step approach (95): 
1) Optimal study design (based on preliminary data) 
2) Development and internal validation of PK-model 
3) External validation of PK-model 
4) Prospective validation in clinical study 
5) Proposed individualized dosing regimen 
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patient, male gender and the use of synthetic or short-acting opioids (92). Tolerance and 
withdrawal symptoms can occur after five days of continuous infusion of opioids or 
benzodiazepines. Validated PD tools to assess withdrawal are the Withdrawal Assessment 
Tool-1 (WAT-1) and the Sophia Observation withdrawal Symptoms score (SOS) (34, 45).  
The clinical management of opioid tolerance and subsequent withdrawal is multimodal. 
Gradual weaning of opioids and replacing intravenous short-acting opioids with non-IV 
administered long-acting opioids is the recommended pharmacological therapy. Tolerance 
and withdrawal may be prevented or delayed by using daily interruption of sedation, nurse-
controlled analgesia, or sequential rotation of analgesics (45, 92). Vet et al. showed that daily 
interruption of sedation in critically ill children decreased withdrawal symptoms, but did not 
improve clinical outcome (94). The influence of pharmacogenetics on the cellular changes that 
lead to tolerance is not yet clear (92).  
Towards model-based dosing regimens using population 
pharmacokinetic modelling 
Population pharmacokinetic modelling 
Population PK modelling paves the way to estimate PK parameters such as CL and Vd (based 
on concentration-time profiles) and to translate them in model-based dosing regimens, which 
should take into account information on (before, during and after) ECMO, cooling and 
CPB. The development of such dosing regimens using PK data is illustrated in figure 2 and 
consists of a multi-step approach (95): 
1) Optimal study design (based on preliminary data) 
2) Development and internal validation of PK-model 
3) External validation of PK-model 
4) Prospective validation in clinical study 
5) Proposed individualized dosing regimen 
In the first step, previous PK studies must be evaluated on quality and the amount of data, 
such as clinical characteristics, drug concentrations in plasma, number of patients and time of 
sampling, retrieved from these studies (96). In addition, attention should also be given to the 
above-mentioned clinical characteristics when designing a new study. In the second step, a 
population PK model can be generated by using concentrations collected during studies or 
clinical practice. The development of a population PK-model is in three different steps: 
identification of the a) structural model; b) statistical model; c) covariate model (97). In the 
structural model, a population concentration-time curve is derived from the estimated 
parameters (Figure 1b) by pooling all concentrations obtained from all patients (Figure 1a to 
1b), whereas the statistical model quantifies all levels of variability (inter-individual variability 
(between-subjects), intra individual variability (within subject) and residual variability (assay 
error, error in recording sampling time, error in dosage preparation (Figure 2). Thus, the model 
takes into account the differences among observations (Figure 1c). In the covariate model, the 
use of patient and treatment characteristics is aimed is to (partly) understand and explain the 
inter-individual and intra-individual variability in the model parameters. These characteristics 
are often subdivided in maturational (age, weight), demographic (sex, race, genotype) and 
treatment characteristics (HT, ECMO, CPB, surgery) but can also be time-varying covariates 
(for example pre- vs post-CPB) (Figure 1). Different methods are available to quantify the 
influence of maturational changes on PK parameters of drugs in children, including allometric 
scaling using bodyweight-based functions with fixed exponents (98). This can be combined 
with additional age-based maturation functions (99) or more data-driven approaches in which 
a systematic covariate analysis drives the definition of the statistically most appropriate 
relationship to describe maturational changes in observed data (97). For morphine, the 
maturation of clearance has for instance been described using different parameterizations, 
based on bodyweight, age or a combination of both (19, 100-102). PK covariates can then be 
used to determine if and how dosing can be individualized to yield similar drug exposure for 
different subpopulations or even individual patients. This is irrespective of whether the source 
of inter-individual differences is maturational or non-maturational and irrespective of the 
chosen parameterization for the influence of maturational changes on PK parameters, as long 
as the obtained relationships are properly validated (37, 103). For example, if a covariate, such 
as age, influences Vd, the loading dose needs to be adjusted based on age. Covariates can thus 
be used to determine if and how dosing can be individualized (37).  
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The advantage of the population approach is that an entire concentration-time curve does not 
need to be obtained for every patient. This enables sparse blood sampling, which is preferred 
for neonates and children. Another advantage is that samples taken from clinical care or even 
scavenged sampling can be used, instead of designing complete experimental studies. The last 
part of the second step is the internal validation, in which the stability of the PK parameter 
estimates and the final model robustness are assessed to estimate the predictive property in 
terms of general trends in the population and on variability.  
Figure 2: multistep approach for development of dosing regimens using PK/PD data 
Figure adapted with permission from Ince et al. (95) 
The third step is the external validation, which implies investigating the accuracy of the model 
in new patients from the same population that was used for model building. This step is often 
not performed, however, due to the lack of an external dataset even though historical or 
clinical data can be used for this purpose. Prospective validation in a trial is the fourth step. 
During this step the model is clinically tested to check whether the dosing advice derived from 
this model will reach the desired target range, and to identify patients in which the dosing 
regimen does not provide the correct concentrations or effects and must therefore be further 
elaborated. These might for instance include postoperative cardiac patients who have 
different PK parameters than postoperative non-cardiac patients (78). In the fifth step, 
individualized dosing regimens are achieved, and preferably incorporated in guidelines and 
formularies for use in clinical care. 
Looking beyond morphine and acetaminophen for postoperative pain 
Of the drugs commonly used to treat postoperative pain, morphine and acetaminophen have 
been extensively evaluated (34). Concerning morphine for postoperative pain, all five steps 
leading to PK-based individualized dosing regimens have been completed for neonates and 
children (range 0-3 years of age) (20). For both morphine and paracetamol, the PK has been 
identified and dosing guidelines have been proposed for the entire pediatric age range, 
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The advantage of the population approach is that an entire concentration-time curve does not 
need to be obtained for every patient. This enables sparse blood sampling, which is preferred 
for neonates and children. Another advantage is that samples taken from clinical care or even 
scavenged sampling can be used, instead of designing complete experimental studies. The last 
part of the second step is the internal validation, in which the stability of the PK parameter 
estimates and the final model robustness are assessed to estimate the predictive property in 
terms of general trends in the population and on variability.  
Figure 2: multistep approach for development of dosing regimens using PK/PD data 
Figure adapted with permission from Ince et al. (95) 
The third step is the external validation, which implies investigating the accuracy of the model 
in new patients from the same population that was used for model building. This step is often 
not performed, however, due to the lack of an external dataset even though historical or 
clinical data can be used for this purpose. Prospective validation in a trial is the fourth step. 
During this step the model is clinically tested to check whether the dosing advice derived from 
this model will reach the desired target range, and to identify patients in which the dosing 
regimen does not provide the correct concentrations or effects and must therefore be further 
elaborated. These might for instance include postoperative cardiac patients who have 
different PK parameters than postoperative non-cardiac patients (78). In the fifth step, 
individualized dosing regimens are achieved, and preferably incorporated in guidelines and 
formularies for use in clinical care. 
Looking beyond morphine and acetaminophen for postoperative pain 
Of the drugs commonly used to treat postoperative pain, morphine and acetaminophen have 
been extensively evaluated (34). Concerning morphine for postoperative pain, all five steps 
leading to PK-based individualized dosing regimens have been completed for neonates and 
children (range 0-3 years of age) (20). For both morphine and paracetamol, the PK has been 
identified and dosing guidelines have been proposed for the entire pediatric age range, 
although the last step (prospective evaluation) still deserves more attention (33, 104). It 
should be realized, however, that the morphine and acetaminophen dosages are 
recommended for major non-cardiac surgery only (19). For other drugs used in the 
postoperative setting such as remifentanil (postoperative pain after cardiac surgery), 
diclofenac (105, 106), nalbuphine (107) and ketorolac (108), PK-parameters derived from 
population models are available for certain routes of administration and in various pediatric 
age-groups. For drugs such as ibuprofen, oxycodone or fentanyl, models have not yet been 
developed for neonates or children for postoperative pain treatment.  
In all PK models developed for neonates, infants and children, maturational covariates (weight 
and/or age) are used to (partly) explain inter-patient variability in PK parameters. However, 
besides these maturational covariates, non-maturational covariates could also partly explain 
inter-individual as well as intra-individual variability. Both maturational and non-maturational 
covariates should be taken into account when developing a dosing regimen in the studied 
population. The pre- or post-CPB period are examples of a non-maturational time-varying 
covariate, emerging in the population PK model developed for remifentanil in infants and 
children undergoing cardiac surgery with CPB (81). Vd was increased during and post-CPB 
compared to the pre-CPB period. The authors concluded that following this increase, an extra 
bolus of 25ug must be administered at the start of CPB compared to the pre-CPB period to 
obtain an optimal target concentration of 14ng/ml during CPB and post-CPB (81).  
Conclusion 
PK studies that report on PK parameters and its covariates for morphine, fentanyl and 
acetaminophen are available, but data in specific subpopulations (HT, ECMO or cardiac 
patients) are limited. PK data are also lacking for other commonly used opioids (alfentanil, 
remifentanil, nalbuphine) and non-opioids (e.g. ketorolac) in critically ill neonates, young 
infants and children. PK parameters accounting for maturational and non-maturational 
covariates are important to develop population PK-based dosing advices for the pediatric age 
group. Besides disease characteristics and treatment modalities, PG should also be considered 
as a potential relevant covariate, but the impact of this covariate may depend on both 
maturational and non-maturational covariates. Irrespective of the compound, PD is often not 
investigated as endpoint in combination with PK parameters. PK models should be combined 
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with validated PD outcome data to establish optimal evidence based dosing regimens for 
specific populations and age groups.  
Expert opinion 
PK-parameters derived from population PK-models provide a first step towards individualized 
pain treatment in children. Besides maturational changes, non-maturational changes should 
be considered. In this review, this has been stressed for children undergoing HT, on ECMO, or 
cardiac surgery, including CPB. PK parameters for these subpopulations are considered to 
differ from those for other pediatric populations in an ICU setting. While PK-based dosing 
advices are certainly useful, they will be clinically relevant only if prospectively evaluated in 
proof of principle studies in which both the PK and PD are considered. In this section we will 
mainly focus on missing PK/PD data of routinely used analgesics and possibilities to turn this 
into personalized model-based dosing.  
Most population PK-models report on maturational covariates (weight, age), mainly with 
respect to CL. The impact of non-maturational covariates (ECMO, CPB, disease state, 
inflammation) strongly depends on the type of patient group but can also vary within one and 
the same patient with time and disease progression. Given these differences in maturational 
and non-maturational covariates, attention should not only be paid to age and weight, but 
also to diagnosis and treatment modalities when developing PK-based dosing 
recommendations. For example, in critically ill children on ECMO, variation in PK parameters 
is extensive, with an increase in Vd between 5% and 400% for most drugs, and a decreased CL 
between 0% and 50% compared with children without ECMO (69). In this respect, 
physiologically-based (PB)-PK models can be considered to estimate the impact of non-
maturational covariates on the disposition of specific compounds. PB-PK models use, besides 
PK information, also physiological information such as renal blood flow. These PB-PK models 
could be of interest, especially to explore whether results from one drug can be used to predict 
the PK for similar drugs; for example for drugs which are metabolized by the same route. An 
example is midazolam, which is mostly metabolized by CYP3A4. The PK parameters obtained 
from a PB-PK model of this drug could be evaluated for predictions for other drugs which are 
also CYP3A4 substrates. Physiological based models may be the future when dealing with large 
variability in maturational and non-maturational covariates. However, this will necessitate 
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with validated PD outcome data to establish optimal evidence based dosing regimens for 
specific populations and age groups.  
Expert opinion 
PK-parameters derived from population PK-models provide a first step towards individualized 
pain treatment in children. Besides maturational changes, non-maturational changes should 
be considered. In this review, this has been stressed for children undergoing HT, on ECMO, or 
cardiac surgery, including CPB. PK parameters for these subpopulations are considered to 
differ from those for other pediatric populations in an ICU setting. While PK-based dosing 
advices are certainly useful, they will be clinically relevant only if prospectively evaluated in 
proof of principle studies in which both the PK and PD are considered. In this section we will 
mainly focus on missing PK/PD data of routinely used analgesics and possibilities to turn this 
into personalized model-based dosing.  
Most population PK-models report on maturational covariates (weight, age), mainly with 
respect to CL. The impact of non-maturational covariates (ECMO, CPB, disease state, 
inflammation) strongly depends on the type of patient group but can also vary within one and 
the same patient with time and disease progression. Given these differences in maturational 
and non-maturational covariates, attention should not only be paid to age and weight, but 
also to diagnosis and treatment modalities when developing PK-based dosing 
recommendations. For example, in critically ill children on ECMO, variation in PK parameters 
is extensive, with an increase in Vd between 5% and 400% for most drugs, and a decreased CL 
between 0% and 50% compared with children without ECMO (69). In this respect, 
physiologically-based (PB)-PK models can be considered to estimate the impact of non-
maturational covariates on the disposition of specific compounds. PB-PK models use, besides 
PK information, also physiological information such as renal blood flow. These PB-PK models 
could be of interest, especially to explore whether results from one drug can be used to predict 
the PK for similar drugs; for example for drugs which are metabolized by the same route. An 
example is midazolam, which is mostly metabolized by CYP3A4. The PK parameters obtained 
from a PB-PK model of this drug could be evaluated for predictions for other drugs which are 
also CYP3A4 substrates. Physiological based models may be the future when dealing with large 
variability in maturational and non-maturational covariates. However, this will necessitate 
collecting accurate data on the (patho)physiology in these cases, including but not limited to, 
trends in caloric needs and metabolism, renal and hepatic blood flow and function or body 
composition, including fluid shifts. Development of accurate biomarkers to predict disease 
state, real time organ function, body composition and fluid shifts is essential in furthering our 
efforts to individualize and optimize drug dosing in these patients. Until such data become 
available, semi-physiological function approaches can be considered, as have been used for 
e.g. primary glomerular filtration rate driven aminoglycosides CL throughout pediatric life 
(109). 
Another approach to investigate PK in critically ill children is micro-dosing. Its feasibility in 
children has been demonstrated by Mooij et al. (110). Using a micro dose of C14 labeled 
acetaminophen, maturational changes -in drug metabolism were explored without additional 
risk and only limited burden to the critically ill child (111). As the feasibility of micro-dosing 
has been established, a similar approach can be considered in specific subpopulations like HT, 
ECMO or after cardiac surgery cases to quantify the impact of non-maturational covariates on 
drug disposition.  
At present, PK parameters are not yet known for all routinely used analgesic drugs in children 
postoperatively or on ECMO. Regarding opioids, morphine and remifentanil have been well 
investigated in postoperative children (19, 20). Sufentanil and fentanyl are also often used 
after surgery, but the only report on sufentanil PK dates from 1987 (112). The reported 
changes in PK of sufentanil in infants and children undergoing cardiac surgery may no longer 
be applicable in current clinical practice due to changes in CPB systems and perioperative and 
postoperative care. No report could be retrieved for fentanyl PK after cardiac surgery in 
children. Considering the clinical use of both fentanyl and sufentanil in postoperative patients, 
we would urge to investigate PK parameters with validated PD assessment, applying 
population PK/PD modelling techniques. Regarding non-opioids, acetaminophen has been 
investigated in postoperative infants, although the derived models have not yet been 
implemented in clinical practice (33, 55). Acetaminophen has been less well investigated in 
children after cardiac surgery. Considering the equipotency of IV acetaminophen to morphine 
observed in non-cardiac patients (55), with the benefit of less adverse drug reactions, this is 
certainly worth investigating. We consequently suggest to use the earlier mentioned methods 
(population PK, including semi-physiologic functions or PB-PK, micro-dosing) when focusing 
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on these compounds because of the clinical need and the feasibility. In contrast, NSAIDs PK 
have not been investigated in children on ECMO. NSAIDs carry the risk of prolonged bleeding 
time and renal impairment, making physicians less inclined to use NSAIDs in these patients.  
Once PK-models have been developed, PK/PD can be further investigated. The potential 
relevance of this PK/PD approach has recently been highlighted for morphine in ventilated 
preterm neonates undergoing endotracheal suctioning (113). Using the item response theory, 
an intra-individual relationship between morphine concentrations and pain reduction in 
preterm neonates was unveiled. While the effect of morphine was small, this report illustrates 
the strengths of a PK/PD analysis approach. For morphine, we can conclude that PK-models 
have been developed and validated and that individual dosing regimens have been derived 
for postoperative pain (19, 20). However, the number of PD-models is still small, so further 
research should focus on the PD across the pediatric age range; which could probably help 
explaining the remaining variability (20). One of the difficulties in PD-modelling is the use of 
multi-item scales (e.g. COMFORT) as an outcome variable. Different analgesics and sedatives 
are often administered simultaneously or a loading dose is administered, making it hard to 
link a dosing regimen to a pre-defined clinical endpoint, as other drugs than the one under 
investigation or the loading dose influence the outcome as reflected by the COMFORT score. 
Moreover, muscular paralysis, or the intervention itself (HT) may also affect the possibilities 
to evaluate the PD.  
Article highlights box 
PK-based dosing regimens are lacking for routinely used analgesics in specific groups of 
(preterm) neonates, infants or children in specific subgroups, like e.g. HT, ECMO, or cardiac 
surgery. 
PK parameters depend not only on maturational, but also on non-maturational changes. These 
covariates, combined with intra-patient variability throughout the disease process further add 
to the variability in PK/PD of analgesics and the choice of the drug throughout childhood.  
PD assessment is necessary but difficult given the diversity of the patient population and their 
disease characteristics. Its variability further adds to the intra- and interpatient variability 
observed in the PK/PD relationship.  
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on these compounds because of the clinical need and the feasibility. In contrast, NSAIDs PK 
have not been investigated in children on ECMO. NSAIDs carry the risk of prolonged bleeding 
time and renal impairment, making physicians less inclined to use NSAIDs in these patients.  
Once PK-models have been developed, PK/PD can be further investigated. The potential 
relevance of this PK/PD approach has recently been highlighted for morphine in ventilated 
preterm neonates undergoing endotracheal suctioning (113). Using the item response theory, 
an intra-individual relationship between morphine concentrations and pain reduction in 
preterm neonates was unveiled. While the effect of morphine was small, this report illustrates 
the strengths of a PK/PD analysis approach. For morphine, we can conclude that PK-models 
have been developed and validated and that individual dosing regimens have been derived 
for postoperative pain (19, 20). However, the number of PD-models is still small, so further 
research should focus on the PD across the pediatric age range; which could probably help 
explaining the remaining variability (20). One of the difficulties in PD-modelling is the use of 
multi-item scales (e.g. COMFORT) as an outcome variable. Different analgesics and sedatives 
are often administered simultaneously or a loading dose is administered, making it hard to 
link a dosing regimen to a pre-defined clinical endpoint, as other drugs than the one under 
investigation or the loading dose influence the outcome as reflected by the COMFORT score. 
Moreover, muscular paralysis, or the intervention itself (HT) may also affect the possibilities 
to evaluate the PD.  
Article highlights box 
PK-based dosing regimens are lacking for routinely used analgesics in specific groups of 
(preterm) neonates, infants or children in specific subgroups, like e.g. HT, ECMO, or cardiac 
surgery. 
PK parameters depend not only on maturational, but also on non-maturational changes. These 
covariates, combined with intra-patient variability throughout the disease process further add 
to the variability in PK/PD of analgesics and the choice of the drug throughout childhood.  
PD assessment is necessary but difficult given the diversity of the patient population and their 
disease characteristics. Its variability further adds to the intra- and interpatient variability 
observed in the PK/PD relationship.  
New techniques in modelling, such as (semi-)physiologic models and PK/PD-based models, 
may better describe the clinical situation and estimate the extent of differences between 
specific subpopulations.  
  
Chapter 2
44
References 
Papers on special note have been highlighted as: 
*of interest 
**of considerable interest 
1. Anand KJ, Hickey PR. Pain and its effects in the human neonate and fetus. N Engl J Med. 
1987;317(21):1321-9. 
2. Weisman SJ, Bernstein B, Schechter NL. Consequences of inadequate analgesia during 
painful procedures in children. Arch Pediatr Adolesc Med. 1998;152(2):147-9. 
3. Berde CB, Jaksic T, Lynn AM, Maxwell LG, Soriano SG, Tibboel D. Anesthesia and 
analgesia during and after surgery in neonates. Clin Ther. 2005;27(6):900-21. 
4. Page GG. Are there long-term consequences of pain in newborn or very young infants? 
J Perinat Educ. 2004;13(3):10-7. 
5. Taddio A, Katz J, Ilersich AL, Koren G. Effect of neonatal circumcision on pain response 
during subsequent routine vaccination. Lancet. 1997;349(9052):599-603. 
6. de Graaf J, van Lingen RA, Valkenburg AJ, Weisglas-Kuperus N, Groot Jebbink L, 
Wijnberg-Williams B, et al. Does neonatal morphine use affect neuropsychological outcomes 
at 8 to 9 years of age? Pain. 2013;154(3):449-58. 
7. de Graaf J, van Lingen RA, Simons SH, Anand KJ, Duivenvoorden HJ, Weisglas-Kuperus 
N, et al. Long-term effects of routine morphine infusion in mechanically ventilated neonates 
on children's functioning: five-year follow-up of a randomized controlled trial. Pain. 
2011;152(6):1391-7. 
8. Scholten W. Developing ‘fully evidenced’ paediatric pain guidelines. Eur J Hosp Pharm. 
2013;20(5):262-3. 
9. www.who.int.: Geneva: WHO; 2012 [Available from: 
http://apps.who.int/iris/bitstream/10665/44540/1/9789241548120_Guidelines.pdf. 
10. Hall RW, Anand KJS. Pain Management in Newborns. Clinics in Perinatology. 
2014;41(4):895-+. 
11. Poh YN, Poh PF, Buang SN, Lee JH. Sedation guidelines, protocols, and algorithms in 
PICUs: a systematic review. Pediatr Crit Care Med. 2014;15(9):885-92. 
Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit
Ch
ap
te
r 
2
45
References 
Papers on special note have been highlighted as: 
*of interest 
**of considerable interest 
1. Anand KJ, Hickey PR. Pain and its effects in the human neonate and fetus. N Engl J Med. 
1987;317(21):1321-9. 
2. Weisman SJ, Bernstein B, Schechter NL. Consequences of inadequate analgesia during 
painful procedures in children. Arch Pediatr Adolesc Med. 1998;152(2):147-9. 
3. Berde CB, Jaksic T, Lynn AM, Maxwell LG, Soriano SG, Tibboel D. Anesthesia and 
analgesia during and after surgery in neonates. Clin Ther. 2005;27(6):900-21. 
4. Page GG. Are there long-term consequences of pain in newborn or very young infants? 
J Perinat Educ. 2004;13(3):10-7. 
5. Taddio A, Katz J, Ilersich AL, Koren G. Effect of neonatal circumcision on pain response 
during subsequent routine vaccination. Lancet. 1997;349(9052):599-603. 
6. de Graaf J, van Lingen RA, Valkenburg AJ, Weisglas-Kuperus N, Groot Jebbink L, 
Wijnberg-Williams B, et al. Does neonatal morphine use affect neuropsychological outcomes 
at 8 to 9 years of age? Pain. 2013;154(3):449-58. 
7. de Graaf J, van Lingen RA, Simons SH, Anand KJ, Duivenvoorden HJ, Weisglas-Kuperus 
N, et al. Long-term effects of routine morphine infusion in mechanically ventilated neonates 
on children's functioning: five-year follow-up of a randomized controlled trial. Pain. 
2011;152(6):1391-7. 
8. Scholten W. Developing ‘fully evidenced’ paediatric pain guidelines. Eur J Hosp Pharm. 
2013;20(5):262-3. 
9. www.who.int.: Geneva: WHO; 2012 [Available from: 
http://apps.who.int/iris/bitstream/10665/44540/1/9789241548120_Guidelines.pdf. 
10. Hall RW, Anand KJS. Pain Management in Newborns. Clinics in Perinatology. 
2014;41(4):895-+. 
11. Poh YN, Poh PF, Buang SN, Lee JH. Sedation guidelines, protocols, and algorithms in 
PICUs: a systematic review. Pediatr Crit Care Med. 2014;15(9):885-92. 
12. Jebaraj B, Maitra S, Baidya DK, Khanna P. Intravenous paracetamol reduces 
postoperative opioid consumption after orthopedic surgery: a systematic review of clinical 
trials. Pain Res Treat. 2013;2013:402510. 
13. van Dijk M, de Boer JB, Koot HM, Tibboel D, Passchier J, Duivenvoorden HJ. The 
reliability and validity of the COMFORT scale as a postoperative pain instrument in 0 to 3-year-
old infants. Pain. 2000;84(2-3):367-77. 
14. Boerlage AA, Ista E, Duivenvoorden HJ, de Wildt SN, Tibboel D, van Dijk M. The 
COMFORT behaviour scale detects clinically meaningful effects of analgesic and sedative 
treatment. Eur J Pain. 2015;19(4):473-9. 
15. Matic M, de Wildt SN, Elens L, de Hoon JN, Annaert P, Tibboel D, et al. SLC22A1/OCT1 
Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. Ther Drug Monit. 
2016;38(4):487-92. 
16. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and 
their descendants. Pharmacogenomics. 2002;3(2):229-43. 
17. Foulkes T, Wood JN. Mechanisms of cold pain. Channels (Austin). 2007;1(3):154-60. 
18. Rutkove SB. Effects of temperature on neuromuscular electrophysiology. Muscle 
Nerve. 2001;24(7):867-82. 
19. Wang C, Sadhavisvam S, Krekels EH, Dahan A, Tibboel D, Danhof M, et al. 
Developmental changes in morphine clearance across the entire paediatric age range are best 
described by a bodyweight-dependent exponent model. Clin Drug Investig. 2013;33(7):523-
34. 
20. Krekels EH, Tibboel D, de Wildt SN, Ceelie I, Dahan A, van Dijk M, et al. Evidence-based 
morphine dosing for postoperative neonates and infants. Clin Pharmacokinet. 
2014;53(6):553-63. 
21. K. J. Anand BJS, Patrick McGrath Pain in Neonates and Infants. 3rd ed. New York, 
United States: Elsevier; 2007 1st May. 328 p. 
22. Griffin JP. The Textbook of Pharmaceutical Medicine: Wiley-Blackwell; 2009 
September 2009. 776 p. 
23. Yamamoto Y, Valitalo PA, Wong YC, Huntjens DR, Proost JH, Vermeulen A, et al. 
Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic 
modeling approach. Eur J Pharm Sci. 2018;112:168-79. 
Chapter 2
46
24. Lam J, Koren G. P-glycoprotein in the developing human brain: a review of the effects 
of ontogeny on the safety of opioids in neonates. Ther Drug Monit. 2014;36(6):699-705. 
25. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and 
Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults. 
Pharmaceutics. 2011;3(1):53-72. 
26. Allegaert K, Simons SHP, Tibboel D, Krekels EH, Knibbe CA, van den Anker JN. Non-
maturational covariates for dynamic systems pharmacology models in neonates, infants, and 
children: Filling the gaps beyond developmental pharmacology. Eur J Pharm Sci. 
2017;109:S27-S31. 
27. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental pharmacology--drug disposition, action, and therapy in infants and children. 
N Engl J Med. 2003;349(12):1157-67. 
28. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp 
Pharmacol. 2011;205:51-75. 
29. Mooij MG, Schwarz UI, de Koning BA, Leeder JS, Gaedigk R, Samsom JN, et al. Ontogeny 
of human hepatic and intestinal transporter gene expression during childhood: age matters. 
Drug Metab Dispos. 2014;42(8):1268-74. 
30. Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in 
the neonate. Seminars In Fetal & Neonatal Medicine. 2005;10(2):123-38. 
31. Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug 
Metab Toxicol. 2014;10(8):1069-78. 
32. Krekels EH, Tibboel D, Knibbe CA. Pediatric pharmacology: current efforts and future 
goals to improve clinical practice. Expert Opin Drug Metab Toxicol. 2015;11(11):1679-82. 
33. Wang C, Allegaert K, Tibboel D, Danhof M, van der Marel CD, Mathot RA, et al. 
Population pharmacokinetics of paracetamol across the human age-range from (pre)term 
neonates, infants, children to adults. J Clin Pharmacol. 2014;54(6):619-29. 
34. Baarslag MA, Allegaert K, Knibbe CA, van Dijk M, Tibboel D. Pharmacological sedation 
management in the paediatric intensive care unit. J Pharm Pharmacol. 2016;69(5):498-513. 
35. Krekels EH, van Ham S, Allegaert K, de Hoon J, Tibboel D, Danhof M, et al. 
Developmental changes rather than repeated administration drive paracetamol 
glucuronidation in neonates and infants. Eur J Clin Pharmacol. 2015;71(9):1075-82. 
Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit
Ch
ap
te
r 
2
47
24. Lam J, Koren G. P-glycoprotein in the developing human brain: a review of the effects 
of ontogeny on the safety of opioids in neonates. Ther Drug Monit. 2014;36(6):699-705. 
25. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and 
Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults. 
Pharmaceutics. 2011;3(1):53-72. 
26. Allegaert K, Simons SHP, Tibboel D, Krekels EH, Knibbe CA, van den Anker JN. Non-
maturational covariates for dynamic systems pharmacology models in neonates, infants, and 
children: Filling the gaps beyond developmental pharmacology. Eur J Pharm Sci. 
2017;109:S27-S31. 
27. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 
Developmental pharmacology--drug disposition, action, and therapy in infants and children. 
N Engl J Med. 2003;349(12):1157-67. 
28. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp 
Pharmacol. 2011;205:51-75. 
29. Mooij MG, Schwarz UI, de Koning BA, Leeder JS, Gaedigk R, Samsom JN, et al. Ontogeny 
of human hepatic and intestinal transporter gene expression during childhood: age matters. 
Drug Metab Dispos. 2014;42(8):1268-74. 
30. Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in 
the neonate. Seminars In Fetal & Neonatal Medicine. 2005;10(2):123-38. 
31. Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug 
Metab Toxicol. 2014;10(8):1069-78. 
32. Krekels EH, Tibboel D, Knibbe CA. Pediatric pharmacology: current efforts and future 
goals to improve clinical practice. Expert Opin Drug Metab Toxicol. 2015;11(11):1679-82. 
33. Wang C, Allegaert K, Tibboel D, Danhof M, van der Marel CD, Mathot RA, et al. 
Population pharmacokinetics of paracetamol across the human age-range from (pre)term 
neonates, infants, children to adults. J Clin Pharmacol. 2014;54(6):619-29. 
34. Baarslag MA, Allegaert K, Knibbe CA, van Dijk M, Tibboel D. Pharmacological sedation 
management in the paediatric intensive care unit. J Pharm Pharmacol. 2016;69(5):498-513. 
35. Krekels EH, van Ham S, Allegaert K, de Hoon J, Tibboel D, Danhof M, et al. 
Developmental changes rather than repeated administration drive paracetamol 
glucuronidation in neonates and infants. Eur J Clin Pharmacol. 2015;71(9):1075-82. 
36. Vet NJ, de Hoog M, Tibboel D, de Wildt SN. The effect of inflammation on drug 
metabolism: a focus on pediatrics. Drug Discov Today. 2011;16(9-10):435-42. 
37. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: 
general principles. Eur J Pediatr. 2006;165(11):741-6. 
38. Wildschut ED, de Wildt SN, Mathot RAA, Reiss IKM, Tibboel D, Van den Anker J. Effect 
of hypothermia and extracorporeal life support on drug disposition in neonates. Semin Fetal 
Neonatal Med. 2013;18(1):23-7. 
39. Zwiers AJ, de Wildt SN, Hop WC, Dorresteijn EM, Gischler SJ, Tibboel D, et al. Acute 
kidney injury is a frequent complication in critically ill neonates receiving extracorporeal 
membrane oxygenation: a 14-year cohort study. Crit Care. 2013;17(4):R151. 
40. Leeder JS, Kearns GL. Interpreting pharmacogenetic data in the developing neonate: 
the challenge of hitting a moving target. Clin Pharmacol Ther. 2012;92(4):434-6. 
41. Allegaert K, Van Den Anker JN, De Hoon JN, Van Schaik RHN, Debeer A, Tibboel D, et 
al. Covariates of tramadol disposition in the first months of life. Br J Anaesth. 2008;100(4):525-
32. 
42. Orliaguet G, Hamza J, Couloigner V, Denoyelle F, Loriot MA, Broly F, et al. A case of 
respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol. 
Pediatrics. 2015;135(3):e753-5. 
43. Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, et al. More codeine 
fatalities after tonsillectomy in North American children. Pediatrics. 2012;129(5):e1343-7. 
44. Roka A, Melinda KT, Vasarhelyi B, Machay T, Azzopardi D, Szabo M. Elevated morphine 
concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic 
ischemic encephalopathy. Pediatrics. 2008;121(4):e844-9. 
45. Harris J, Ramelet AS, van Dijk M, Pokorna P, Wielenga J, Tume L, et al. Clinical 
recommendations for pain, sedation, withdrawal and delirium assessment in critically ill 
infants and children: an ESPNIC position statement for healthcare professionals. Intensive 
Care Med. 2016;42(6):972-86. 
46. Knosgaard KR, Foster DJ, Kreilgaard M, Sverrisdottir E, Upton RN, van den Anker JN. 
Pharmacokinetic models of morphine and its metabolites in neonates:: Systematic 
comparisons of models from the literature, and development of a new meta-model. Eur J 
Pharm Sci. 2016;92:117-30. 
Chapter 2
48
47. Crellin DJ, Harrison D, Santamaria N, Babl FE. Systematic review of the Face, Legs, 
Activity, Cry and Consolability scale for assessing pain in infants and children: is it reliable, 
valid, and feasible for use? Pain. 2015;156(11):2132-51. 
48. Krechel SW, Bildner J. CRIES: a new neonatal postoperative pain measurement score. 
Initial testing of validity and reliability. Paediatr Anaesth. 1995;5(1):53-61. 
49. Matic M, Norman E, Rane A, Beck O, Andersson M, Elens L, et al. Effect of UGT2B7 -
900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results 
from a pilot cohort. Pharmacogenomics. 2014;15(12):1589-97. 
50. Matic M, Simons SH, van Lingen RA, van Rosmalen J, Elens L, de Wildt SN, et al. Rescue 
morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT 
genotype. Pharmacogenomics. 2014;15(10):1287-95. 
51. Meesters NJ, van Dijk M, Knibbe CA, Keyzer-Dekker CM, Tibboel D, Simons SH. Infants 
Operated on for Necrotizing Enterocolitis: Towards Evidence-Based Pain Guidelines. 
Neonatology. 2016;110(3):190-7. 
52. Shay JE, Kattail D, Morad A, Yaster M. The postoperative management of pain from 
intracranial surgery in pediatric neurosurgical patients. Paediatr Anaesth. 2014;24(7):724-33. 
53. Anand KJS, Hickey PR. Halothane–morphine compared with high-dose sufentanil for 
anesthesia and postoperative analgesia in neonatal cardiac surgery. New England Journal of 
Medicine. 1992. 
54. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. 
Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain 
Society, the American Society of Regional Anesthesia and Pain Medicine, and the American 
Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and 
Administrative Council. J Pain. 2016;17(2):131-57. 
55. Ceelie I, de Wildt SN, van Dijk M, van den Berg MMJ, van den Bosch GE, Duivenvoorden 
HJ, et al. Effect of Intravenous Paracetamol on Postoperative Morphine Requirements in 
Neonates and Infants Undergoing Major Noncardiac Surgery A Randomized Controlled Trial. 
Jama-Journal of the American Medical Association. 2013;309(2):149-54. 
56. Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E. Pediatric intravenous 
paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr Anaesth. 
2005;15(4):282-92. 
Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit
Ch
ap
te
r 
2
49
47. Crellin DJ, Harrison D, Santamaria N, Babl FE. Systematic review of the Face, Legs, 
Activity, Cry and Consolability scale for assessing pain in infants and children: is it reliable, 
valid, and feasible for use? Pain. 2015;156(11):2132-51. 
48. Krechel SW, Bildner J. CRIES: a new neonatal postoperative pain measurement score. 
Initial testing of validity and reliability. Paediatr Anaesth. 1995;5(1):53-61. 
49. Matic M, Norman E, Rane A, Beck O, Andersson M, Elens L, et al. Effect of UGT2B7 -
900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results 
from a pilot cohort. Pharmacogenomics. 2014;15(12):1589-97. 
50. Matic M, Simons SH, van Lingen RA, van Rosmalen J, Elens L, de Wildt SN, et al. Rescue 
morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT 
genotype. Pharmacogenomics. 2014;15(10):1287-95. 
51. Meesters NJ, van Dijk M, Knibbe CA, Keyzer-Dekker CM, Tibboel D, Simons SH. Infants 
Operated on for Necrotizing Enterocolitis: Towards Evidence-Based Pain Guidelines. 
Neonatology. 2016;110(3):190-7. 
52. Shay JE, Kattail D, Morad A, Yaster M. The postoperative management of pain from 
intracranial surgery in pediatric neurosurgical patients. Paediatr Anaesth. 2014;24(7):724-33. 
53. Anand KJS, Hickey PR. Halothane–morphine compared with high-dose sufentanil for 
anesthesia and postoperative analgesia in neonatal cardiac surgery. New England Journal of 
Medicine. 1992. 
54. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. 
Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain 
Society, the American Society of Regional Anesthesia and Pain Medicine, and the American 
Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and 
Administrative Council. J Pain. 2016;17(2):131-57. 
55. Ceelie I, de Wildt SN, van Dijk M, van den Berg MMJ, van den Bosch GE, Duivenvoorden 
HJ, et al. Effect of Intravenous Paracetamol on Postoperative Morphine Requirements in 
Neonates and Infants Undergoing Major Noncardiac Surgery A Randomized Controlled Trial. 
Jama-Journal of the American Medical Association. 2013;309(2):149-54. 
56. Anderson BJ, Pons G, Autret-Leca E, Allegaert K, Boccard E. Pediatric intravenous 
paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr Anaesth. 
2005;15(4):282-92. 
57. Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. 
Paediatr Drugs. 2010;12(5):313-29. 
58. Rollason V, Desmeules JA. Use of metamizole in children and the risk of 
agranulocytosis: Is the benefit worth the risk? Eur J Anaesthesiol. 2015;32(12):837-8. 
59. Schnabel A, Reichl SU, Meyer-Friessem C, Zahn PK, Pogatzki-Zahn E. Tramadol for 
postoperative pain treatment in children. Cochrane Database Syst Rev. 2015(3):CD009574. 
60. Schnabel A, Reichl SU, Zahn PK, Pogatzki-Zahn E. Nalbuphine for postoperative pain 
treatment in children. Cochrane Database Syst Rev. 2014(7):CD009583. 
61. Baley K, Michalov K, Kossick MA, McDowell M. Intravenous acetaminophen and 
intravenous ketorolac for management of pediatric surgical pain: a literature review. AANA J. 
2014;82(1):53-64. 
62. Monk JP, Beresford R, Ward A. Sufentanil. A review of its pharmacological properties 
and therapeutic use. Drugs. 1988;36(3):286-313. 
63. Lundeberg S, Roelofse JA. Aspects of pharmacokinetics and pharmacodynamics of 
sufentanil in pediatric practice. Paediatr Anaesth. 2011;21(3):274-9. 
64. Greeley WJ, de Bruijn NP. Changes in sufentanil pharmacokinetics within the neonatal 
period. Anesth Analg. 1988;67(1):86-90. 
65. Pokorna P, Wildschut ED, Vobruba V, van den Anker JN, Tibboel D. The Impact of 
Hypothermia on the Pharmacokinetics of Drugs Used in Neonates and Young Infants. Curr 
Pharm Des. 2015;21(39):5705-24. 
66. van den Broek MP, Groenendaal F, Egberts AC, Rademaker CM. Effects of hypothermia 
on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical 
studies. Clin Pharmacokinet. 2010;49(5):277-94. 
67. Meurs KV, Lally KP, Peek G, Zwischenberger JB. ECMO; Extracorporeal 
Cardiopulmonary Support in Critical Care. 3rd ed. Ann Arbor, MI EXTRACORPOREAL LIFE 
SUPPORT ORGANIZATION; 2005. 625 p. 
68. Mulla H, Lawson G, Woodland ED, Peek GJ, Killer H, Firmin RK, et al. Effects of neonatal 
extracorporeal membrane oxygenation circuits on drug disposition. Curr Ther Res Clin Exp. 
2000;61(11):838-48. 
69. Wildschut ED, van Saet A, Pokorna P, Ahsman MJ, Van den Anker JN, Tibboel D. The 
Impact of Extracorporeal Life Support and Hypothermia on Drug Disposition in Critically Ill 
Infants and Children. Pediatr Clin North Am. 2012;59(5):1184-204. 
Chapter 2
50
70. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients 
receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27(6):741.e9-.e18. 
71. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary Studies of the 
Effects of Extracorporeal Membrane-Oxygenator on the Disposition of Common Pediatric 
Drugs. Therapeutic Drug Monitoring. 1993;15(4):263-6. 
72. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D. Morphine metabolite 
pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. 
Clin Pharmacokinet. 2006;45(7):705-14. 
73. Association of Paediatric Anaesthetists of Great B, Ireland. Good practice in 
postoperative and procedural pain management, 2nd edition. Paediatr Anaesth. 2012;22 
Suppl 1:1-79. 
74. Lucas SS, Nasr VG, Ng AJ, Joe C, Bond M, DiNardo JA. Pediatric Cardiac Intensive Care 
Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care: Sedation, 
Analgesia and Muscle Relaxant. Pediatr Crit Care Med. 2016;17(3 Suppl 1):S3-S15. 
75. Dagan O, Klein J, Bohn D, Barker G, Koren G. Morphine pharmacokinetics in children 
following cardiac surgery: Effects of disease and inotropic support. J CARDIOTHORAC VASC 
ANESTH. 1993;7(4):396-8. 
76. Lynn A, Nespeca MK, Bratton SL, Strauss SG, Shen DD. Clearance of morphine in 
postoperative infants during intravenous infusion: The influence of age and surgery. Anesth 
Analg. 1998;86(5):958-63. 
77. Elkomy MH, Drover DR, Glotzbach KL, Galinkin JL, Frymoyer A, Su F, et al. 
Pharmacokinetics of Morphine and Its Metabolites in Infants and Young Children After 
Congenital Heart Surgery. AAPS J. 2016;18(1):124-33. 
78. van Saet A, de Wildt SN, Knibbe CA, Bogers AJ, Stolker RJ, Tibboel D. The effect of adult 
and pediatric cardiopulmonary bypass on pharmacokinetic and pharmacodynamic 
parameters. Curr Clin Pharmacol. 2013;8(4):297-318. 
79. Valkenburg AJ, Calvier EA, van Dijk M, Krekels EH, O'Hare BP, Casey WF, et al. 
Pharmacodynamics and Pharmacokinetics of Morphine After Cardiac Surgery in Children With 
and Without Down Syndrome. Pediatr Crit Care Med. 2016;17(10):930-8. 
80. Rigby-Jones AE, Priston MJ, Sneyd JR, McCabe AP, Davis GI, Tooley MA, et al. 
Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation 
after cardiac surgery. Br J Anaesth. 2007;99(2):252-61. 
Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit
Ch
ap
te
r 
2
51
70. Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients 
receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27(6):741.e9-.e18. 
71. Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary Studies of the 
Effects of Extracorporeal Membrane-Oxygenator on the Disposition of Common Pediatric 
Drugs. Therapeutic Drug Monitoring. 1993;15(4):263-6. 
72. Peters JW, Anderson BJ, Simons SH, Uges DR, Tibboel D. Morphine metabolite 
pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. 
Clin Pharmacokinet. 2006;45(7):705-14. 
73. Association of Paediatric Anaesthetists of Great B, Ireland. Good practice in 
postoperative and procedural pain management, 2nd edition. Paediatr Anaesth. 2012;22 
Suppl 1:1-79. 
74. Lucas SS, Nasr VG, Ng AJ, Joe C, Bond M, DiNardo JA. Pediatric Cardiac Intensive Care 
Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care: Sedation, 
Analgesia and Muscle Relaxant. Pediatr Crit Care Med. 2016;17(3 Suppl 1):S3-S15. 
75. Dagan O, Klein J, Bohn D, Barker G, Koren G. Morphine pharmacokinetics in children 
following cardiac surgery: Effects of disease and inotropic support. J CARDIOTHORAC VASC 
ANESTH. 1993;7(4):396-8. 
76. Lynn A, Nespeca MK, Bratton SL, Strauss SG, Shen DD. Clearance of morphine in 
postoperative infants during intravenous infusion: The influence of age and surgery. Anesth 
Analg. 1998;86(5):958-63. 
77. Elkomy MH, Drover DR, Glotzbach KL, Galinkin JL, Frymoyer A, Su F, et al. 
Pharmacokinetics of Morphine and Its Metabolites in Infants and Young Children After 
Congenital Heart Surgery. AAPS J. 2016;18(1):124-33. 
78. van Saet A, de Wildt SN, Knibbe CA, Bogers AJ, Stolker RJ, Tibboel D. The effect of adult 
and pediatric cardiopulmonary bypass on pharmacokinetic and pharmacodynamic 
parameters. Curr Clin Pharmacol. 2013;8(4):297-318. 
79. Valkenburg AJ, Calvier EA, van Dijk M, Krekels EH, O'Hare BP, Casey WF, et al. 
Pharmacodynamics and Pharmacokinetics of Morphine After Cardiac Surgery in Children With 
and Without Down Syndrome. Pediatr Crit Care Med. 2016;17(10):930-8. 
80. Rigby-Jones AE, Priston MJ, Sneyd JR, McCabe AP, Davis GI, Tooley MA, et al. 
Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation 
after cardiac surgery. Br J Anaesth. 2007;99(2):252-61. 
81. Sam WJ, Hammer GB, Drover DR. Population pharmacokinetics of remifentanil in 
infants and children undergoing cardiac surgery. BMC Anesthesiol. 2009;9(5). 
82. Kleiber N, de Wildt SN, Cortina G, Clifford M, Ducruet T, Tibboel D, et al. Clonidine as a 
First-Line Sedative Agent After Neonatal Cardiac Surgery: Retrospective Cohort Study. Pediatr 
Crit Care Med. 2016;17(4):332-41. 
83. Wolf A, McKay A, Spowart C, Granville H, Boland A, Petrou S, et al. Prospective 
multicentre randomised, double-blind, equivalence study comparing clonidine and midazolam 
as intravenous sedative agents in critically ill children: the SLEEPS (Safety profiLe, Efficacy and 
Equivalence in Paediatric intensive care Sedation) study. Health Technol Assess. 
2014;18(71):1-212. 
84. Potts AL, Larsson P, Eksborg S, Warman G, Lonnqvist PA, Anderson BJ. Clonidine 
disposition in children; a population analysis. Paediatr Anaesth. 2007;17(10):924-33. 
85. Su F, Gastonguay MR, Nicolson SC, DiLiberto M, Ocampo-Pelland A, Zuppa AF. 
Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery. Anesth 
Analg. 2016;122(5):1556-66. 
86. Hall RI. Cardiopulmonary bypass and the systemic inflammatory response: effects on 
drug action. J Cardiothorac Vasc Anesth. 2002;16(1):83-98. 
87. Ji B, Undar A. An evaluation of the benefits of pulsatile versus nonpulsatile perfusion 
during cardiopulmonary bypass procedures in pediatric and adult cardiac patients. ASAIO J. 
2006;52(4):357-61. 
88. Boehne M, Sasse M, Karch A, Dziuba F, Horke A, Kaussen T, et al. Systemic 
inflammatory response syndrome after pediatric congenital heart surgery: Incidence, risk 
factors, and clinical outcome. J Card Surg. 2017;32(2):116-25. 
89. Vet NJ, Brussee JM, de Hoog M, Mooij MG, Verlaat CW, Jerchel IS, et al. Inflammation 
and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. Am J Respir 
Crit Care Med. 2016. 
90. Hammaren E, Rosenberg PH, Hynynen M. Coating of extracorporeal circuit with 
heparin does not prevent sequestration of propofol in vitro. Br J Anaesth. 1999;82(1):38-40. 
91. Koren G, Crean P, Klein J. Sequestration of fentanyl by the cardiopulmonary bypass 
(CPBP). EUR J CLIN PHARMACOL. 1984;27(1):51-6. 
Chapter 2
52
92. Anand KJ, Willson DF, Berger J, Harrison R, Meert KL, Zimmerman J, et al. Tolerance 
and withdrawal from prolonged opioid use in critically ill children. Pediatrics. 
2010;125(5):e1208-25. 
93. Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation 
and analgesia of children in the pediatric intensive care unit. Crit Care Med. 2000;28(6):2122-
32. 
94. Vet NJ, de Wildt SN, Verlaat CW, Knibbe CA, Mooij MG, van Woensel JB, et al. A 
randomized controlled trial of daily sedation interruption in critically ill children. Intensive 
Care Med. 2016;42(2):233-44. 
95. Ince I, de Wildt SN, Tibboel D, Danhof M, Knibbe CA. Tailor-made drug treatment for 
children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug 
Discov Today. 2009;14(5-6):316-20. 
96. Aarons L, Ogungbenro K. Optimal design of pharmacokinetic studies. Basic Clin 
Pharmacol Toxicol. 2010;106(3):250-5. 
97. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of 
population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67 Suppl 
1:5-16. 
98. Mahmood I. Prediction of Drug Clearance in Premature and Mature Neonates, Infants, 
and Children </=2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric 
Models. J Clin Pharmacol. 2016;56(6):733-9. 
99. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to 
predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25-36. 
100. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NHG. Developmental 
pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br 
J Anaesth. 2004;92(2):208-17. 
101. Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B, et al. Morphine 
pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results 
from the NEOPAIN trial. Br J Anaesth. 2008;101(5):680-9. 
102. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, et al. 
Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. 
Clin Pharmacokinet. 2009;48(6):371-85. 
Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit
Ch
ap
te
r 
2
53
92. Anand KJ, Willson DF, Berger J, Harrison R, Meert KL, Zimmerman J, et al. Tolerance 
and withdrawal from prolonged opioid use in critically ill children. Pediatrics. 
2010;125(5):e1208-25. 
93. Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation 
and analgesia of children in the pediatric intensive care unit. Crit Care Med. 2000;28(6):2122-
32. 
94. Vet NJ, de Wildt SN, Verlaat CW, Knibbe CA, Mooij MG, van Woensel JB, et al. A 
randomized controlled trial of daily sedation interruption in critically ill children. Intensive 
Care Med. 2016;42(2):233-44. 
95. Ince I, de Wildt SN, Tibboel D, Danhof M, Knibbe CA. Tailor-made drug treatment for 
children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug 
Discov Today. 2009;14(5-6):316-20. 
96. Aarons L, Ogungbenro K. Optimal design of pharmacokinetic studies. Basic Clin 
Pharmacol Toxicol. 2010;106(3):250-5. 
97. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of 
population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67 Suppl 
1:5-16. 
98. Mahmood I. Prediction of Drug Clearance in Premature and Mature Neonates, Infants, 
and Children </=2 Years of Age: A Comparison of the Predictive Performance of 4 Allometric 
Models. J Clin Pharmacol. 2016;56(6):733-9. 
99. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to 
predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25-36. 
100. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NHG. Developmental 
pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br 
J Anaesth. 2004;92(2):208-17. 
101. Anand KJ, Anderson BJ, Holford NH, Hall RW, Young T, Shephard B, et al. Morphine 
pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results 
from the NEOPAIN trial. Br J Anaesth. 2008;101(5):680-9. 
102. Knibbe CA, Krekels EH, van den Anker JN, DeJongh J, Santen GW, van Dijk M, et al. 
Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. 
Clin Pharmacokinet. 2009;48(6):371-85. 
103. Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of 
the descriptive and predictive performance of paediatric morphine population models. Pharm 
Res. 2011;28(4):797-811. 
104. Mian P KC, Tibboel D, Allegaert K. . What dose of paracetamol is needed in neonates 
with pain? Arch of Dis in Childh 2017;in press. 
105. Standing JF, Howard RF, Johnson A, Savage I, Wong IC. Population pharmacokinetics of 
oral diclofenac for acute pain in children. Br J Clin Pharmacol. 2008;66(6):846-53. 
106. van der Marel CD, Anderson BJ, Romsing J, Jacqz-Aigrain E, Tibboel D. Diclofenac and 
metabolite pharmacokinetics in children. Paediatr Anaesth. 2004;14(6):443-51. 
107. Bressolle F, Khier S, Rochette A, Kinowski JM, Dadure C, Capdevila X. Population 
pharmacokinetics of nalbuphine after surgery in children. Br J Anaesth. 2011;106(4):558-65. 
108. Mohammed BS, Engelhardt T, Hawwa AF, Cameron GA, McLay JS. The enantioselective 
population pharmacokinetics of intravenous ketorolac in children using a stereoselective 
assay suitable for microanalysis. J Pharm Pharmacol. 2015;67(9):1179-87. 
109. De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, et al. 
Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin 
clearance from neonates to adults: towards a semi-physiological function for maturation in 
glomerular filtration. Pharm Res. 2014;31(10):2643-54. 
110. Mooij MG, de Koning BA, Huijsman ML, de Wildt SN. Ontogeny of oral drug absorption 
processes in children. Expert Opin Drug Metab Toxicol. 2012;8(10):1293-303. 
111. Mooij MG, van Duijn E, Knibbe CA, Allegaert K, Windhorst AD, van Rosmalen J, et al. 
Successful Use of [14C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug 
Metabolism. Clin Pharmacokinet. 2017. 
112. Davis PJ, Cook DR, Stiller RL, Davin-Robinson KA. Pharmacodynamics and 
pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. 
ANESTH ANALG. 1987;66(3):203-8. 
113. Valitalo PA, van Dijk M, Krekels EH, Gibbins S, Simons SH, Tibboel D, et al. Pain and 
distress caused by endotracheal suctioning in neonates is better quantified by behavioural 
than physiological items: A comparison based on Item Response Theory modelling. Pain. 
2016;157(8):1611-7. 
  

Journal of  Cardiothoracic Surgery, 2018 jun 8;13(1):64 
Gerdien A. Zeilmaker-Roest | Annewil van Saet | Joost van Rosmalen  
Soma Bahmany | Antony van Dijk | Enno D. Wildschut | Dick Tibboel  
Ad J.J.C. Bogers 
Potentially clinically relevant 
concentrations of  cefazolin, 
midazolam, propofol, and sufentanil 
in auto-transfused blood in congenital 
cardiac surgery 
Chapter 3
Chapter 3
56
Abstract 
Background: use of donor blood in congenital cardiac surgery increases the risk for 
postoperative morbidity and mortality. To reduce the need for allogenic blood transfusion a 
technique for peri-operative mechanical red cell salvage is applied. Blood from the operation 
site is collected in a reservoir, processed, passed through a lipophilic filter and returned to the 
patient. Influence of this cell saver system on coagulation, fibrinolysis and inflammatory 
markers is known. To our knowledge no studies have been performed on the effects of 
autotransfusion on drug concentrations. A clinically relevant drug dose could potentially be 
returned to the patient through the auto-transfused blood, leading to unwanted drug 
reactions postoperatively. We aimed to measure drug concentrations in blood salvaged from 
the operation site and in the auto-transfused blood to determine if a clinically relevant drug 
dose is returned to the patient.  
Methods: The study was performed at the Department of Cardiothoracic Surgery of a tertiary 
university hospital. Blood samples were taken from the reservoir, after processing before the 
lipophilic filter, the auto-transfused blood, and the waste fluid. Samples were stored at -80 
Celsius and drug concentration for sufentanil, propofol, midazolam and cefazolin were 
measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Drug 
concentrations measured in the reservoir and the auto-transfused blood were compared and 
the relative reduction was calculated for each patient.  
Results: Blood samples were taken from 18 cell saver runs in 18 patients, age 0-13 years. Drug 
concentrations in the reservoir were comparable to concomitant concentrations in the 
patient. For sufentanil 34% (median, IQR 27-50) of drug concentration was retained from the 
reservoir in the auto-transfused blood, for midazolam 6% (median, IQR 4-10), for cefazolin 5% 
(median, IQR 2-6) and for propofol 0% (median, IQR 0-0) respectively.  
Conclusion: Depending on the drug, up to 34% of the drug concentration salvaged from the 
operation site is returned to the patient through autotransfusion, potentially causing 
unwanted drug reactions postoperatively. Additionally, influence of a cell saver system should 
be considered in pharmacological research during and after congenital cardiac surgery and 
could result in dose adjustments in the postoperative phase.  
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Abstract 
Background: use of donor blood in congenital cardiac surgery increases the risk for 
postoperative morbidity and mortality. To reduce the need for allogenic blood transfusion a 
technique for peri-operative mechanical red cell salvage is applied. Blood from the operation 
site is collected in a reservoir, processed, passed through a lipophilic filter and returned to the 
patient. Influence of this cell saver system on coagulation, fibrinolysis and inflammatory 
markers is known. To our knowledge no studies have been performed on the effects of 
autotransfusion on drug concentrations. A clinically relevant drug dose could potentially be 
returned to the patient through the auto-transfused blood, leading to unwanted drug 
reactions postoperatively. We aimed to measure drug concentrations in blood salvaged from 
the operation site and in the auto-transfused blood to determine if a clinically relevant drug 
dose is returned to the patient.  
Methods: The study was performed at the Department of Cardiothoracic Surgery of a tertiary 
university hospital. Blood samples were taken from the reservoir, after processing before the 
lipophilic filter, the auto-transfused blood, and the waste fluid. Samples were stored at -80 
Celsius and drug concentration for sufentanil, propofol, midazolam and cefazolin were 
measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Drug 
concentrations measured in the reservoir and the auto-transfused blood were compared and 
the relative reduction was calculated for each patient.  
Results: Blood samples were taken from 18 cell saver runs in 18 patients, age 0-13 years. Drug 
concentrations in the reservoir were comparable to concomitant concentrations in the 
patient. For sufentanil 34% (median, IQR 27-50) of drug concentration was retained from the 
reservoir in the auto-transfused blood, for midazolam 6% (median, IQR 4-10), for cefazolin 5% 
(median, IQR 2-6) and for propofol 0% (median, IQR 0-0) respectively.  
Conclusion: Depending on the drug, up to 34% of the drug concentration salvaged from the 
operation site is returned to the patient through autotransfusion, potentially causing 
unwanted drug reactions postoperatively. Additionally, influence of a cell saver system should 
be considered in pharmacological research during and after congenital cardiac surgery and 
could result in dose adjustments in the postoperative phase.  
Background 
Allogenic donor blood is used in almost all small patients undergoing congenital cardiac 
surgery. This is mainly due to hemodilution caused by the use of cardiopulmonary bypass 
(CPB). The technique of mechanical red cell salvage is applied during congenital cardiac 
surgery. Equipment designed to undertake this task is routinely referred to as an 
autotransfusion or cell saver system. Using the cell saver system blood from the operation site 
is collected in a reservoir, processed, passed through a lipophilic filter after which it is returned 
to the patient. The use of donor blood during surgery increases postoperative morbidity, 
mainly infections (1). The cell saver system is used to reduce the need for allogenic blood 
transfusion and may therefore improve the outcome after surgery. The auto-transfused blood 
is usually returned to the patient postoperatively on the paediatric intensive care unit (PICU).  
Influence of this cell saver system on coagulation, fibrinolysis and inflammatory markers is 
known (2, 3). In contrast, published literature on the effects of blood loss, volume replacement 
and use of a cell saver system on plasma drug concentration is limited. Sue et al. investigated 
the effect of surgical blood loss and fluid replacement on antibiotic pharmacokinetics in adult 
patients during cardiac surgery and determined the total cefazolin plasma concentration at 
several time points (4). In their study a cell saver system was used in six of eight patients. 
Reinfusion of cefazolin-containing blood did not appear to substantially effect postoperative 
plasma cefazolin concentration in this study. However, cell saver use was not specified per 
patient and fluid management during surgery will have changed since 1989. The authors state 
that major pharmacological effects may occur through infusion of auto-transfused blood in 
drugs that are highly protein bound or hydrophilic. Rohling et al. showed that plasma 
concentration of muscle relaxants were stable in autologous blood that was predonated after 
induction of anaesthesia and returned by the end of surgery without processing with a cell 
saver system. Recurarization occurred in two out of 18 studied patients (5).  
To our knowledge, drug concentration in auto-transfused blood and influence of a cell saver 
system on plasma drug concentrations has not been investigated in infants and children. 
However, based on published literature, highly protein bound or hydrophilic drugs could 
persist in the auto-transfused blood. In our clinic, propofol, midazolam, sufentanil and 
cefazolin are routinely used anaesthetic agents that fit this risk profile. Our hypothesis was 
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that potentially relevant drug doses of propofol, midazolam, sufentanil and cefazolin could be 
returned to the patient through the auto-transfused blood. This influence could be important, 
because it may lead to unwanted drug reactions postoperatively.  
We aimed to measure drug concentrations in blood salvaged from the operation site and in 
the blood processed by a cell saver system during congenital cardiac surgery to determine if a 
clinically relevant drug dose is returned to the patient.  
Methods 
The study was performed at the Department of Cardiothoracic Surgery of a tertiary university 
hospital. Induction and maintenance of anaesthesia was performed by the attending 
anaesthesiologist as per local protocol. Either inhalation induction was performed with 
sevoflurane, or intravenous induction with midazolam or propofol, sufentanil and 
pancuronium. Maintenance of anaesthesia was performed with continuous infusions of 
sufentanil, midazolam or propofol. Cefazolin was administered before, during and after the 
surgical procedure. CPB technique was dependent on patient weight and operation 
procedure, and will be described extensively in the CPB-PHARM study publications. No patient 
underwent deep hypothermia or circulatory arrest during the procedure. We used an Electa 
cell saver system (Livanova, München, Germany), with a 55 ml processing bowl. Cell saver 
processing was done as per local protocol, according to manufacturer’s settings. Blood from 
the operation site was mixed in the suction tubes with heparinized normal saline to prevent 
clotting in the tubes. Washing of the cell saver blood was done with NaCl 0.9%. After 
processing, the cell saver blood was filtered with a Pall Lipiguard blood filter (Haemonetics 
S.A., Signy, Switzerland), resulting in the end product, the auto-transfused blood. All residual 
blood volume from the CPB system was also directly transferred to and processed by the cell 
saver system after decannulation. The auto-transfused blood is composed according to the 
standard of the manufacturer, with 55-60% erythrocytes in NaCl 0.9%.  
Blood samples were taken from the reservoir, after processing of salvaged blood before the 
lipophilic filter, the auto-transfused blood, and from the waste fluid. Samples were collected 
at the end of surgery. If there was a need to run the cell saver system both during and after 
surgery, samples were taken after the first run for best comparison. Samples were stored at 
4o Celsius until processing. Samples were centrifuged (10 min at 3600 rpm) and the plasma 
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that potentially relevant drug doses of propofol, midazolam, sufentanil and cefazolin could be 
returned to the patient through the auto-transfused blood. This influence could be important, 
because it may lead to unwanted drug reactions postoperatively.  
We aimed to measure drug concentrations in blood salvaged from the operation site and in 
the blood processed by a cell saver system during congenital cardiac surgery to determine if a 
clinically relevant drug dose is returned to the patient.  
Methods 
The study was performed at the Department of Cardiothoracic Surgery of a tertiary university 
hospital. Induction and maintenance of anaesthesia was performed by the attending 
anaesthesiologist as per local protocol. Either inhalation induction was performed with 
sevoflurane, or intravenous induction with midazolam or propofol, sufentanil and 
pancuronium. Maintenance of anaesthesia was performed with continuous infusions of 
sufentanil, midazolam or propofol. Cefazolin was administered before, during and after the 
surgical procedure. CPB technique was dependent on patient weight and operation 
procedure, and will be described extensively in the CPB-PHARM study publications. No patient 
underwent deep hypothermia or circulatory arrest during the procedure. We used an Electa 
cell saver system (Livanova, München, Germany), with a 55 ml processing bowl. Cell saver 
processing was done as per local protocol, according to manufacturer’s settings. Blood from 
the operation site was mixed in the suction tubes with heparinized normal saline to prevent 
clotting in the tubes. Washing of the cell saver blood was done with NaCl 0.9%. After 
processing, the cell saver blood was filtered with a Pall Lipiguard blood filter (Haemonetics 
S.A., Signy, Switzerland), resulting in the end product, the auto-transfused blood. All residual 
blood volume from the CPB system was also directly transferred to and processed by the cell 
saver system after decannulation. The auto-transfused blood is composed according to the 
standard of the manufacturer, with 55-60% erythrocytes in NaCl 0.9%.  
Blood samples were taken from the reservoir, after processing of salvaged blood before the 
lipophilic filter, the auto-transfused blood, and from the waste fluid. Samples were collected 
at the end of surgery. If there was a need to run the cell saver system both during and after 
surgery, samples were taken after the first run for best comparison. Samples were stored at 
4o Celsius until processing. Samples were centrifuged (10 min at 3600 rpm) and the plasma 
transferred to polypropylene cryogenic vials with polypropylene screw caps (Sarstedt 
Aktiengesellschaft & Co, Nümbrecht, Germany). Samples were stored at -80o Celsius until 
analysis.  
Drug concentration were measured at the pharmacological laboratories of the Erasmus MC. 
A certified research technician from the ISO certified pharmacy laboratory performed the FDA 
validated drug analyses. In all analyses quality control samples are included, as is obliged in 
FDA analyses and ISO and GCP certified laboratory. Drug concentrations for propofol 
(Fresenius Kabi Nederland BV, Zeist, the Netherlands), midazolam and midazolam metabolites 
(Actavis Group PTC ehf., Hafnarfjördur, Iceland) were measured using LC-MS/MS (Waters 
Corp., Milford, MA, USA). Drug concentration for sufentanil (Hameln Pharma Plus GmbH, 
Hameln, Germany) and cefazolin (Kefzol®, Eurocept BV, Ankeveen, the Netherlands) were 
measured using LC-MS/MS (Thermo Fisher Scientific, Waltham, MA, USA). 
Lower and upper limits of quantification (LLOQ and ULOQ, respectively) were: sufentanil, 
LLOQ 0.25 mcg/L, ULOQ 50 mcg/L; propofol LLOQ 100 mcg /L, ULOQ 25000 mcg /L; midazolam 
LLOQ 2 mcg/L, ULOQ 2400 mcg/L; OH-midazolam LLOQ 3 mcg/L, ULOQ 2300 mcg/L, 
midazolam glucuronide LLOQ 10 mcg/L, ULOQ 3000 mcg/L; cefazolin LLOQ 1 mg/L, ULOQ 100 
mg/L. Drug concentrations for propofol were not measurable after auto-transfusion and were 
treated as zero in the analysis. 
Samples size calculation 
The sample size was set at 18 patients. Due to a lack of published literature on this subject, a 
formal sample size calculation or power analysis was not considered feasible. The chosen 
sample size of 18 patients should be sufficient to estimate the median and the variability of 
the drug concentrations with reasonable precision.  
Statistical analysis 
The ratio between drug concentrations measured in the reservoir and drug concentrations 
measured in the auto-transfused blood was calculated for each patient. The distributions of 
the drug concentrations in the reservoir and in the auto-transfused blood and their ratios were 
summarized with the median and the interquartile range (IQR) per drug, to give an indication 
of the percentage of the drug concentration remains in the auto-transfused blood. The 
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correlation between the absolute drug concentrations measured in the reservoir and 
concentrations in the auto-transfused blood were calculated using Spearman’s rank 
correlation coefficients. Drug concentrations did not follow a normal distribution and were 
log(10) transformed in order to calculate the relative reduction. Relative reduction per drug 
was calculated by subtracting the log(10) transformed concentration in the auto-transfused 
blood from the log(10) transformed concentration in the reservoir. The relative reduction per 
drug is plotted against the reservoir concentration to predict the relative reduction per 
starting concentration in figures 3a-d, together with a linear regression line. The R2 was used 
to show the predictive value of the drug concentration in the auto-transfused blood based on 
the starting concentration in the reservoir, with a R2 of 0 representing no correlation and a R2 
of 1 representing a perfect correlation. The reported R2 and the 95% confidence interval (CI) 
in figures 3a-d are based on the linear regression of the log(10) transformed relative 
reductions on the log(10) transformed concentrations in the reservoir.  
This study was a part of the CPB-PHARM study, investigating pharmacokinetics (PK) and 
pharmacodynamics (PD) of routinely used drugs in neonates and children during cardiac 
surgery with the use of cardiopulmonary bypass (approved by IRB Erasmus MC, protocol 
number 2011-400, Dutch Trial Registry NTR3579). Informed consent was obtained for all study 
participants according to Dutch law. 
Results 
Blood samples were taken from 18 cell saver runs in 18 paediatric patients. CPB was used in 
all surgical procedures. Patient characteristics are shown in Table 1. As shown in Table 1, the 
cell saver volume processed postoperatively is larger than the total blood loss during surgery 
because of addition of the residual volume of the CPB. The amount of washing fluid used is 
mainly dependent on the processed cell saver volume. Not all patients received all tested 
drugs (see Table 2). 
Patient drug concentrations for sufentanil, cefazolin, midazolam and propofol were measured 
for the CPB-PHARM study (MEC2011-400). This study investigates the influence of the 
cardiopulmonary bypass on the PK and PD of routinely used drugs during and after congenital 
cardiac surgery. Patient drug samples taken from the arterial catheter during surgery were 
compared to drug concentrations measured in the reservoir. Drug concentrations measured 
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correlation between the absolute drug concentrations measured in the reservoir and 
concentrations in the auto-transfused blood were calculated using Spearman’s rank 
correlation coefficients. Drug concentrations did not follow a normal distribution and were 
log(10) transformed in order to calculate the relative reduction. Relative reduction per drug 
was calculated by subtracting the log(10) transformed concentration in the auto-transfused 
blood from the log(10) transformed concentration in the reservoir. The relative reduction per 
drug is plotted against the reservoir concentration to predict the relative reduction per 
starting concentration in figures 3a-d, together with a linear regression line. The R2 was used 
to show the predictive value of the drug concentration in the auto-transfused blood based on 
the starting concentration in the reservoir, with a R2 of 0 representing no correlation and a R2 
of 1 representing a perfect correlation. The reported R2 and the 95% confidence interval (CI) 
in figures 3a-d are based on the linear regression of the log(10) transformed relative 
reductions on the log(10) transformed concentrations in the reservoir.  
This study was a part of the CPB-PHARM study, investigating pharmacokinetics (PK) and 
pharmacodynamics (PD) of routinely used drugs in neonates and children during cardiac 
surgery with the use of cardiopulmonary bypass (approved by IRB Erasmus MC, protocol 
number 2011-400, Dutch Trial Registry NTR3579). Informed consent was obtained for all study 
participants according to Dutch law. 
Results 
Blood samples were taken from 18 cell saver runs in 18 paediatric patients. CPB was used in 
all surgical procedures. Patient characteristics are shown in Table 1. As shown in Table 1, the 
cell saver volume processed postoperatively is larger than the total blood loss during surgery 
because of addition of the residual volume of the CPB. The amount of washing fluid used is 
mainly dependent on the processed cell saver volume. Not all patients received all tested 
drugs (see Table 2). 
Patient drug concentrations for sufentanil, cefazolin, midazolam and propofol were measured 
for the CPB-PHARM study (MEC2011-400). This study investigates the influence of the 
cardiopulmonary bypass on the PK and PD of routinely used drugs during and after congenital 
cardiac surgery. Patient drug samples taken from the arterial catheter during surgery were 
compared to drug concentrations measured in the reservoir. Drug concentrations measured 
in the reservoir of the cell saver system before processing were comparable to concomitant 
concentrations in the patient, as was expected, and are thus clinically relevant doses. Drug 
levels for the different drugs and compartments are shown in Table 2. For all drugs, the 
decrease in drug concentration was largest after washing of the cell saver blood. The effect of 
the lipophilic filter further decreased drug concentrations in all drugs except sufentanil. 
Considerable concentrations of all drugs were measured in the waste fluid.  
Table 1: Patient characteristics  
Characteristic N (mean, minimum – maximum) 
Age   2 y 6 months (2 months -13 y 11 months ) 
Female /male 10 / 8 
Surgical procedure 
Correction ASD type 2 
TCPC 
Correction TOF 
Correction CAVSD 
Miscellaneous  
 
6 
3 
3 
2 
4 
Total peroperative blood loss (ml/kg) 12.6 (1.6 – 62.7) 
Cell saver volume processed (ml) 290 (135-910) 
Cell saver product after processing (ml/kg) 12 (3.9 – 26) 
Washing fluid used (ml) 783 (300-1200) 
Kg: kilogram, ml: millilitre, y: years. Surgical abbreviations: ASD: Atrial Septal Defect, TOF: 
Tetralogy of Fallot, TCPC: Total Cavopulmonary Connection, CAVSD: Complete Atrioventricular 
Septal Defect. Miscellaneous: correction Partial Abnormal Pulmonary Venous Return (1), 
Chauvaud procedure (1), Mitral Valve Replacement (1), Correction Subaortic Stenosis (1).  
 
Median sufentanil concentration in the reservoir was 0.27 mcg/L (IQR 0.18-0.35). Median 
sufentanil concentration in the auto-transfused blood was 0.10 mcg/L (IQR 0.09-0.10). 
Therefore 34% (median, IQR 27-50) of drug concentration was retained from the reservoir in 
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the auto-transfused blood. Detailed concentrations per sample site and percentage recovery 
are shown in Table 2 and Figure 1. 
Median midazolam concentrations in the reservoir and the auto-transfused blood were 
192.69 mcg/L (IQR 49.06-316.42) and 11.87 mcg/L (IQR 7.16-20.16) (6%, median IQR 4-10) 
respectively. Details of midazolam recovery are shown in Table 2. Biologically active 
midazolam metabolites, 1-hydroxy-midazolam and midazolam glucuronide, were also 
measured. Recovery of 1-hydroxy-midazolam and midazolam glucuronide was 11% (median, 
IQR 7-29) and 6 % (median, IQR 4-8) respectively. Details of 1-hydroxymidazolam and 
midazolam glucuronide recovery are shown in Table 2 and Figure 1.  
Median cefazolin concentration in the reservoir and the auto-transfused blood was 228.44 
mg/L (IQR 118.47-295.85) and 8.7 mg/L (IQR 5.13-11.44) (5%, median, IQR 2-6) respectively. 
Detailed concentrations per sample site and percentage recovery are shown in Table 2 and 
Figure 1. 
Median propofol concentration in the reservoir and in the waste fluid was 0.65 mg/L (IQR 
0.21-1.86) and 0.18 mg/L (IQR 0.11-0.25) respectively. Propofol concentration could not be 
measured after processing and in the auto-transfused blood. Detailed concentrations per 
sample site and percentage recovery are shown in Table 2 and Figure 1.  
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the auto-transfused blood. Detailed concentrations per sample site and percentage recovery 
are shown in Table 2 and Figure 1. 
Median midazolam concentrations in the reservoir and the auto-transfused blood were 
192.69 mcg/L (IQR 49.06-316.42) and 11.87 mcg/L (IQR 7.16-20.16) (6%, median IQR 4-10) 
respectively. Details of midazolam recovery are shown in Table 2. Biologically active 
midazolam metabolites, 1-hydroxy-midazolam and midazolam glucuronide, were also 
measured. Recovery of 1-hydroxy-midazolam and midazolam glucuronide was 11% (median, 
IQR 7-29) and 6 % (median, IQR 4-8) respectively. Details of 1-hydroxymidazolam and 
midazolam glucuronide recovery are shown in Table 2 and Figure 1.  
Median cefazolin concentration in the reservoir and the auto-transfused blood was 228.44 
mg/L (IQR 118.47-295.85) and 8.7 mg/L (IQR 5.13-11.44) (5%, median, IQR 2-6) respectively. 
Detailed concentrations per sample site and percentage recovery are shown in Table 2 and 
Figure 1. 
Median propofol concentration in the reservoir and in the waste fluid was 0.65 mg/L (IQR 
0.21-1.86) and 0.18 mg/L (IQR 0.11-0.25) respectively. Propofol concentration could not be 
measured after processing and in the auto-transfused blood. Detailed concentrations per 
sample site and percentage recovery are shown in Table 2 and Figure 1.  
 
 
 
 
 
 
 
 
 
Table 2: Drug concentration per sample site. 
Drug  Patients 
(n) 
Concentration (median, IQR) Ratio reservoir 
vs 
autotransfused 
blood in % 
(median, IQR) 
Reservoir  After 
processing, 
before 
filter 
Auto-
transfused 
blood 
Waste 
fluid 
Sufentanil 
(mcg/L) 
18 0.27 
(0.18-
0.35) 
0.10 (0.09-
0.12) 
0.10 (0.09-
0.10) 
0.13 
(0.10-
0.16) 
34 (27-50) 
Midazolam 
(mcg/L) 
18 192.69 
(49.06-
316.42) 
18.68 
(4.91-
29.88) 
11.87(7.16-
20.16) 
56.48 
(17.25-
75.18) 
6 (4-10) 
1-hydroxy-
midazolam 
(mcg/L) 
18 36.56 
(9.45-
62.74) 
6.23 (4.39-
11.52) 
4.67 (3.82-
5.95) 
3.51 
(2.72-
3.84) 
11 (7-29) 
Midazolam 
glucuronide 
(mcg/L) 
18 348.21 
(236.63-
592.21) 
36.41 
(15.83-
57.13) 
29.22 
(21.40-
41.82) 
114.07 
(75.33-
189.71) 
6 (4-8) 
Cefazolin 
(mg/L) 
18 228.44 
(118.47-
295.85) 
10.50 
(6.63-
17.47) 
8.70 (5.13-
11.44) 
59.34 
(40.68-
77.80) 
5 (2-6) 
Propofol 
(mg/L) 
6 0.65 
(0.21-
1.86) 
0 (0-0)* 0 (0-0)* 0.18 
(0.25-
0.11) 
0 (0-0) 
IQR: interquartile range, L: liter, Mcg: microgram, mg: milligram, n.a.: not applicable *Drug 
concentrations for propofol were not measurable after autotransfusion and were treated as 
zero in the analysis. 
Chapter 3
64
Figure 1: drug recovery per sample site (%). Drug concentration in the reservoir is set as 100%. 
 
The correlations between drug concentrations measured in the reservoir and concentrations 
in the auto-transfused blood are shown in figures 2a-e. The relative reduction per drug is 
plotted against the reservoir concentration to predict the relative reduction per starting 
concentration in figures 3a-e.  
Figure 2a-e: correlation of drug concentration in the reservoir and the auto-transfused blood. 
(a Sufentanil, b) cefazolin, c) midazolam, d) 1-hydroxy midazolam, e) midazolam glucuronide. 
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Figure 1: drug recovery per sample site (%). Drug concentration in the reservoir is set as 100%. 
 
The correlations between drug concentrations measured in the reservoir and concentrations 
in the auto-transfused blood are shown in figures 2a-e. The relative reduction per drug is 
plotted against the reservoir concentration to predict the relative reduction per starting 
concentration in figures 3a-e.  
Figure 2a-e: correlation of drug concentration in the reservoir and the auto-transfused blood. 
(a Sufentanil, b) cefazolin, c) midazolam, d) 1-hydroxy midazolam, e) midazolam glucuronide. 
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Figure 3a-e: relative reduction predicted by concentration in reservoir (with dotted line 95% 
CI). a) sufentanil, b) cefazolin, c) midazolam, d) 1-hydroxy midazolam, e) midazolam 
glucuronide. 
 
Chapter 3
68
 
 
 
 
 
Potentially clinically relevant concentrations in auto-transfused blood in congenital cardiac surgery
Ch
ap
te
r 
3
69
 
 
 
 
 
 
Discussion 
To our knowledge this is the first study to measure drug concentrations in auto-transfused 
blood after paediatric cardiac surgery. Drug recovery varies between drugs in the auto-
transfused blood and not all drugs are found in clinically relevant concentrations. For 
sufentanil 34% (IQR 27-50) of drug concentration was retained from the reservoir in the auto-
transfused blood, for midazolam 6% (IQR 4-10), for cefazolin 5% (IQR 2-6) and for propofol 0% 
(IQR 0-0), respectively. For midazolam mainly the 1-hydroxy-midazolam metabolite was 
recovered in the auto-transfused blood. 1-hydroxy-midazolam is at least as active as 
midazolam and may contribute to the overall activity of midazolam (6). The potential influence 
of the return of auto-transfused blood processed in a cell saver system on plasma drug 
concentration in infants and children has not previously been investigated. 
Based on the literature by Sue et al (4) and our own experience with extra corporeal 
membrane oxygenation (ECMO) circuit characteristics (7), the expectation was that lipophilic 
drugs would be sequestered in the synthetic components of the cell saver system and the 
lipophilic filter and thus be prevented from returning in the auto-transfused blood whereas 
more hydrophilic drugs could be retained in the auto-transfused blood.  
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Any lipophilic compounds that are left in the auto-transfused blood after washing should be 
removed by the lipophilic filter. According to the manufacturer proteins and lipids should be 
completely washed from the end product so that it contains only erythrocytes and NaCl 0.9%. 
We have shown that washing of the cell saver blood is the most effective step in clearing drugs 
from the auto-transfused blood. However both protein bound as well as lipophilic drugs were 
recovered in the end product. Interestingly sufentanil concentrations were markedly higher 
compared to the other lipophilic drugs. Drug characteristics of sufentanil, propofol and 
midazolam regarding protein binding and lipophilicity are fairly similar. With a logP of 3.95, 
sufentanil is highly lipophilic, with 93% protein binding, mainly to albumin. Propofol and 
midazolam are also both highly lipophilic with logP’s of 3.79 and 3.89 respectively, with a 
slightly higher protein binding than sufentanil, of 95-99% and 97% respectively. Therefore 
lipophilicity or protein binding do not seem to predict drug concentrations in the auto-
transfused blood.  
Redistribution of lipophilic drugs from erythrocytes into the auto-transfused blood could 
explain why lipophilic drugs are recovered. Redistribution may occur because of a shift of 
drugs from the erythrocyte to the NaCl 0.9% solution, or because of haemolysis of the 
erythrocyte. Also, measuring propofol by the precipitation method instead of LC-MS/MS may 
have resulted in measurable propofol concentrations after processing. Overall, the recovered 
absolute drug concentrations of the tested drugs where low. Therefore the absolute 
differences in plasma drug concentration in the patient and drug concentration in the auto-
transfused blood may not be substantial. 
The hydrophilic drug, cefazolin, was almost entirety washed from the auto-transfused blood. 
With a logP of -0.58 cefazolin was the most water-soluble drug we have measured. Our results 
are probably explained by the washing of the cell saver blood with NaCl 0.9%. It is likely that 
cefazolin dissolved in the NaCl 0.9% solution and was washed from the auto-transfused blood, 
even though cefazolin concentrations in the waste fluid were low.  
Unwanted drug reactions due to auto-transfused blood may not be clinically relevant in all 
patients. Most at risk for clinical effects are small patients who have had major cardiac surgery 
with the use of CPB, where the volume of returned cell saver blood is relatively large compared 
to the patient’s own circulating volume. Also, due to long CPB time, organ perfusion will be 
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Any lipophilic compounds that are left in the auto-transfused blood after washing should be 
removed by the lipophilic filter. According to the manufacturer proteins and lipids should be 
completely washed from the end product so that it contains only erythrocytes and NaCl 0.9%. 
We have shown that washing of the cell saver blood is the most effective step in clearing drugs 
from the auto-transfused blood. However both protein bound as well as lipophilic drugs were 
recovered in the end product. Interestingly sufentanil concentrations were markedly higher 
compared to the other lipophilic drugs. Drug characteristics of sufentanil, propofol and 
midazolam regarding protein binding and lipophilicity are fairly similar. With a logP of 3.95, 
sufentanil is highly lipophilic, with 93% protein binding, mainly to albumin. Propofol and 
midazolam are also both highly lipophilic with logP’s of 3.79 and 3.89 respectively, with a 
slightly higher protein binding than sufentanil, of 95-99% and 97% respectively. Therefore 
lipophilicity or protein binding do not seem to predict drug concentrations in the auto-
transfused blood.  
Redistribution of lipophilic drugs from erythrocytes into the auto-transfused blood could 
explain why lipophilic drugs are recovered. Redistribution may occur because of a shift of 
drugs from the erythrocyte to the NaCl 0.9% solution, or because of haemolysis of the 
erythrocyte. Also, measuring propofol by the precipitation method instead of LC-MS/MS may 
have resulted in measurable propofol concentrations after processing. Overall, the recovered 
absolute drug concentrations of the tested drugs where low. Therefore the absolute 
differences in plasma drug concentration in the patient and drug concentration in the auto-
transfused blood may not be substantial. 
The hydrophilic drug, cefazolin, was almost entirety washed from the auto-transfused blood. 
With a logP of -0.58 cefazolin was the most water-soluble drug we have measured. Our results 
are probably explained by the washing of the cell saver blood with NaCl 0.9%. It is likely that 
cefazolin dissolved in the NaCl 0.9% solution and was washed from the auto-transfused blood, 
even though cefazolin concentrations in the waste fluid were low.  
Unwanted drug reactions due to auto-transfused blood may not be clinically relevant in all 
patients. Most at risk for clinical effects are small patients who have had major cardiac surgery 
with the use of CPB, where the volume of returned cell saver blood is relatively large compared 
to the patient’s own circulating volume. Also, due to long CPB time, organ perfusion will be 
decreased, resulting in a lower clearance of drugs from the body (8). Returning a large volume 
of auto-transfused blood to a small patient with a decreased drug clearance could lead to an 
accumulation of drugs, resulting in adverse effects and toxicity especially for sufentanil. Also, 
the cell saver blood is generally administered as a bolus, rather than a continuous infusion. 
This may be particularly problematic in patients who are not on mechanical ventilation when 
the auto-transfused blood is administered. However, the concentration of sufentanil in the 
auto-transfused blood is 0.1 mcg/L. In a worst case scenario, when 1 litre of auto-transfused 
blood is returned to a patient with a bodyweight of 3 kg, the sufentanil dose administered 
with the auto-transfused blood would be 0.033 mcg/kg. The target sufentanil dose at 
induction of anaesthesia is 0.6 mcg/kg (9). Therefore, if the auto-transfused blood is returned 
to the patient during or very shortly after surgery, the sufentanil concentration in the patient 
is higher than the sufentanil concentration in the auto-transfused blood and dilution of plasma 
sufentanil concentration will occur. If the auto-transfused blood is given in a bolus sometime 
after sufentanil is stopped, a peak in plasma concentration may still occur.  
Influence of the auto-transfused blood on adverse drug reaction is therefore dependent on 
weight of the child, plasma drug concentration at the time of cell saver processing, and 
amount, speed and timing of administration of the auto-transfused blood. 
The influence of cell saver systems should be accounted for when performing pharmacological 
trials after cardiac surgery. Optimizing drug dosing in neonates, infants and children during 
and after cardiac surgery is important to improve clinical care, especially in an era where fast 
track recovery is becoming more important. Ideally, potential effects of the CPB- and cell saver 
systems on drug concentrations should be incorporated in dosing advices (8). The current 
study provides insight into the potential return of drugs through auto-transfused blood. 
Population pharmacokinetics can be used to determine subsequent dose adjustments of the 
investigated drugs (8, 10).  
Future research should focus mainly on lipophilic anaesthetic drugs that could cause a 
potential adverse reaction when given to patients postoperatively through the auto-
transfused blood. Also, future endeavours should aim to incorporate the results of the CPB-
PHARM trial and the results of this trial into a new dosing regimen for routinely used drugs for 
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neonates, infants and children during and after cardiac surgery. This new dosing regimen will 
take into account the influence of the CPB and the cell saver system.  
Conclusion 
Depending on the drug, up to 34% of the drug concentration salvaged from the operation site 
is returned to the patient through autotransfusion, potentially causing unwanted drug 
reactions postoperatively. Additionally, influence of a cell saver system should be considered 
in pharmacological research during and after congenital cardiac surgery. 
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Abstract 
Objective: cardiopulmonary bypass (CPB) is often necessary in congenital cardiac surgery, but 
CPB can alter drug pharmacokinetic parameters resulting in underdosing. Inadequate plasma 
levels of antibiotics could lead to postoperative infections with increased morbidity. The 
influence of pediatric CPB systems on cefazolin and clindamycin plasma levels is not known. 
We have measured plasma levels of cefazolin and clindamycin in in vitro pediatric CPB 
systems.  
Design: we have tested three types of CPB systems. All systems were primed and spiked with 
clindamycin and cefazolin. Samples were taken at different time points to measure recovery 
of cefazolin and clindamycin. Linear mixed model analyses were performed to assess if drug 
recovery was different between type of CPB system and sampling time point.  
Setting: the experiments were conducted at a tertiary university hospital. 
Measurements and results: 81 samples were analyzed. There was a significant difference in 
the recovery over time between CPB systems for cefazolin and clindamycin (p< 0.001). 
Cefazolin recovery after 180 minutes was 106% (95%CI; 91-123) for neonatal, 99% (95%CI; 85-
115) for infant, and 77% (95%CI; 67-89) for pediatric systems. Clindamycin recovery after 180 
minutes was 143% (95%CI; 116-177) for neonatal, 111% (95%CI; 89-137) for infant, and 120% 
(95%CI; 97-149) for pediatric systems. Clindamycin recovery after 180 minutes compared to 
the theoretical concentration was 0.4% for neonatal, 1.2% for infants, and 0.6% for pediatric 
systems. 
Conclusion: recovery of cefazolin was high in the neonatal and infant CPB systems and 
moderate in the pediatric system. We found a large discrepancy between the theoretical and 
measured concentrations of clindamycin in all tested CPB systems. 
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Abstract 
Objective: cardiopulmonary bypass (CPB) is often necessary in congenital cardiac surgery, but 
CPB can alter drug pharmacokinetic parameters resulting in underdosing. Inadequate plasma 
levels of antibiotics could lead to postoperative infections with increased morbidity. The 
influence of pediatric CPB systems on cefazolin and clindamycin plasma levels is not known. 
We have measured plasma levels of cefazolin and clindamycin in in vitro pediatric CPB 
systems.  
Design: we have tested three types of CPB systems. All systems were primed and spiked with 
clindamycin and cefazolin. Samples were taken at different time points to measure recovery 
of cefazolin and clindamycin. Linear mixed model analyses were performed to assess if drug 
recovery was different between type of CPB system and sampling time point.  
Setting: the experiments were conducted at a tertiary university hospital. 
Measurements and results: 81 samples were analyzed. There was a significant difference in 
the recovery over time between CPB systems for cefazolin and clindamycin (p< 0.001). 
Cefazolin recovery after 180 minutes was 106% (95%CI; 91-123) for neonatal, 99% (95%CI; 85-
115) for infant, and 77% (95%CI; 67-89) for pediatric systems. Clindamycin recovery after 180 
minutes was 143% (95%CI; 116-177) for neonatal, 111% (95%CI; 89-137) for infant, and 120% 
(95%CI; 97-149) for pediatric systems. Clindamycin recovery after 180 minutes compared to 
the theoretical concentration was 0.4% for neonatal, 1.2% for infants, and 0.6% for pediatric 
systems. 
Conclusion: recovery of cefazolin was high in the neonatal and infant CPB systems and 
moderate in the pediatric system. We found a large discrepancy between the theoretical and 
measured concentrations of clindamycin in all tested CPB systems. 
 
  
Introduction 
During pediatric cardiac surgery the use of the cardiopulmonary bypass (CPB) is often 
necessary. However, CPB has several effects that can alter drug pharmacokinetic parameters 
leading to potentially increased or decreased plasma drug concentration in the patient. This 
may be a problem when dosing antibiotics to prevent surgical site infections (SSI), since 
inadequate antibiotic plasma concentration may lead to an increased risk to develop SSI and 
subsequent morbidity and mortality (1). 
The most profound changes CPB systems induce on drug concentrations are due to 
hemodilution, causing changes in drug distribution and clearance, changed hemodynamic 
status and protein binding, hypothermia and occasionally hemofiltration. The influence of 
these changes on plasma drug concentration is known for some routinely used drugs, such as 
midazolam and propofol (2). 
The CPB system itself also has an effect on drugs administered during surgery. Mainly lipophilic 
drugs are known to sequester in the CPB system (3, 4). Factors that can contribute are type 
and coating of tubing (5, 6) and type of priming fluid (2). Studies on effects of CPB on drugs 
plasma levels have not been performed recently and may no longer be comparable to current 
practice, since CPB systems and peri-operative management may have changed. Data on 
pediatric CPB systems is lacking, since published literature on in vitro assessment of the CPB 
systems investigates only adult CPB systems. The size of the system, added volume and 
composition of priming fluid are different in adult CPB systems compared to pediatric CPB 
systems and data from adult CPB systems cannot simply be extrapolated to pediatric systems. 
We have designed the CPB-PHARM study to investigate the influence of CPB on routinely used 
drugs during and after pediatric cardiac surgery (MEC2011-400). We have added an in vitro 
sub-study to investigate the effects of the CPB without the influence of surgery or patients. 
This in vitro study describes the influence of different pediatric CPB systems on plasma levels 
of cefazolin and clindamycin, our first and second choice antibiotic prophylaxis. We did not 
receive funding for these studies.  
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Material and methods 
We have investigated three types of pediatric CPB systems used at the department of Cardio-
Thoracic Surgery of the Erasmus MC, Rotterdam, The Netherlands. Since all experiments were 
in vitro and no patients were involved, there is no issue of informed consent in accordance 
with Dutch law. Circuits that would soon expire were made available free of charge by Terumo 
Europe NV, Leuven, Belgium and Sorin group, Mirandola, Italy. Terumo Europe NV and Sorin 
group had no influence on study design and protocol, data collection and analyses or 
publication.  
CPB systems 
We have tested three CPB systems used for congenital cardiac surgery in our institution. The 
neonatal, infant and pediatric CPB systems are used for patients with bodyweights of under 
10 kg, 10-20 kg, and 20-40 kg respectively. An overview of the components of these CPB 
systems is given (Table 1).  
Recovery of  cefazolin and clindamycin in in vitro pediatric CPB systems 
Ch
ap
te
r 
4
79
Material and methods 
We have investigated three types of pediatric CPB systems used at the department of Cardio-
Thoracic Surgery of the Erasmus MC, Rotterdam, The Netherlands. Since all experiments were 
in vitro and no patients were involved, there is no issue of informed consent in accordance 
with Dutch law. Circuits that would soon expire were made available free of charge by Terumo 
Europe NV, Leuven, Belgium and Sorin group, Mirandola, Italy. Terumo Europe NV and Sorin 
group had no influence on study design and protocol, data collection and analyses or 
publication.  
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In summary, all systems consist of a hollow-fiber oxygenator and an open hard-shell reservoir. 
The oxygenator of the neonatal and pediatric systems are coated with X-coating™ (poly(2-
methoxyethylacrylate) (PMEA)), a non-heparin biocompatible polymere with hydrophilic and 
hydrophobic properties. The neonatal and pediatric systems have an integrated arterial filter, 
whereas the infant system has a stand-alone arterial filter. The arterial filter is a polyester 
screen type filter in the neonatal and pediatric systems and a phosphorylchloride screen type 
filter in the infant system, with varying surface areas. The venous reservoirs are made of 
polycarbonate with capacities of respectively 1000 ml, 1500 ml and 3000 to 4000 ml for the 
neonatal, infant and pediatric CPB systems. A roller pump is used in the neonatal and infant 
systems. In the pediatric system a centrifugal pump is used, with a pump casing of 
polycarbonate. A combination of silicone an PVC (polyvinylchloride) tubing is used in the 
neonatal and infant systems. In the pediatric system only PVC tubing is used. The tubing in all 
systems is coated with Phisio coating: a non-heparin, biomimatic layer consisting of a 
phosphorylcholine polymere.  
Three system were assembled for each category and placed on a mast mounted, remote pump 
head console (Stöcker S5 Perfusion System, Sorin Group, Mirandola, Italy), with a pediatric 
configuration. A ¼- ¼ or a ¼ - ⅜ connection piece was used to make the CPB systems 
continuous. 
All systems were primed according to hospital protocol (Table 2). Priming fluid in all systems 
consist of fresh frozen plasma (FFP), Gelofusine (B. Braun, Melsungen, Germany), red blood 
cells (RBC’s), human albumin (Sanquin Plasma Products BV, Amsterdam, the Netherlands) and 
sodium bicarbonate 8.4% (Fesenius Kabi Nederland BV, Zeist, NL). Heparin was added to avoid 
clotting of blood in the system. Hematocrit was aimed to be 28% during CPB. FFP’s and RBC’s 
those were just expired were obtained from the local blood bank.  
CPB systems were kept running at a temperature of 36oC for six hours, since this is the 
maximum runtime for which the quality is guaranteed by the manufacturers. Before start of 
the experiments the pCO2, pO2, and pH were measured with iStat (Abbot BV, Hoofddorp, The 
Netherlands). These parameters were kept within physiologic ranges during the experiments 
using sweep gas flow, gas composition and if needed, additional of sodium bicarbonate 8.4%.  
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Three system were assembled for each category and placed on a mast mounted, remote pump 
head console (Stöcker S5 Perfusion System, Sorin Group, Mirandola, Italy), with a pediatric 
configuration. A ¼- ¼ or a ¼ - ⅜ connection piece was used to make the CPB systems 
continuous. 
All systems were primed according to hospital protocol (Table 2). Priming fluid in all systems 
consist of fresh frozen plasma (FFP), Gelofusine (B. Braun, Melsungen, Germany), red blood 
cells (RBC’s), human albumin (Sanquin Plasma Products BV, Amsterdam, the Netherlands) and 
sodium bicarbonate 8.4% (Fesenius Kabi Nederland BV, Zeist, NL). Heparin was added to avoid 
clotting of blood in the system. Hematocrit was aimed to be 28% during CPB. FFP’s and RBC’s 
those were just expired were obtained from the local blood bank.  
CPB systems were kept running at a temperature of 36oC for six hours, since this is the 
maximum runtime for which the quality is guaranteed by the manufacturers. Before start of 
the experiments the pCO2, pO2, and pH were measured with iStat (Abbot BV, Hoofddorp, The 
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using sweep gas flow, gas composition and if needed, additional of sodium bicarbonate 8.4%.  
 
Table 2: Prime fluid composition 
 Neonatal Infant Pediatric 
Priming volume (ml) 263.4 430 683 
RBC (ml) 135 235 365 
FFP (ml) 30 40 50 
Gelofusine (ml) 30 40 50 
Albumine 20 % (ml) 40 50 100 
Mannitol 15 % (ml 20 50 100 
NaHCO3 8.4 % (ml) 3 15 18 
Heparin (ml) 0.4 0.5 1 
Flow (l/min) 0.5 1.5 3 
Temperature (°C) 36 36 36 
Line pressure (mmHg) 100 100 100 
RBC: red blood cell, FFP: fresh frozen plasma, ml: milliliter, L: liter, min: minutes 
Flow rates were kept at 0.5 L/minute, 1.5 L/minute and 3 L/minute for the neonatal, infant 
and pediatric CPB systems. Using the venous clamp postmembrane pressures were kept 
constant at 100 mmHg.  
Drug administration 
Drug doses were standardized based on the average weight for a patient for the neonatal, 
infant and pediatric CPB system. Drugs for the neonatal system were based on a 5 kg patient, 
for the infant system on a 15 kg patient and for the pediatric system a 30 kg patient. Drugs 
were dosed according to our institutional guidelines for the induction for general anesthesia, 
i.e. cefazolin at 30 mg/kg and clindamycin at 12 mg/kg for neonates and 6.7 mg/kg for children 
with a body weight of above 10 kg (see Table 3). 
Drugs were injected into the CPB systems at the venous side of the system via a manifold 
sample port. After each drug a 2 ml physiological saline solution (0.9%) flush was injected to 
prevent pooling or crystallization of drugs in the sample port. Drugs were administered in the 
same order for all systems and all experiments.  
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Table 3: drug concentration administered to the CPB systems 
 Neonate Infant Pediatric 
Cefazolin (Kefzol®, Eurocept BV, 
Ankeveen, the Netherlands, 100 mg/ml) 
250 mg 750 mg 1500 mg 
Clindamycin (Dalacin®, Pfizer BV, Capelle 
aan den IJssel, the Netherlands) 
60 mg 100 mg 200 mg 
 
Samples 
From each CPB system four ml blood samples were taken at different time points. The first 
samples was immediately after injection of the drugs (T1), thereafter samples were taken at 
2, 5, 7, 10, 30, 60, 180 and 300 minutes. Samples were taken from the arterial 
(postoxygenator) side of the CPB system via a manifold sample port. Polypropylene EDTA 
tubes were used (7.2 mg EDTA, BD Vacutainer®, BD Life Sciences, Plymouth, UK).  
Samples were stored at 40C until centrifugation (10 minutes at 3600 rpm). The supernatant 
serum was transferred to polypropylene cryogenic vials with polypropylene screw caps 
(Sarstedt Aktiengesellschaft & Co, Nümbrecht, Germany) and stored at -800C until further 
analysis.  
Assay methods 
Liquid chromatography mass spectrometry (LC-MS/MS) was used to measure total plasma 
drug concentrations of cefazolin and clindamycin. 
Drug concentrations for clindamycin were measured using LC-MS/MS in a Thermo TSQ 
Quantiva triple-stage quadrupole mass spectrometer (Thermo Fisher Scientific, Waltham, MA, 
USA) at the pharmacy laboratory of the University Medical Center Groningen, the 
Netherlands.  
Drug concentrations for cefazolin were measured using LC-MS/MS in an AB SCIEX QTRAP® 
5500 triple quadrupole mass spectrometer (AB SCIEX, Concord, Ontario, Canada) and Analyst® 
software version 1.6.2 (AB SCIEX, Concord, Ontario, Canada) at the IBMP Institute for 
Biomedical and Pharmaceutical Research in Nürnberg-Heroldsberg, Germany. 
Recovery of  cefazolin and clindamycin in in vitro pediatric CPB systems 
Ch
ap
te
r 
4
85
Table 3: drug concentration administered to the CPB systems 
 Neonate Infant Pediatric 
Cefazolin (Kefzol®, Eurocept BV, 
Ankeveen, the Netherlands, 100 mg/ml) 
250 mg 750 mg 1500 mg 
Clindamycin (Dalacin®, Pfizer BV, Capelle 
aan den IJssel, the Netherlands) 
60 mg 100 mg 200 mg 
 
Samples 
From each CPB system four ml blood samples were taken at different time points. The first 
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2, 5, 7, 10, 30, 60, 180 and 300 minutes. Samples were taken from the arterial 
(postoxygenator) side of the CPB system via a manifold sample port. Polypropylene EDTA 
tubes were used (7.2 mg EDTA, BD Vacutainer®, BD Life Sciences, Plymouth, UK).  
Samples were stored at 40C until centrifugation (10 minutes at 3600 rpm). The supernatant 
serum was transferred to polypropylene cryogenic vials with polypropylene screw caps 
(Sarstedt Aktiengesellschaft & Co, Nümbrecht, Germany) and stored at -800C until further 
analysis.  
Assay methods 
Liquid chromatography mass spectrometry (LC-MS/MS) was used to measure total plasma 
drug concentrations of cefazolin and clindamycin. 
Drug concentrations for clindamycin were measured using LC-MS/MS in a Thermo TSQ 
Quantiva triple-stage quadrupole mass spectrometer (Thermo Fisher Scientific, Waltham, MA, 
USA) at the pharmacy laboratory of the University Medical Center Groningen, the 
Netherlands.  
Drug concentrations for cefazolin were measured using LC-MS/MS in an AB SCIEX QTRAP® 
5500 triple quadrupole mass spectrometer (AB SCIEX, Concord, Ontario, Canada) and Analyst® 
software version 1.6.2 (AB SCIEX, Concord, Ontario, Canada) at the IBMP Institute for 
Biomedical and Pharmaceutical Research in Nürnberg-Heroldsberg, Germany. 
Limits of quantification are specified in Table 4. A certified research technician from the ISO 
certified laboratories performed the FDA validated drug analyses. In all analyses quality 
control samples are included, as is obliged in FDA analyses and ISO and GCP certified 
laboratory. 
Table 4: Limits of quantification 
Drug Lower Limit of Quantification (LLOQ) Upper Limit of Quantification (ULOQ) 
Cefazolin 209.3 mg/L 2009.23 mg/L 
Clindamycin 0.6 mg/L 57.00 mg/L 
Mg: milligram, L: liter 
Statistical analysis 
We performed linear mixed model analyses with drug concentration as dependent variable, 
and type of CPB system and sample time point as independent variables. We used mixed 
models analysis because a correlation can be expected between multiple measurements of 
the same variable (drug concentration) in the same subject (CPB systems). Given the non-
normal distribution of the drug concentrations, the dependent variable in the linear mixed 
model was defined as the log-transformed concentration of cefazolin and clindamycin. The 
independent variables were treated as categorical variables, and an interaction effect 
between the independent variables was included in the model. We used a random intercept 
and assumed a first-order autoregressive error covariance matrix to correct for within-system 
correlations between time points. This model specification was chosen by comparing values 
of the Akaike information criterion between different structures for the random effects and 
the error covariance matrix. 
The predicted values for the log-transformed concentration for each CPB system and at each 
time point were provided by the linear mixed models. We calculated the differences between 
the predicted values for each time point and each CPB system and T1, including the 95% 
Confidence Interval (95% CI) of this difference. We exponentiated this difference and the 95% 
CI to obtain drug recovery (percentage of drugs still present in the system) for T2 to T300. We 
calculated the maximum expected concentration (MEC) of drug in the CPB systems by dividing 
the amount of drug added to the CPB systems by the total priming volume in the systems. We 
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used the MEC since it was unclear whether the drug was mixed completely with the prime 
fluid at T1. 
Statistical analyses were performed using IBM SPSS Statistics 24, and all statistical tests used 
a two-sided significance level of 0.05. 
Results  
A total of 81 samples, 27 for each CPB system category, was analyzed. We encountered no 
technical problems during execution of the experiments.  
Figure 1 shows predicted drug recovery (based on the estimated marginal means of the linear 
mixed models) versus time for cefazolin and clindamycin, for each CPB-system category. Based 
on the interaction effects in the mixed models, there was a significant difference in the pattern 
of recovery over time between systems for both cefazolin and clindamycin (p < 0.001). For 
cefazolin, the lowest drug recovery was in the pediatric systems, while the highest drug 
recovery was in the neonatal systems. In the pediatric system, cefazolin concentration seems 
to show an initial decline, but then increased again to the starting drug concentration. This 
maximum in recovered concentration was found after two hours of CPB runtime. After these 
first two hours cefazolin concentration decreased to approximately 50% recovery at the end 
of the experiment. 
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Figure 1: Predicted recovery of cefazolin and clindamycin (in % of theoretical concentration) 
versus time 
 
For clindamycin, the highest recovery was observed in the neonatal systems, whilst the lowest 
recovery was in the infant systems. The clindamycin concentration was relatively stable during 
the experiment, with a mild increase in drug recovery in all systems starting at 60 minutes to 
the end of the experiment.  
Mean recovery for cefazolin after 60 and 180 minutes, compared to T1, was 94% (95% CI; 81-
109) and 106% (95% CI; 91-123) for the neonatal systems, 96% (95% CI; 83-112) and 99% (95% 
CI; 85-115) for the infant systems, and 124% (95% CI; 107-144) and 77% (95% CI; 67-89) for 
the pediatric systems. 
Mean recovery for clindamycin after 60 and 180 minutes, compared to T1, was 110% (95% CI; 
89-136) and 143% (95% CI; 116-177) for the neonatal CPB systems, 99% (95%CI; 80-123) and 
111% (95% CI; 89-137) for the infant systems, and 107% (95% CI; 86-132) and 120% (95% CI; 
97-149) for the pediatric systems.  
For cefazolin the MEC was in the range of the measurements of T1 and T2, indicating complete 
mixing of cefazolin after injection in the CB system. For clindamycin MEC was much higher 
than all measurements, indicating a steep decline after injection. Mean clindamycin recovery 
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after 60 and 180 minutes compared to the MEC was 0.3% and 0.4% for neonatal systems, 1.1% 
and 1.2% for infants systems, and 0.5% and 0.6% for pediatric systems.  
Discussion 
Influence of pediatric CPB systems on plasma drug concentration is largely unknown. 
However, use of CPB is inevitable in most congenital cardiac surgery procedures. For adult 
patients, in vivo and in vitro studies have been published (4, 7-9). We have investigated 
cefazolin and clindamycin plasma concentration in three pediatric CPB systems that are used 
in our institution. 
For cefazolin, there are no previous in vitro publications for adult or pediatric CPB systems. 
However, cefazolin was investigated in vitro in pediatric extracorporeal membrane 
oxygenation systems (ECMO) (10). In these experiments recovery of cefazolin was high for 
both neonatal and pediatric ECMO systems, with an average cefazolin recovery at 2 minutes 
of 87%, and recovery at 180 minutes of 84.3%, with almost no difference between systems. 
After approximately 10 minutes plasma cefazolin concentration reached steady state. These 
results are much in line with our findings. Our findings indicate that cefazolin mixes within 
minutes in the CPB systems and concentration moderately decreases throughout the 
experiments. Only in our pediatric systems the cefazolin concentration decreased by 50% by 
the end of the experiment. We cannot fully explain this decrease in only the pediatric systems. 
The components of the neonatal and pediatric CPB systems are similar, and cefazolin plasma 
concentration is stable in the neonatal systems. The type and length of tubing could make a 
difference, with a larger contact surface area in the pediatric CPB systems. Absorption of drugs 
to PVC tubing with various coatings have been shown for fentanyl and morphine. This may 
also effect cefazolin plasma concentration and account for the more profound decrease in the 
larger CPB system. Recently, de Cock et al. published in vivo data on cefazolin plasma 
concentration during and after pediatric cardiac surgery (11). The authors collected blood 
samples from children undergoing cardiac surgery and concentration-time profiles were 
analyzed using population pharmacokinetic modelling (12). The authors estimated that the 
volume of distribution of the CPB compartment in the pharmacokinetic model was equal to 
the priming volume of the CPB system. This means there should be no sequestration of 
cefazolin in the CPB system. However, duration of surgical procedure and subsequent CPB use 
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after 60 and 180 minutes compared to the MEC was 0.3% and 0.4% for neonatal systems, 1.1% 
and 1.2% for infants systems, and 0.5% and 0.6% for pediatric systems.  
Discussion 
Influence of pediatric CPB systems on plasma drug concentration is largely unknown. 
However, use of CPB is inevitable in most congenital cardiac surgery procedures. For adult 
patients, in vivo and in vitro studies have been published (4, 7-9). We have investigated 
cefazolin and clindamycin plasma concentration in three pediatric CPB systems that are used 
in our institution. 
For cefazolin, there are no previous in vitro publications for adult or pediatric CPB systems. 
However, cefazolin was investigated in vitro in pediatric extracorporeal membrane 
oxygenation systems (ECMO) (10). In these experiments recovery of cefazolin was high for 
both neonatal and pediatric ECMO systems, with an average cefazolin recovery at 2 minutes 
of 87%, and recovery at 180 minutes of 84.3%, with almost no difference between systems. 
After approximately 10 minutes plasma cefazolin concentration reached steady state. These 
results are much in line with our findings. Our findings indicate that cefazolin mixes within 
minutes in the CPB systems and concentration moderately decreases throughout the 
experiments. Only in our pediatric systems the cefazolin concentration decreased by 50% by 
the end of the experiment. We cannot fully explain this decrease in only the pediatric systems. 
The components of the neonatal and pediatric CPB systems are similar, and cefazolin plasma 
concentration is stable in the neonatal systems. The type and length of tubing could make a 
difference, with a larger contact surface area in the pediatric CPB systems. Absorption of drugs 
to PVC tubing with various coatings have been shown for fentanyl and morphine. This may 
also effect cefazolin plasma concentration and account for the more profound decrease in the 
larger CPB system. Recently, de Cock et al. published in vivo data on cefazolin plasma 
concentration during and after pediatric cardiac surgery (11). The authors collected blood 
samples from children undergoing cardiac surgery and concentration-time profiles were 
analyzed using population pharmacokinetic modelling (12). The authors estimated that the 
volume of distribution of the CPB compartment in the pharmacokinetic model was equal to 
the priming volume of the CPB system. This means there should be no sequestration of 
cefazolin in the CPB system. However, duration of surgical procedure and subsequent CPB use 
was the primary factor for not achieving the optimal cefazolin plasma levels. Considering the 
apparent lack for sequestration in the CPB systems, other factors may be responsible for the 
moderate decrease in cefazolin plasma levels that are not yet understood.  
For clindamycin, the measured plasma concentrations remained stable over time, but the 
difference between the MEC and measured plasma concentration was large. These results 
were comparable for all tested CPB systems.  
There are no previous studies published on clindamycin use during cardiac surgery in adults 
or children. Our results therefore are the first to present these plasma concentrations. 
Measured clindamycin concentration remains stable during the CPB run, with an increase in 
concentration towards the end of the experiment. This mild increase may be due to 
recirculation of clindamycin from tubing or other CPB components. The most striking result is 
the large difference between the MEC and the first measured plasma concentration. This large 
difference may have several reasons. The first reason may be incomplete mixing of 
clindamycin with the prime fluid after injection in the CPB systems. This may lead to a 
preferential flow in the reservoir causing clindamycin to precipitate without circulating in the 
entire CPB system. An open hard-shell reservoir is used in all CPB systems and this may be the 
compartment to cause clindamycin precipitation. However, we cannot explain the cause of 
precipitation other than incomplete mixing. Another potential cause for the discrepancy 
between MEC and measured concentration, is sequestration of clindamycin to the plastic 
components or the defoaming area in the CPB system. Hydrophilic drugs such as clindamycin 
are not known to sequester in CPB systems. Sequestration in these systems is expected for 
lipophilic drugs, such as sufentanil or midazolam (13). As shown by Shekar et al (14) in ECMO 
circuits, drugs with a LogP greater than 2.3 have a significantly higher decrease in 
concentration compared to less lipophilic or hydrophilic drugs. As both cefazolin and 
clindamycin have a lower LogP they are not expected to sequester in the CPB systems (see 
Table 5).  
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Table 5: Drug characteristics 
Drug  Blood/plasma 
ratio 
LogP Protein binding 
(%) 
Vd 
(l/kg) 
pKa 
Cefazolin 1.21 -0.4 74-86 12L 3.03 (strongest acidic) 
Clindamycin Unavailable 1.59 92-94 70L 6.74 (strongest basic) 
Vd: volume of distribution, pKa: acid dissociation constant at logarithmic scale, L: liter, Kg: 
kilogram, LogP: logarithm of partition coefficient 
Highly protein bound drugs (>80% protein bound) also sequester significantly more in ECMO 
systems, and this could be a possible cause for sequestration of clindamycin, since clindamycin 
is strong protein bound. The Vd of clindamycin is mainly influenced by albumin and alpha-1 
acid glycoprotein (15). Albumin, but not alpha-1 acid glycoprotein was added to the prime 
fluid and may have caused a shift in clindamycin protein binding resulting in a higher unbound 
fraction. However, we have measured total serum concentration and we would not expect 
this concentration to change so dramatically due to changes in protein binding. The acid 
dissociation constant (pKa) could make a difference in mixing and recovery, with cefazolin 
being a strong acid compared to clindamycin. To our knowledge no influence of pKa on 
sequestration of drugs in CPB or ECMO circuits has been published before. During the 
experiments clindamycin concentration seems to gradually increase to above 100% of the T1 
concentration, but not to the MEC values. No previous results have been published on a 
potential reversible binding of hydrophilic drugs to CPB compartments. However, considering 
our results this may be a potential explanation for the increasing clindamycin concentration, 
or we may have an incomplete mixing of clindamycin that gradually evolves. We cannot 
completely exclude an error in medication administration or analysis. However, the CPB 
systems were run on several days and medication was always double-checked.  
Our experiments show the effects of pediatric CPB systems on plasma concentration of 
cefazolin and clindamycin. Adequate concentration of cefazolin and clindamycin are 
imperative to prevent SSI. In children after cardiac surgery SSI reportedly occur in 1.9-8% of 
patients (16). Correct plasma concentrations of antibiotics are a relatively easily modifiable 
factor to prevent SSI, and are therefore important to investigate in vitro and in vivo. As shown 
by Shah et al. incorrect dosing of antibiotics gives a 1.7-fold increased risk of developing a SSI 
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this concentration to change so dramatically due to changes in protein binding. The acid 
dissociation constant (pKa) could make a difference in mixing and recovery, with cefazolin 
being a strong acid compared to clindamycin. To our knowledge no influence of pKa on 
sequestration of drugs in CPB or ECMO circuits has been published before. During the 
experiments clindamycin concentration seems to gradually increase to above 100% of the T1 
concentration, but not to the MEC values. No previous results have been published on a 
potential reversible binding of hydrophilic drugs to CPB compartments. However, considering 
our results this may be a potential explanation for the increasing clindamycin concentration, 
or we may have an incomplete mixing of clindamycin that gradually evolves. We cannot 
completely exclude an error in medication administration or analysis. However, the CPB 
systems were run on several days and medication was always double-checked.  
Our experiments show the effects of pediatric CPB systems on plasma concentration of 
cefazolin and clindamycin. Adequate concentration of cefazolin and clindamycin are 
imperative to prevent SSI. In children after cardiac surgery SSI reportedly occur in 1.9-8% of 
patients (16). Correct plasma concentrations of antibiotics are a relatively easily modifiable 
factor to prevent SSI, and are therefore important to investigate in vitro and in vivo. As shown 
by Shah et al. incorrect dosing of antibiotics gives a 1.7-fold increased risk of developing a SSI 
in pediatric patients (17). Sub-optimal dosing due to influence of the CPB system, may affect 
the occurrence of SSI. To date, no uniform guidelines for dosing of antibiotic prophylaxis in 
children is available. Also, potentially increased risks of SSI after cardiac surgery are not 
incorporated in current dosing advices (11). Several procedural risk factors, such as the use of 
a bladder catheter, longer duration of CPB or prolonged surgery time, may increase the risk of 
SSI in pediatric cardiac surgery patients (1). Our results show that plasma cefazolin 
concentration only moderately decreases during CPB in the pediatric system. Cefazolin 
concentration remains stable over time in the neonatal and infant systems. The increased risk 
of SSI with longer CPB runtime may be associated with other surgery and patient related 
factors, such as systemic inflammatory response syndrome (SIRS) and increased volume of 
distribution with subsequent lower plasma concentration. The most important moment to 
obtain adequate plasma concentrations is at the time of wound closure. This should be 
investigated in vivo, with the added patient related influence on plasma drug concentration. 
The loss of clindamycin in the CPB systems, with the recovery of only 0.3-1.2% compared to 
the MEC, should be further investigated. If this indeed holds true, antibiotic prophylaxis with 
clindamycin is not effective for children undergoing cardiac surgery.  
Our study has several limitations. Firstly, we have not corrected for the blood/plasma ratio of 
the measured drugs. For clindamycin the blood/plasma ratio is not known. The blood/plasma 
ratio for cefazolin could potentially slightly change the measured plasma concentration. 
However, the measured concentrations are relatively high compared to clinically relevant 
values and therefore the blood/plasma ratio was not considered a large influence. Also, the 
blood/plasma ratio remains constant over time and does therefore not influence the increase 
or decrease of drug concentration. Secondly, we did not correct for spontaneous degradation. 
Spontaneous degradation may introduce a potential bias in the measured plasma 
concentration, since this is a cause for drug loss. However, a study on spontaneous 
degradation of cefazolin by Donnelly showed that cefazolin remains stable over 30 days (18). 
To our knowledge no data have been published on clindamycin stability. From personal 
communication with our laboratory we know clindamycin to be stable for two years when 
kept at -200 Celsius between processing and analysis, as is in line with good laboratory 
practice. Finally, during cardiac surgery, antibiotic administration is often repeated at start of 
the CPB system. In contrast, we spiked the CPB systems at the beginning of the experiments, 
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and did not administer a re-dose during the experiment. This timing of administration only 
resembles short cardiac surgical procedures, without redosing at onset of CPB. However, this 
method is often used in in vitro studies and most accurately reflects the influence of CPB 
runtime on drugs.  
Conclusion 
In conclusion, our study shows high recovery of cefazolin in the neonatal and infant CPB 
system, and moderate recovery of cefazolin in the pediatric CPB system. We found a large 
discrepancy between the MEC and measured concentrations of clindamycin in all tested CPB 
systems. Our results do not explain this discrepancy, and this should be further investigated 
to ensure adequate antibiotic prophylaxis in children undergoing cardiac surgery.  
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to ensure adequate antibiotic prophylaxis in children undergoing cardiac surgery.  
  
References  
1. Bucher BT, Guth RM, Elward AM, Hamilton NA, Dillon PA, Warner BW, et al. Risk factors 
and outcomes of surgical site infection in children. J Am Coll Surg. 2011;212(6):1033-8 e1. 
2. van Saet A, de Wildt SN, Knibbe CA, Bogers AJ, Stolker RJ, Tibboel D. The effect of adult 
and pediatric cardiopulmonary bypass on pharmacokinetic and pharmacodynamic 
parameters. Curr Clin Pharmacol. 2013;8(4):297-318. 
3. Hynynen M, Hammaren E, Rosenberg PH. Propofol sequestration within the 
extracorporeal circuit. Can J Anaesth. 1994;41(7):583-8. 
4. Hudson RJ, Thomson IR, Jassal R. Effects of cardiopulmonary bypass on sufentanil 
pharmacokinetics in patients undergoing coronary artery bypass surgery. Anesthesiology. 
2004;101(4):862-71. 
5. Preston TJ, Ratliff TM, Gomez D, Olshove VE, Jr., Nicol KK, Sargel CL, et al. Modified 
surface coatings and their effect on drug adsorption within the extracorporeal life support 
circuit. J Extra Corpor Technol. 2010;42(3):199-202. 
6. Baksaas ST, Videm V, Fosse E, Karlsen H, Pedersen T, Mollnes TE, et al. In vitro 
evaluation of new surface coatings for extracorporeal circulation. Perfusion. 1999;14(1):11-9. 
7. Peter J. Dawson, Andrew R. Bjorksten, Duncan W. Blake, Goldblatt JC. The Effects of 
Cardiopulmonary Bypass on Total and Unbound Plasma Concentrations of Propofol and 
Midazolam. Journal of Cardiothoracic and Vascular Anesthesia. 1997;11(5):556-61. 
8. Hammaren E, Rosenberg PH, Hynynen M. Coating of extracorporeal circuit with 
heparin does not prevent sequestration of propofol in vitro. Br J Anaesth. 1999;82(1):38-40. 
9. Su HB, Tseng CC, Jenn CT, Chang CL, Huang JD. Changes of propofol levels in isolated 
cardiopulmonary bypass circuit. Acta Anaesthesiol Sin. 1996;34(1):17-20. 
10. Wildschut ED, Ahsman MJ, Allegaert K, Mathot RAA, Tibboel D. Determinants of drug 
absorption in different ECMO circuits. Intensive Care Medicine. 2010;36(12):2109-16. 
11. De Cock PA, Mulla H, Desmet S, De Somer F, McWhinney BC, Ungerer JP, et al. 
Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to 
optimize dosing regimens for children undergoing cardiac surgery. J Antimicrob Chemother. 
2017;72(3):791-800. 
12. Benet LZ, Zia-Amirhosseini P. Basic principles of pharmacokinetics. Toxicol Pathol. 
1995;23(2):115-23. 
Chapter 4
94
13. Raffaeli G, Allegaert K, Koch B, Cavallaro G, Mosca F, Tibboel D, et al. In Vitro 
Adsorption of Analgosedative Drugs in New Extracorporeal Membrane Oxygenation Circuits. 
Pediatr Crit Care Med. 2018;19(5):e251-e8. 
14. Shekar K, Roberts JA, McDonald CI, Ghassabian S, Anstey C, Wallis SC, et al. Protein-
bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: 
results from an ex vivo study. Crit Care. 2015;19:164. 
15. Smith MJ, Gonzalez D, Goldman JL, Yogev R, Sullivan JE, Reed MD, et al. 
Pharmacokinetics of Clindamycin in Obese and Nonobese Children. Antimicrob Agents 
Chemother. 2017;61(4). 
16. Costello JM, Graham DA, Morrow DF, Morrow J, Potter-Bynoe G, Sandora TJ, et al. Risk 
factors for surgical site infection after cardiac surgery in children. Ann Thorac Surg. 
2010;89(6):1833-41; discussion 41-2. 
17. Shah GS, Christensen RE, Wagner DS, Pearce BK, Sweeney J, Tait AR. Retrospective 
evaluation of antimicrobial prophylaxis in prevention of surgical site infection in the pediatric 
population. Paediatr Anaesth. 2014;24(9):994-8. 
18. Donnelly RF. Stability of cefazolin sodium in polypropylene syringes and 
polyvinylchloride minibags. Can J Hosp Pharm. 2011;64(4):241-5. 
 
  
13. Raffaeli G, Allegaert K, Koch B, Cavallaro G, Mosca F, Tibboel D, et al. In Vitro 
Adsorption of Analgosedative Drugs in New Extracorporeal Membrane Oxygenation Circuits. 
Pediatr Crit Care Med. 2018;19(5):e251-e8. 
14. Shekar K, Roberts JA, McDonald CI, Ghassabian S, Anstey C, Wallis SC, et al. Protein-
bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: 
results from an ex vivo study. Crit Care. 2015;19:164. 
15. Smith MJ, Gonzalez D, Goldman JL, Yogev R, Sullivan JE, Reed MD, et al. 
Pharmacokinetics of Clindamycin in Obese and Nonobese Children. Antimicrob Agents 
Chemother. 2017;61(4). 
16. Costello JM, Graham DA, Morrow DF, Morrow J, Potter-Bynoe G, Sandora TJ, et al. Risk 
factors for surgical site infection after cardiac surgery in children. Ann Thorac Surg. 
2010;89(6):1833-41; discussion 41-2. 
17. Shah GS, Christensen RE, Wagner DS, Pearce BK, Sweeney J, Tait AR. Retrospective 
evaluation of antimicrobial prophylaxis in prevention of surgical site infection in the pediatric 
population. Paediatr Anaesth. 2014;24(9):994-8. 
18. Donnelly RF. Stability of cefazolin sodium in polypropylene syringes and 
polyvinylchloride minibags. Can J Hosp Pharm. 2011;64(4):241-5. 
 
  

Journal of  Cardiothoracic and Vascular Anesthesia 00 (2019) 1-9. 
Annewil van Saet | Gerdien A Zeilmaker-Roest | Marloes PJ van Hoeven 
Birgit CP Koch | Joost van Rosmalen | Martina Kinzig | Fritz Sörgel 
Enno Wildschut | Robert J Stolker | Dick Tibboel | Ad JJC Bogers 
In vitro recovery of  sufentanil, 
midazolam, propofol and 
methylprednisolone in pediatric 
cardiopulmonary bypass systems 
Chapter 5
Chapter 5
98
Abstract 
 
Objectives: To evaluate in vitro drug recovery in cardiopulmonary bypass (CPB) systems used 
for pediatric cardiac surgery. 
 
Design: Observational in vitro study. 
 
Setting: Single-center university hospital. 
 
Participants: In vitro CPB systems used for pediatric cardiac surgery. 
 
Interventions: Three full neonatal, infant, and pediatric CPB systems were primed according 
to hospital protocol and kept running for 6 hours. Midazolam, propofol, sufentanil, and 
methylprednisolone were added to the venous side of the systems in doses commonly used 
for induction of general anesthesia. Blood samples were taken from the postoxygenator side 
of the circuit immediately after injection of the drugs and after 2, 5, 7, 10, 30, 60, 180, and 
300 minutes. 
 
Measurements and Main Results: Linear mixed model analyses were performed to assess the 
relationship between log-transformed drug concentration (dependent variable) and type of 
CPB system and sample time point (independent variables). The mean percentage of drug 
recovery after 60 and 180 minutes compared with T1 was 41.7% (95% confidence interval [CI] 
35.9-47.4) and 23.0% (95% CI 9.2-36.8) for sufentanil, 87.3% (95% CI 64.9-109.7) and 82.0% 
(95% CI 64.6-99.4) for midazolam, 41.3% (95% CI 15.5-67.2) and 25.0% (95% CI 4.7-45.3) for 
propofol, and 119.3% (95% CI 101.89-136.78) and 162.0% (95% CI 114.09-209.91) for 
methylprednisolone, respectively. 
 
Conclusions: The present in vitro experiment with neonatal, infant, and pediatric CPB systems 
shows a variable recovery of routinely used drugs with significant differences between drugs, 
but not between system categories (with the exception of propofol). The decreased recovery 
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Abstract 
 
Objectives: To evaluate in vitro drug recovery in cardiopulmonary bypass (CPB) systems used 
for pediatric cardiac surgery. 
 
Design: Observational in vitro study. 
 
Setting: Single-center university hospital. 
 
Participants: In vitro CPB systems used for pediatric cardiac surgery. 
 
Interventions: Three full neonatal, infant, and pediatric CPB systems were primed according 
to hospital protocol and kept running for 6 hours. Midazolam, propofol, sufentanil, and 
methylprednisolone were added to the venous side of the systems in doses commonly used 
for induction of general anesthesia. Blood samples were taken from the postoxygenator side 
of the circuit immediately after injection of the drugs and after 2, 5, 7, 10, 30, 60, 180, and 
300 minutes. 
 
Measurements and Main Results: Linear mixed model analyses were performed to assess the 
relationship between log-transformed drug concentration (dependent variable) and type of 
CPB system and sample time point (independent variables). The mean percentage of drug 
recovery after 60 and 180 minutes compared with T1 was 41.7% (95% confidence interval [CI] 
35.9-47.4) and 23.0% (95% CI 9.2-36.8) for sufentanil, 87.3% (95% CI 64.9-109.7) and 82.0% 
(95% CI 64.6-99.4) for midazolam, 41.3% (95% CI 15.5-67.2) and 25.0% (95% CI 4.7-45.3) for 
propofol, and 119.3% (95% CI 101.89-136.78) and 162.0% (95% CI 114.09-209.91) for 
methylprednisolone, respectively. 
 
Conclusions: The present in vitro experiment with neonatal, infant, and pediatric CPB systems 
shows a variable recovery of routinely used drugs with significant differences between drugs, 
but not between system categories (with the exception of propofol). The decreased recovery 
of mainly sufentanil and propofol could lead to suboptimal dosing of patients during cardiac 
surgery with CPB.  
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Introduction 
CPB is necessary to facilitate most cardiac surgery in children. The effect of CPB on in vivo drug 
concentrations in patients can be profound and is attributed to hemodilution, altered 
hemodynamic status, hypothermia, systemic inflammation, changes in acid-base status, 
exclusion of the lungs from the circulation and hemofiltration (1). Furthermore, the plastic 
components of the CPB-system themselves have been shown to absorb drugs (2-7).  
In our institution multiple experiments have taken place to determine in vitro drug recovery 
in ECMO-systems (8, 9). Drug recovery has been defined as the concentration of drug present 
in the priming fluid after a certain amount of time has passed since addition of the drug to the 
CPB-system (8, 9). Previous publications have used the term absorption to indicate the 
decrease in concentration of drug in the priming fluid. In our institution, recovery has been 
deemed a more precise definition, since not all drug is actually absorbed by the system 
components. Drugs are also subject to spontaneous degradation, for example, providing an 
altogether different reason for a decrease in drug concentration than absorption of drug to 
components of the CPB-system (8). There is a lack of data in the literature concerning pediatric 
CPB-systems. As part of our CPB-PHARM study, aiming to measure and model drug 
concentrations during CPB for pediatric cardiac surgery (registered at the Netherlands Trial 
Register no NTR3579), the current in vitro experiments were undertaken. The ultimate goal is 
to incorporate these data into in vivo population pharmacological models. 
Methods 
The study was conducted at the Department of Cardiothoracic Surgery of a tertiary teaching 
hospital. No human subjects were involved in the study, so the need for medical ethical review 
board approval was waived according to Dutch law. 
Soon to be expired CPB-systems were made available free of charge by Terumo Europe NV 
(Terumo Europe NV, Leuven, Belgium) and Sorin Group (Sorin Group, Mirandola, Italy). This 
research did not receive any specific grant from funding agencies in the public, commercial or 
not-for-profit sectors. There was no role for Terumo Europe NV or Sorin Group in the design 
of the study, collection, analysis and interpretation of data, writing of the report or the 
decision to submit the report for publication. 
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Introduction 
CPB is necessary to facilitate most cardiac surgery in children. The effect of CPB on in vivo drug 
concentrations in patients can be profound and is attributed to hemodilution, altered 
hemodynamic status, hypothermia, systemic inflammation, changes in acid-base status, 
exclusion of the lungs from the circulation and hemofiltration (1). Furthermore, the plastic 
components of the CPB-system themselves have been shown to absorb drugs (2-7).  
In our institution multiple experiments have taken place to determine in vitro drug recovery 
in ECMO-systems (8, 9). Drug recovery has been defined as the concentration of drug present 
in the priming fluid after a certain amount of time has passed since addition of the drug to the 
CPB-system (8, 9). Previous publications have used the term absorption to indicate the 
decrease in concentration of drug in the priming fluid. In our institution, recovery has been 
deemed a more precise definition, since not all drug is actually absorbed by the system 
components. Drugs are also subject to spontaneous degradation, for example, providing an 
altogether different reason for a decrease in drug concentration than absorption of drug to 
components of the CPB-system (8). There is a lack of data in the literature concerning pediatric 
CPB-systems. As part of our CPB-PHARM study, aiming to measure and model drug 
concentrations during CPB for pediatric cardiac surgery (registered at the Netherlands Trial 
Register no NTR3579), the current in vitro experiments were undertaken. The ultimate goal is 
to incorporate these data into in vivo population pharmacological models. 
Methods 
The study was conducted at the Department of Cardiothoracic Surgery of a tertiary teaching 
hospital. No human subjects were involved in the study, so the need for medical ethical review 
board approval was waived according to Dutch law. 
Soon to be expired CPB-systems were made available free of charge by Terumo Europe NV 
(Terumo Europe NV, Leuven, Belgium) and Sorin Group (Sorin Group, Mirandola, Italy). This 
research did not receive any specific grant from funding agencies in the public, commercial or 
not-for-profit sectors. There was no role for Terumo Europe NV or Sorin Group in the design 
of the study, collection, analysis and interpretation of data, writing of the report or the 
decision to submit the report for publication. 
CPB-systems 
Table 1 shows the composition of the different CPB-systems used. All systems contained a 
hollow-fiber membrane oxygenator with a PMP membrane. For the neonatal and pediatric 
systems an arterial filter was integrated in the oxygenator, for the infant system a stand-alone 
arterial filter was used. Silicone- and PVC-tubing with different lengths and diameters were 
used in the neonatal and infant roller-pump systems. In the pediatric system a centrifugal 
pump was used, and the silicone tubing was discarded. Tubing was made continuous via a ¼- 
¼ or a ¼-⅜ connection piece. A venous reservoir completed the systems. Terumo components 
of the systems were coated with X-coating™ (PMEA): a non-heparin biocompatible polymer 
with hydrophilic and hydrophobic properties. Sorin components of the systems were coated 
with Phisio coating: a non-heparin, biomimatic layer consisting of a phosphorylcholine 
polymer.  
All systems were placed on a conventional mast mounted, remote pump head console 
(Stöcker S5 Perfusion System, Sorin Group, Mirandola, Italy) with a specific pediatric 
configuration.  
Three full systems were assembled for each category (neonatal, infant and pediatric) and 
primed according to hospital based protocol (see Table 2). Priming fluid contained FFP and 
Gelofusine (B. Braun, Melsungen, Germany). RBC’s were added to the priming to achieve a 
hematocrit of 28%. Recently expired RBC’s and FFP’s obtained from our local blood bank were 
used for priming. The priming fluid was completed with human albumin (Sanquin Plasma 
Products BV, Amsterdam, The Netherlands) and 2-5 ml sodium bicarbonate 8.4% (Fresenius 
Kabi Nederland BV, Zeist, The Netherlands). Heparin was added to the system according to 
hospital protocol to prevent clotting. 
The CPB-systems were kept running for 6 hours. This is the maximum runtime with guaranteed 
quality by the manufacturers. The temperature was maintained at 36°C. pO2, pCO2 and pH 
were measured with an iStat™ handheld device (Abbot BV, Hoofddorp, The Netherlands) and 
maintained within physiologic ranges by titration of sweep gas flow, gas composition and 
addition of sodium bicarbonate 8.4 % if needed. 
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A flow rate of 0.5 l min-1 was maintained for the neonatal circuits, 1.5 L min-1 for the infant 
circuits and 3 L min-1 for the pediatric circuits. Post membrane pressures were kept at 100 
mmHg by adapting the resistance using the venous clamp. 
Drug administration 
For the neonatal system we used a standardized body weight of 5 kg, for the infant system 15 
kg and for the pediatric system 30 kg. Drugs were added to the venous reservoir via a manifold 
sample port in a dose that would normally be used for the induction of general anesthesia 
according to our institution’s guidelines: midazolam (Actavis Group PTC ehf., Hafnarfjördur, 
Iceland, 1 mg ml-1) 0.2 mg kg-1, propofol (Fresenius Kabi Nederland BV, Zeist, The Netherlands) 
10 mg ml-1) 2 mg kg-1, sufentanil (Hameln Pharma Plus GmbH, Hameln, Germany, 50 mcg ml-
1) 2 mcg kg-1 and methylprednisolone (Pfizer BV, Capelle a/d IJssel, The Netherlands) 30 mg 
kg-1. Drugs were injected in the same order for all systems. Between each drug and after the 
last drug the sample port was flushed with 2 ml of saline 0.9% solution to prevent 
crystallization or pooling of drug. Midazolam, propofol, sufentanil and methylprednisolone 
were used because these drugs are commonly used in pediatric cardiac anesthesia in our 
institution.  
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A flow rate of 0.5 l min-1 was maintained for the neonatal circuits, 1.5 L min-1 for the infant 
circuits and 3 L min-1 for the pediatric circuits. Post membrane pressures were kept at 100 
mmHg by adapting the resistance using the venous clamp. 
Drug administration 
For the neonatal system we used a standardized body weight of 5 kg, for the infant system 15 
kg and for the pediatric system 30 kg. Drugs were added to the venous reservoir via a manifold 
sample port in a dose that would normally be used for the induction of general anesthesia 
according to our institution’s guidelines: midazolam (Actavis Group PTC ehf., Hafnarfjördur, 
Iceland, 1 mg ml-1) 0.2 mg kg-1, propofol (Fresenius Kabi Nederland BV, Zeist, The Netherlands) 
10 mg ml-1) 2 mg kg-1, sufentanil (Hameln Pharma Plus GmbH, Hameln, Germany, 50 mcg ml-
1) 2 mcg kg-1 and methylprednisolone (Pfizer BV, Capelle a/d IJssel, The Netherlands) 30 mg 
kg-1. Drugs were injected in the same order for all systems. Between each drug and after the 
last drug the sample port was flushed with 2 ml of saline 0.9% solution to prevent 
crystallization or pooling of drug. Midazolam, propofol, sufentanil and methylprednisolone 
were used because these drugs are commonly used in pediatric cardiac anesthesia in our 
institution.  
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Samples 
Four ml blood samples were taken from the arterial (post oxygenator) side of the circuit via a 
manifold sample port in a PLP EDTA tube (7.2 mg EDTA, BD Vacutainer®, BD Life Sciences, 
Plymouth, UK). Samples were taken immediately after injection of the drugs (T1) and after 2, 
5, 7, 10, 30, 60, 180 and 300 min.  
Samples were stored at 4°C until processing. After centrifugation (10 min at 3600 rpm) the 
supernatant serum was transferred to PLP cryogenic vials with PLP screw caps (Sarstedt 
Aktiengesellschaft & Co, Nümbrecht, Germany) and stored at -80°C until analysis.  
Assay methods 
Drug concentrations for sufentanil, midazolam, propofol and methylprednisolone were 
measured using liquid chromatography mass spectrometry (LC-MS/MS). Methods were 
validated according to U.S. FDA guidelines for bioanalytical method validation (10). All 
analyses included quality control samples, as is obliged in FDA analyses and ISO and GCP 
certified laboratories, and were performed by a certified research technician.  
Drug concentrations for sufentanil were measured using a Thermo TSQ Vantage triple-stage 
quadrupole mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) at the 
pharmacy laboratory of the Erasmus MC. 
Drug concentrations for midazolam were measured using a Quattro Premier mass 
spectrometer from Waters Corp (Waters Corp., Milford, MA, USA) at the pharmacy laboratory 
of the Erasmus MC. 
Propofol was measured using a Thermo TSQ Quantiva triple-stage quadrupole mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) at the pharmacy laboratory of 
the University Medical Center in Groningen, the Netherlands.  
Drug concentrations for methylprednisolone were measured using a SCIEX TriplequadTM 
6500+ mass spectrometer (AB SCIEX, Concord, Ontario, Canada) and Analyst® software version 
1.7 (AB SCIEX, Concord, Ontario, Canada) at the IBMP Institute for Biomedical and 
Pharmaceutical Research in Nürnberg-Heroldsberg, Germany. 
Chapter 5
108
LLOQ was 0.25 mcg l-1 for sufentanil, 2.0 mcg l-1 for midazolam, 100.0 mcg l-1 for propofol and 
0.01 mcg ml-1 for methylprednisolone. ULOQ was 50.0 mcg l-1 for sufentanil, 2400 mcg l-1 for 
midazolam, unknown for propofol and 30.1 mcg ml-1 for methylprednisolone. 
Statistical analysis 
We assessed the relationship between log-transformed drug concentration (dependent 
variable) and type of CPB-system and sample time point (independent variables) with linear 
mixed model analyses. Linear mixed model analyses were used because a correlation can be 
expected between repeated measurements of the same variable (i.e. drug concentration) in 
the same subject (i.e. individual CPB-systems). Both independent variables were treated as 
categorical variables and a two-way interaction effect between the type of CPB-system and 
sample time point was included in the model. To correct for within-system correlations 
between time points we used a random intercept and assumed a first-order autoregressive 
(AR1) error covariance matrix. This model specification was chosen by comparing values of 
the Akaike information criterion between different structures for the random effects and the 
error covariance matrix.  
For each time point and each CPB-system we calculated the difference between the predicted 
log-transformed estimated marginal means(11) at T1 and the predicted log-transformed 
concentration at the different time points and the 95 % CI of this difference. Finally, this 
difference and the 95 % CI were exponentiated to obtain the percentage drug recovery (the 
percentage of drug still present in the system) for T2-T300. We calculated MEC (the maximum 
expected concentration of drug in the CPB-systems) by dividing the amount of drug added to 
the CPB-systems by the total priming volume used, because it was unclear whether mixing of 
drug with the priming fluid would be complete at T1. 
Spearman correlations were calculated to assess the relationship between drug recovery at 
60 and 180 min and logP, protein binding and pKa among the four drugs (i.e. with a sample 
size of n = 4 drugs). For each drug, the recovery used for the calculation of this correlation was 
based on the estimated marginal means of the linear mixed model. 
Statistical analyses were performed using IBM SPSS Statistics 24. All statistical tests used a 
two-sided significance level of 0.05. 
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Statistical analysis 
We assessed the relationship between log-transformed drug concentration (dependent 
variable) and type of CPB-system and sample time point (independent variables) with linear 
mixed model analyses. Linear mixed model analyses were used because a correlation can be 
expected between repeated measurements of the same variable (i.e. drug concentration) in 
the same subject (i.e. individual CPB-systems). Both independent variables were treated as 
categorical variables and a two-way interaction effect between the type of CPB-system and 
sample time point was included in the model. To correct for within-system correlations 
between time points we used a random intercept and assumed a first-order autoregressive 
(AR1) error covariance matrix. This model specification was chosen by comparing values of 
the Akaike information criterion between different structures for the random effects and the 
error covariance matrix.  
For each time point and each CPB-system we calculated the difference between the predicted 
log-transformed estimated marginal means(11) at T1 and the predicted log-transformed 
concentration at the different time points and the 95 % CI of this difference. Finally, this 
difference and the 95 % CI were exponentiated to obtain the percentage drug recovery (the 
percentage of drug still present in the system) for T2-T300. We calculated MEC (the maximum 
expected concentration of drug in the CPB-systems) by dividing the amount of drug added to 
the CPB-systems by the total priming volume used, because it was unclear whether mixing of 
drug with the priming fluid would be complete at T1. 
Spearman correlations were calculated to assess the relationship between drug recovery at 
60 and 180 min and logP, protein binding and pKa among the four drugs (i.e. with a sample 
size of n = 4 drugs). For each drug, the recovery used for the calculation of this correlation was 
based on the estimated marginal means of the linear mixed model. 
Statistical analyses were performed using IBM SPSS Statistics 24. All statistical tests used a 
two-sided significance level of 0.05. 
Results 
We encountered no technical problems during the experiments. A total of 81 samples (27 for 
each CPB-system category) were analyzed. No loss of drug samples occurred.  
Figure 1 shows predicted drug recovery (based on the estimated marginal means of the linear 
mixed models) versus time for propofol, for each CPB-system category. There is a sharp and 
significant decline in recovery of propofol compared to T1 in all the system categories in the 
first 60 min, to 41.3 % (95 % CI 15.5-67.2, based on the estimated marginal means of the linear 
mixed models), meaning that approximately 59 % of the added drug has been lost from the 
circulating prime fluid at this time. After that, recovery continues to decrease slightly but 
significantly throughout the study period to 25 % (95 % CI 4.7-45.3) after 180 minutes and 19 
(95 % CI 5.2-32.8) after 300 min. Based on the interaction effects in the mixed models, there 
was a significant difference in the pattern of recovery over time between systems for propofol 
(p < 0.001). Recovery is highest in the infant system, followed by the pediatric system. The 
neonatal systems appear to absorb the largest amount of propofol to their system 
components. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5
110
Figure 1: Drug recovery versus time based on estimated marginal means for propofol, for each 
cardiopulmonary bypass system category, expressed as means and 95% confidence interval 
based on the linear mixed models. MEC, maximum expected concentration in case of perfect 
mixture of drug. *p < 0.002. 
 
 
Figure 2 shows predicted drug recovery (based on the estimated marginal means of the linear 
mixed models) versus time for sufentanil, midazolam and methylprednisolone. Because there 
was no significant interaction effect between the type of CPB-system and sample time point 
for sufentanil (p = 0.111), midazolam (p = 0.213) or methylprednisolone p = 0.829), a single 
graph is used to depict decrease of drug recovery over time for all three systems. The pattern 
of decline in recovery of sufentanil shows stable drug concentrations in the first 7 minutes, 
with a significant decline compared to T1 from T10 onward. Drug recovery is 41.7 % (95 % CI 
35.9-47.4, based on the estimated margical means of the linear mixed models) at 60 minutes. 
After 60 minutes recovery continues to decrease slightly but significantly throughout the study 
period. For sufentanil recovery is 23.0 % (95 % CI 9.2-36.8) after 180 minutes and 15 % (95 % 
CI -1.3-31.3) after 300 min.  
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was no significant interaction effect between the type of CPB-system and sample time point 
for sufentanil (p = 0.111), midazolam (p = 0.213) or methylprednisolone p = 0.829), a single 
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Figure 2: Drug recovery versus time based on estimated marginal means for midazolam, 
sufentanil, and methylprednisolone, expressed as means and 95% confidence interval based 
on the linear mixed models. MEC, maximum expected concentration in case of perfect mixture 
of drug. *p < 0.05 
 
  
For midazolam there is also stable drug recovery in the first 7 minutes. The decline in drug 
recovery compared to T1 reaches significance at T10 and from T60 forward. Drug recovery is 
87.3 % (95 % CI 64.9-109.7) after 60 minutes and 82.0 % (95 % CI 64.6-99.4) after 180 min. For 
Chapter 5
112
methylprednisolone there is stable recovery of drug in the first 30 minutes. After that, 
recovery increases significantly compared to T1 to values much higher than 100 %.  
We found no significant correlation between log P and percentage recovery of the four drugs 
at 60 and 180 min (ρ -0.324, p = 0.304). We did find a decreased recovery of highly protein 
bound drugs (ρ = -0.822, p = 0.007). The third factor correlated to percentage recovery at 60 
and 180 min in our study was pKa (ρ = 0.822, p = 0.007).  
Discussion  
This in vitro experiment investigated drug recovery in three different pediatric CPB-systems 
used in our center. Decrease of drug concentration in the circulating prime fluid for propofol 
and sufentanil is fast in the first 60 minutes. Since 60 minutes is a relatively common bypass 
time in pediatric cardiac surgery this period is clinically very relevant. The decreasing speed of 
decrease in drug concentration after 60 minutes may be an indication of near complete 
saturation of binding places on the different components of the CPB-systems. It is, however, 
unknown if there is a finite amount of binding places and if complete saturation of these 
binding places is possible. Hammaren (12) and Myers (13) have shown that for propofol there 
appears to be no maximum saturation of binding places in complete adult CPB-systems even 
at very high propofol concentrations. Binding of propofol may be concentration dependent 
(12). In contrast, complete saturation of oxygenator membrane fragments has been shown 
for fentanyl in in vitro studies (5).  
In our study midazolam recovery is remarkably large in both centrifugal and roller pump 
systems. Unfortunately, there are no in vitro studies of pediatric CPB-systems to compare our 
results with. An ECMO study performed in our hospital showed a recovery pattern similar to 
our experiment in systems with a centrifugal pump(8). In roller pump systems there was just 
7.5 % recovery after 2 min and 0.6 % recovery after 180 min. For midazolam we have to take 
into account, however, that the concentrations measured in our study were far above the 
ULOQ. We believe that this may at least partly be the reason that the MEC is lower than the 
measured concentrations. This introduces an unknown amount of bias, but we do not expect 
that this measurement bias would explain the high recovery rates. An error in the addition of 
medication to the system or a lab error are also not expected, since the experiments were 
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at 60 and 180 min (ρ -0.324, p = 0.304). We did find a decreased recovery of highly protein 
bound drugs (ρ = -0.822, p = 0.007). The third factor correlated to percentage recovery at 60 
and 180 min in our study was pKa (ρ = 0.822, p = 0.007).  
Discussion  
This in vitro experiment investigated drug recovery in three different pediatric CPB-systems 
used in our center. Decrease of drug concentration in the circulating prime fluid for propofol 
and sufentanil is fast in the first 60 minutes. Since 60 minutes is a relatively common bypass 
time in pediatric cardiac surgery this period is clinically very relevant. The decreasing speed of 
decrease in drug concentration after 60 minutes may be an indication of near complete 
saturation of binding places on the different components of the CPB-systems. It is, however, 
unknown if there is a finite amount of binding places and if complete saturation of these 
binding places is possible. Hammaren (12) and Myers (13) have shown that for propofol there 
appears to be no maximum saturation of binding places in complete adult CPB-systems even 
at very high propofol concentrations. Binding of propofol may be concentration dependent 
(12). In contrast, complete saturation of oxygenator membrane fragments has been shown 
for fentanyl in in vitro studies (5).  
In our study midazolam recovery is remarkably large in both centrifugal and roller pump 
systems. Unfortunately, there are no in vitro studies of pediatric CPB-systems to compare our 
results with. An ECMO study performed in our hospital showed a recovery pattern similar to 
our experiment in systems with a centrifugal pump(8). In roller pump systems there was just 
7.5 % recovery after 2 min and 0.6 % recovery after 180 min. For midazolam we have to take 
into account, however, that the concentrations measured in our study were far above the 
ULOQ. We believe that this may at least partly be the reason that the MEC is lower than the 
measured concentrations. This introduces an unknown amount of bias, but we do not expect 
that this measurement bias would explain the high recovery rates. An error in the addition of 
medication to the system or a lab error are also not expected, since the experiments were 
performed on different days for the different systems and all the percentage recovery versus 
time curves show a similar pattern.  
Methylprednisolone concentrations in the first hour are much lower than would be 
anticipated from the MEC. This is most likely caused by a problem with the mixing of 
methylprednisolone with priming fluid. Another explanation would be very fast binding of 
methylprednisolone to components of the CPB-system and release of drug from those binding 
sites after 60 minutes. It is however unknown if binding of drug to components of a CPB-
system is a reversible process.  
The substantial differences in recovery we found between drugs suggest that drug 
characteristics influence the interaction with components of the CPB-system (Table 3). From 
previous studies in ECMO-systems, recovery of drugs seems highly dependent on lipophilicity 
(8, 9, 14, 15). In our study we found no correlation between log P and recovery percentage. 
This is likely caused by the recovery profile of midazolam. Significantly decreased recovery of 
highly protein bound (> 80 %) drugs was also shown (15). We did find a generally decreased 
recovery of highly protein bound drugs, which may be caused by binding of drug to protein 
adhered to system components (15). In contrast, midazolam is also a highly protein bound and 
highly lipophilic drug but shows relatively high recovery in our study. The similar recovery 
patterns of propofol and sufentanil suggest there is a common physicochemical property of 
both drugs causing this effect. We can however not explain why the recovery pattern of 
midazolam is different, since the physicochemical properties known to influence recovery 
percentage are very similar to propofol and sufentanil. Another factor correlated to 
percentage recovery at 60 and 180 min in our study was pKa. To our knowledge no correlation 
between pKa and recovery has been described previously. The surface coated CPB-systems 
are negatively charged, making electrostatic attraction of positively charged molecules a 
possible mechanism for absorption of drugs to CPB-system components. Drugs with a high 
pKa are unlikely to be dissociated at normal pH, which was maintained during the study 
period.  
We found a significant difference in drug recovery between the different types of CPB-system 
only for propofol. In general one would expect a larger system to have more binding sites for 
drugs and thus a lower recovery for drugs with similar properties. The surface area of the 
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oxygenator and the PVC-tubing in our pediatric systems are much larger than that in our 
neonatal and infant systems. In our study midazolam and methylprednisolone do indeed show 
lower recovery in larger systems, though not significantly so. For propofol there is however 
higher recovery in larger systems. The differences are smaller than would be expected if 
system size were the only factor involved.  
Different components of the CPB-system are capable of absorbing drugs to their plastics. 
Differences in drug recovery between different types of oxygenator have been extensively 
described (5, 16). With the new PMP and PLP membranes the oxygenator does not appear to 
be a factor of considerable interest in drug recovery anymore. Based on a study by Preston et 
al 80 % of drug is lost to PVC tubing, with a small additional amount of drug (of just 5 %) lost 
to the oxygenator (17). Silicone tubing has been shown to decrease the recovery of drugs 
compared to PVC tubing (2, 8). The effect of different surface coatings on both oxygenator 
and tubing on drug recovery has been investigated by several authors (7, 12, 13), suggesting 
different effects for different coatings for different types of drugs. Addition of an arterial filter 
may also lead to decreased drug recovery (13). Many factors are thus at play and interact with 
each other. 
It is unclear which differences in system composition play a role in our study. The interplay of 
differences in surface area, coating, tubing type and pump type makes it difficult to draw firm 
conclusions about the influence of individual system components on drug recovery. In an 
earlier study by Preston et al a Terumo Baby Rx oxygenator was used (17). We used the 
Terumo Capiox® Fx05 in our neonatal systems, which is the same oxygenator with the same 
membrane, the same coating and the same surface area, but with an integrated arterial filter. 
The Baby Rx oxygenator absorbed 3 % of fentanyl added to the system in the study by Preston 
et al, which amounts to 0.6 ng/cm². Raffaeli et al have shown that sufentanil absorption is 
similar to fentanyl absorption in their ECMO systems (9). Assuming the above holds true the 
amount of drug absorbed in our neonatal systems just by the tubing and the arterial filter 
would be 4.2 mcg of sufentanil at 180 minutes for our systems (total uptake of sufentanil 72 
% at 180 min of 10 mcg added to the neonatal systems minus the amount absorbed by the 
oxygenator). Because our neonatal systems use silicone tubing, this relatively low amount of 
absorption seems unlikely.  
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conclusions about the influence of individual system components on drug recovery. In an 
earlier study by Preston et al a Terumo Baby Rx oxygenator was used (17). We used the 
Terumo Capiox® Fx05 in our neonatal systems, which is the same oxygenator with the same 
membrane, the same coating and the same surface area, but with an integrated arterial filter. 
The Baby Rx oxygenator absorbed 3 % of fentanyl added to the system in the study by Preston 
et al, which amounts to 0.6 ng/cm². Raffaeli et al have shown that sufentanil absorption is 
similar to fentanyl absorption in their ECMO systems (9). Assuming the above holds true the 
amount of drug absorbed in our neonatal systems just by the tubing and the arterial filter 
would be 4.2 mcg of sufentanil at 180 minutes for our systems (total uptake of sufentanil 72 
% at 180 min of 10 mcg added to the neonatal systems minus the amount absorbed by the 
oxygenator). Because our neonatal systems use silicone tubing, this relatively low amount of 
absorption seems unlikely.  
A similar calculation for our pediatric systems is possible. The Capiox® Fx15 oxygenator would 
absorb 9 mcg in total, due to its larger surface area. After 180 min 76 % of the 60 mcg of 
sufentanil added to the system would be absorbed. Further calculation shows that this would 
mean that the Sorin® tubing would absorb 25.1 ng/cm² of sufentanil. This would however 
mean that all the sufentanil in our neonatal system would have to have been absorbed, which 
is not the case. For a more extensive calculation we refer to the supplemental materials.  
Hynynen (18) describes propofol recovery of 25 % after 120 min of circulation in an adult 
system. Hammaren and Myers (12, 13) describe recovery of 37 and 43 % respectively after 60 
minutes. These values are remarkably similar to ours, even though completely different CPB-
systems were used. Given the calculations performed above and the results by Hynynen, 
Hammaren and Meyers it appears that it is very difficult to translate research performed in 
individual centers to one’s own clinical practice, given the amount of factors and interaction 
at play. It is clear that not all factors influencing absorption to different components of CPB-
systems are known. A possible lack of generalizability may thus be seen as a limitation to our 
study, as well as other studies already performed in this field.  
 Several authors have found no influence of temperature management on the recovery of 
drugs in their systems (16, 19, 20). Therefore we did not attempt to simulate a cooling 
protocol. 
Despite the significant decrease in recovery of drug from the priming fluid of the CPB-system 
found in our in vitro studies, clinically patients do not wake up on initiation or during CPB. A 
clinical study in adult patients has shown no change or even a decrease in BIS values during 
CPB (21). This is most likely caused by an increase in unbound drug concentration caused by 
decreased protein concentration on initiation of CPB (21-23), causing a greater amount of drug 
available for end organ effect.  
Our study has several other limitations. We only tested complete systems, thus we have no 
information as to which amount of drug was absorbed by which system component. 
Unfortunately this type of research is costly, due to the costs of systems, blood products for 
priming and the cost of drug concentration measurements. Also, for our purposes, namely the 
integration of these in vitro results with the results of the in vivo part of the CPB-PHARM study, 
we wanted to mimic every day practice in our hospital as closely as possible, making testing 
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of individual components less useful. For the same reasons, we have not performed isolated 
drug studies. It is not known if there is competition for binding sites to components of the 
CPB-system for different individual drugs. Although theoretically this is an interesting topic, in 
clinical practice patients receive multiple medications at the same time.  
We used just three full systems in each category. This may seem like a small number, but our 
sample size is comparable to that of other publications performed in both CPB- and ECMO- 
systems and cited in this article. 
Spontaneous degradation may produce bias in our study because it causes a decrease in drug 
concentrations not caused by adherence of drug to components of the CPB-system. Previous 
studies in our hospital have shown that spontaneous degradation over 24 hours for 
midazolam is 11,4 % and for sufentanil is 0 % (9). For propofol spontaneous degradation in 
glass bottles with daylight and room temperature is around 5 % after 6 hours (24). For 
methylprednisolone no references were found for spontaneous degradation. Since 
degradation is usually calculated over 24 hours, the effect on our results would be constant 
over time. 
For the calculation of MEC we did not correct for blood-plasma ratio. In previous studies in 
our hospital midazolam was shown to have a blood-plasma ratio of 75 % (8). Since our MEC 
value is calculated in blood, but drug concentrations are measured in plasma MEC would be 
underestimated for midazolam. Since propofol is highly bound to red blood cells in vivo a high 
blood-plasma ratio would be expected, and our MEC would be overestimated. 
We did not aim for a similar drug concentration in the different types of CPB-systems. Instead 
we added the dose of drug that would be administered to a typical patient connected to a 
neonatal, infant or pediatric CPB-system in our daily clinical setting, since the goal of this study 
was to mimic our everyday practice as closely as possible, so that in the future we will be able 
to incorporate CPB-system recoveries in a larger population pharmacokinetic model of the 
influence of cardiopulmonary bypass on drug concentrations in children.  
Due to the high doses of drug added to our systems, drug concentrations were above the 
ULOQ for some drug assays, necessitating additional dilution before quantification. The high 
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of individual components less useful. For the same reasons, we have not performed isolated 
drug studies. It is not known if there is competition for binding sites to components of the 
CPB-system for different individual drugs. Although theoretically this is an interesting topic, in 
clinical practice patients receive multiple medications at the same time.  
We used just three full systems in each category. This may seem like a small number, but our 
sample size is comparable to that of other publications performed in both CPB- and ECMO- 
systems and cited in this article. 
Spontaneous degradation may produce bias in our study because it causes a decrease in drug 
concentrations not caused by adherence of drug to components of the CPB-system. Previous 
studies in our hospital have shown that spontaneous degradation over 24 hours for 
midazolam is 11,4 % and for sufentanil is 0 % (9). For propofol spontaneous degradation in 
glass bottles with daylight and room temperature is around 5 % after 6 hours (24). For 
methylprednisolone no references were found for spontaneous degradation. Since 
degradation is usually calculated over 24 hours, the effect on our results would be constant 
over time. 
For the calculation of MEC we did not correct for blood-plasma ratio. In previous studies in 
our hospital midazolam was shown to have a blood-plasma ratio of 75 % (8). Since our MEC 
value is calculated in blood, but drug concentrations are measured in plasma MEC would be 
underestimated for midazolam. Since propofol is highly bound to red blood cells in vivo a high 
blood-plasma ratio would be expected, and our MEC would be overestimated. 
We did not aim for a similar drug concentration in the different types of CPB-systems. Instead 
we added the dose of drug that would be administered to a typical patient connected to a 
neonatal, infant or pediatric CPB-system in our daily clinical setting, since the goal of this study 
was to mimic our everyday practice as closely as possible, so that in the future we will be able 
to incorporate CPB-system recoveries in a larger population pharmacokinetic model of the 
influence of cardiopulmonary bypass on drug concentrations in children.  
Due to the high doses of drug added to our systems, drug concentrations were above the 
ULOQ for some drug assays, necessitating additional dilution before quantification. The high 
doses might also have resulted in potential differences in absorption rates, as has been shown 
for propofol (12). 
In our study we found indications that mixing of drug with the priming fluid is not always 
complete. This may have clinical consequences if drugs are added to the CPB-system during 
CPB, rather than given directly to the patient. 
Despite these limitations our study is the first comprehensive in vitro testing of CPB-systems 
used in pediatric congenital cardiac surgery.  
In conclusion, our in vitro experiment with neonatal, infant and pediatric CPB-systems shows 
a variable recovery of routinely used drugs with significant differences between drugs, but not 
between system categories, except for propofol. We have also shown that the generalizability 
of this type of research may be limited. The clinical consequences of our research will have to 
be further investigated. The decreased recovery of sufentanil and propofol could lead to 
suboptimal dosing of patients during cardiac surgery with the use of CPB, even though 
clinically this doesn’t show. It is thus important that these findings are integrated with the 
results of in vivo studies into population pharmacokinetic models, to further investigate the 
clinical relevance of our findings and the implications for perioperative patient care.  
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Abstract  
Objective: The mainstay of pain treatment after paediatric cardiac surgery is the use of 
opioids. Current guidelines for its optimal use are based on small, non-randomized clinical 
trials, and data on the pharmacokinetics (PK) and pharmacodynamics (PD) of opioids are 
lacking. This study aims at providing an overview of international hospital practices on the 
treatment of pain and sedation after paediatric cardiac surgery. 
Design: A multicentre survey study assessed the management of pain and sedation in children 
aged 0-18 years after cardiac surgery.  
Setting: PICUs of nineteen tertiary children’s hospitals worldwide were invited to participate. 
The focus of the survey was on type and dose of analgesic and sedative drugs and the tools 
used for their pharmacodynamic assessment. 
Results: Fifteen hospitals (response rate 79%) filled out the survey. Morphine was the primary 
analgesic in most hospitals and its doses for continuous infusion ranged from 10-60 mcg kg-1 
h-1 in children aged 0-36 months. Benzodiazepines were the first choice for sedation, with 
midazolam used in all study hospitals. Eight hospitals (53%) reported routine use of sedatives 
with pain treatment. Overall, type and dosing of analgesic and sedative drugs differed 
substantially between hospitals. All participating hospitals used validated pain and sedation 
assessment tools.  
Conclusion: There was a large variation in the type and dosing of drugs employed in the 
treatment of pain and sedation after paediatric cardiac surgery. As a consequence, there is a 
need to rationalize pain and sedation management for this vulnerable patient group. 
What is known about the subject 
• There is large variability in choice and dosing of analgesics and sedatives after cardiac 
surgery in children worldwide.  
• Validated pain and sedation tools were used extensively.  
What this study adds 
• Insight into clinical protocols on use of analgesics and sedatives in children after 
cardiac surgery, showing large variability in choice and dosing of analgesics and 
sedatives.  
• Morphine is the first choice analgesic, midazolam the first choice sedative. Dosing of 
both drugs differ considerably between hospitals.  
• Use of validated PD assessment tools is not standard in clinical practise. Lack of a 
validated PD assessment tool could result in oversedation.  
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Introduction  
Congenital heart disease (CHD) accounts for almost one third of all congenital defects (1). 
Adequate postoperative sedation and pain management is important in these patients 
because untreated pain can lead to a delayed recovery, prolonged adverse behavioural 
consequences and negative physiologic responses (2-4). 
Morphine is widely used for analgesia after major surgery in neonates and children. Several 
studies on morphine PK/PD have resulted in age specific dosing algorithms in children after 
non-cardiac surgery. Ceelie et al. showed equipotency of paracetamol as primary analgesic as 
compared to morphine in neonates and children < 1 year of age after major non-cardiac 
surgery. It is currently unclear if these data can be extrapolated to children after cardiac 
surgery (5, 6). 
Postoperative analgosedation in children after cardiac surgery is mainly achieved with opioids 
combined with sedatives. The most common opioid used is morphine, with doses ranging 
from 5-80 mcg kg-1 h-1 (7). Morphine is recommended as drug of first choice by the Association 
of Paediatric Anaesthetists of Great Britain and Ireland (8). However, this guideline is based 
on small, non-randomized clinical trials. PK data are available for the routinely prescribed 
analgesics and sedatives, but combined PK/PD data are scarce.  
Lynn et al. described adequate pain relief after cardiac surgery with continuous morphine 
infusions of 10-38.5 mcg kg-1 h-1 (9, 10). Even though adequate analgesia can be achieved, 
plasma morphine concentrations above 20 ng ml-1 have been associated with adverse effects, 
such as hypotension and respiratory depression (9, 11). Patients with cyanotic heart defects 
showed lower morphine requirements and higher plasma concentrations compared to 
patients with non-cyanotic heart defects, indicating that type of defect or type of surgery may 
be associated with altered PK/PD necessitating different dosing regimens (12).  
A recent review by Lucas et al. (13) on pharmacotherapies in paediatric cardiac critical care 
provides an extensive overview of PK of analgesic and sedative drugs used in children after 
cardiac surgery but focused less on their use in protocols for clinical practice. Changes in 
clearance and volume of distribution (PK) and/or PD due to the use of cardiopulmonary bypass 
(CPB), disease processes, low cardiac output syndrome, surgical procedure and age may alter 
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Introduction  
Congenital heart disease (CHD) accounts for almost one third of all congenital defects (1). 
Adequate postoperative sedation and pain management is important in these patients 
because untreated pain can lead to a delayed recovery, prolonged adverse behavioural 
consequences and negative physiologic responses (2-4). 
Morphine is widely used for analgesia after major surgery in neonates and children. Several 
studies on morphine PK/PD have resulted in age specific dosing algorithms in children after 
non-cardiac surgery. Ceelie et al. showed equipotency of paracetamol as primary analgesic as 
compared to morphine in neonates and children < 1 year of age after major non-cardiac 
surgery. It is currently unclear if these data can be extrapolated to children after cardiac 
surgery (5, 6). 
Postoperative analgosedation in children after cardiac surgery is mainly achieved with opioids 
combined with sedatives. The most common opioid used is morphine, with doses ranging 
from 5-80 mcg kg-1 h-1 (7). Morphine is recommended as drug of first choice by the Association 
of Paediatric Anaesthetists of Great Britain and Ireland (8). However, this guideline is based 
on small, non-randomized clinical trials. PK data are available for the routinely prescribed 
analgesics and sedatives, but combined PK/PD data are scarce.  
Lynn et al. described adequate pain relief after cardiac surgery with continuous morphine 
infusions of 10-38.5 mcg kg-1 h-1 (9, 10). Even though adequate analgesia can be achieved, 
plasma morphine concentrations above 20 ng ml-1 have been associated with adverse effects, 
such as hypotension and respiratory depression (9, 11). Patients with cyanotic heart defects 
showed lower morphine requirements and higher plasma concentrations compared to 
patients with non-cyanotic heart defects, indicating that type of defect or type of surgery may 
be associated with altered PK/PD necessitating different dosing regimens (12).  
A recent review by Lucas et al. (13) on pharmacotherapies in paediatric cardiac critical care 
provides an extensive overview of PK of analgesic and sedative drugs used in children after 
cardiac surgery but focused less on their use in protocols for clinical practice. Changes in 
clearance and volume of distribution (PK) and/or PD due to the use of cardiopulmonary bypass 
(CPB), disease processes, low cardiac output syndrome, surgical procedure and age may alter 
optimal way of dosing analgesics and sedatives in children after cardiac surgery (14). These 
expected PK/PD differences are not incorporated in existing guidelines and it is unclear if they 
are introduced into local protocols.  
While current dosing is commonly titrated to effect (sedation or pain score), quantification of 
that effect can be difficult as pain and sedation scores are not always validated for different 
patient groups. A one size fits all dosing regimen may lead to over or under sedation resulting 
in less efficacy or increased toxicity. As clear individualized evidence based dosing guidelines 
are lacking a wide variety can be expected in clinical practice. 
Our primary objective was to ascertain international analgosedation practices after paediatric 
cardiac surgery with a self-reported survey. Our main focus was the use of local protocols, 
choice and dosing range of analgesics and sedatives, use of pain and sedation scores and the 
use of treatment algorithms. 
Methods 
Design 
A self-designed web-based survey (Monkey Survey, https://nl.surveymonkey.com/) was 
circulated to medical specialists in tertiary cardiac care hospitals who are responsible for the 
treatment of children after cardiac surgery. Hospitals were selected based on expertise and 
yearly conduct of more than 150 paediatric on-pump cardiac surgical procedures. The survey 
was designed by a small focus group consisting of a congenital cardiothoracic surgeon, three 
paediatric intensivists and a paediatric cardiac anaesthesiologist because of the absence of 
validated questionnaires. The potential respondents were instructed that this survey aimed 
at collecting data on the current treatment strategies concerning the use of analgesics and 
sedatives, as well as the tools used for the measurement of pain and sedation, according to 
their local protocols and not their personal preference. The survey has been provided in the 
appendix.  
The survey focused primarily on the choice and dosing regimens of analgesic and sedative 
drugs prescribed in the surveyed institutions as well as the PD assessment tools that were 
used in these circumstances. Additional questions related to the characteristics of the unit.  
Chapter 7
144
Potential participants initially received a letter asking for their involvement in the survey. If 
they agreed details of the survey as well as the link to enter their answers were provided by 
email. If necessary an additional email to remind the participants about the survey was sent 
two and four weeks after the initial letter. Data were collected between June and August 2014. 
Ethical approval was not needed for this study, since no patients are involved neither person 
related questions are raised to the individual hospitals.  
Results 
Hospital characteristics 
A total of 19 hospitals on three different continents were willing to participate; 15 (response 
rate 79%) hospitals completed the survey in full. Twelve respondents (80%) were from 
European hospitals. Three respondents were from non-European hospitals based in New-
Zealand, Australia and Canada. Non-respondents were based in the USA (1), United Kingdom 
(2) and China (1). Respondents were physicians, mainly paediatric intensivists or paediatric 
cardio-anaesthesiologists who work in paediatric cardiac critical care units. Two paediatric 
intensivists reported that they had consulted a paediatric cardio-anaesthesiologist on 
questions relating to the perioperative management.  
The participating hospitals perform a total of over 3000 on-pump paediatric cardio-surgical 
procedures annually with a postoperative ICU stay ranging between 2 and 7 days.  
The number of procedures per age category varied between hospitals, however about two 
third of the procedures were performed in children under the age of 1 year.  
Medication 
Table 1 shows the type and dosing of reported analgesics. Table 2 shows the type and dosing 
of reported sedatives. Both tables show the results for treatment protocol in neonates and 
children until the age of two years.  
There was a wide range of choices and dosing regimens of drugs reported for both analgesics 
and sedatives. Moreover, polypharmacy is often used to accomplish the desired effects for 
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email. If necessary an additional email to remind the participants about the survey was sent 
two and four weeks after the initial letter. Data were collected between June and August 2014. 
Ethical approval was not needed for this study, since no patients are involved neither person 
related questions are raised to the individual hospitals.  
Results 
Hospital characteristics 
A total of 19 hospitals on three different continents were willing to participate; 15 (response 
rate 79%) hospitals completed the survey in full. Twelve respondents (80%) were from 
European hospitals. Three respondents were from non-European hospitals based in New-
Zealand, Australia and Canada. Non-respondents were based in the USA (1), United Kingdom 
(2) and China (1). Respondents were physicians, mainly paediatric intensivists or paediatric 
cardio-anaesthesiologists who work in paediatric cardiac critical care units. Two paediatric 
intensivists reported that they had consulted a paediatric cardio-anaesthesiologist on 
questions relating to the perioperative management.  
The participating hospitals perform a total of over 3000 on-pump paediatric cardio-surgical 
procedures annually with a postoperative ICU stay ranging between 2 and 7 days.  
The number of procedures per age category varied between hospitals, however about two 
third of the procedures were performed in children under the age of 1 year.  
Medication 
Table 1 shows the type and dosing of reported analgesics. Table 2 shows the type and dosing 
of reported sedatives. Both tables show the results for treatment protocol in neonates and 
children until the age of two years.  
There was a wide range of choices and dosing regimens of drugs reported for both analgesics 
and sedatives. Moreover, polypharmacy is often used to accomplish the desired effects for 
both analgesia and sedation. Eleven different analgesics and eight different sedatives were 
reported.  
None of the hospitals based analgosedation according to protocol on cardiac diagnosis, 
severity scores or type of surgery. One hospital added fentanyl for analgesic therapy in 
patients returning from the operating room with an open sternum.  
Analgesics  
Opioids were the preferred analgesic; morphine was the opioid of choice in 13 (87%) of the 
hospitals. Dosing ranged from 10-60 mcg kg-1 h-1 for a continuous infusion and from 50-500 
mcg kg-1 for a bolus dose. Morphine was supplemented with a second analgesic in 73% of 
hospitals, either as standard practice or rescue therapy. The primary choice of analgesics 
varied between hospitals but did not differ between age groups within hospitals. Most drugs 
were dosed according to weight. However, overall dosing ranges in neonates tended to be 
lower compared to infants and children. Furthermore in children over two years of age more 
alternative analgesic drugs were reported as used per protocol in some hospitals; namely 
oxycodone, nalbuphine and diclofenac.  
Dexmedetomidine could be considered a sedative but was reported as an analgesic in the 
survey and therefore reported as such. 
Table1: Results of the international survey for type and dose of analgesics in children after 
cardiac surgery 
Medication Neonates 0-28 days Infants 29 days – 2 years  
Use in 
hospitals 
(n) 
doses Use in 
hospitals (n) 
doses 
Morphine IV bolus mcg kg-1 9  50-200 9  50-500 
Morphine IV mcg kg-1 h-1 12  5-40 12 10-60 
Piritramide IV bolus mg kg-1 1  0.2-1.2 2  0.05-0.4 
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 Neonates 0-28 days Infants 29 days – 2 years 
Piritramide IV mg kg-1 day-1 n.a. n.a. 1  1.2 
Fentanyl IV bolus mcg kg-1 1  1-2 1  1-2 
Fentanyl IV mcg kg-1 h-1 3  1-6 3  1-6 
Remifentanil IV bolus mcg kg-1 1  1 1  1 
Remifentanil IV mcg kg-1 min-1 1  0.1-0.2 1  0.1-0.2 
Sufentanil IV mcg kg-1 h-1 1  1- 2 1  1- 2 
Dexmedetomidine IV bolus mcg kg-1 n.a. n.a. 1  50 
Dexmedetomidine IV mcg kg-1 h n.a. n.a. 2  0.5-1.5 
Paracetamol IV mg kg-1 Q6h 5  7.5 7  7.5-15 
Paracetamol PO/PR mg kg-1 day-1 5  45-90 7  45-90 
Metamizol IV mg kg-1 1  40 1  40 
Diclofenac IV/PR mg kg-1 day-1 n.a. n.a. 3  1-3 
Ibuprofen PO bolus mg kg-1 n.a. n.a. 2  5-10 
Dexketoprofen IV mg kg-1 1  0.5-1 1  0.5-1 
Hospitals represented in the survey: Erasmus MC-Sophia, Rotterdam; LUMC, Leiden; UMC 
Utrecht; UMC Groningen; Our Lady’s Children’s Hospital, Crumlin; Children’s Hospital 
Bambino Gesù, Rome; Royal Brompton Hospital, London; Royal Children’s Hospital, 
Melbourne; University Hospital, Leuven; University Hospital La Paz, Madrid; Starship 
Children’s Hospital, Auckland; Hospital for Sick Children, Toronto; German Heart Centre, 
Munich; Queen Silvia Hospital Gothenburg, Memorial Hospital – Child Health Centre, Warsaw. 
IV: intravenous, mcg: microgram, kg: kilogram, h: hour, Q: each, min: minute, PO: per oral, PR: 
per rectum, n.a.: not applicable 
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Sedatives 
Midazolam was the primary sedative in 100% of hospitals, either as a bolus or a continuous 
infusion. Eight hospitals (53%) reported routine use of sedatives with pain treatment. The 
other hospitals only started sedatives in response to discomfort. Of eight hospitals who 
routinely use sedatives with pain treatment, six used morphine as primary analgesic in an 
average dose of 10-30 mcg kg-1 h-1 with one outlier using morphine from 30-60 mcg kg-1 h-1, in 
neonates and infants, respectively. Two other hospitals who routinely use sedatives with pain 
treatment used piritramide (dose 1.2 mg kg-1 d-1) and fentanyl (dose 5 mcg kg-1 h-1) as primary 
analgesics. Average dosing of morphine in hospitals without routine sedation was 5-40 mcg 
kg-1 h-1. Overall morphine dosing in hospitals that use standard sedatives are comparable or 
lower than hospitals that do not use standard sedatives.  
Sedatives were used as per protocol or at the attending physician’s discretion. Treatment 
strategies between neonates and infants varied less for sedatives than for analgesics. There 
were no reported differences in choice of drugs and dosing between infants 29 days-2 years 
and children older than 2 years.  
Table 2: Results of the international survey for type and dose of sedatives in children after 
cardiac surgery. 
Medication Neonates 0-28 days Infants 29 days – 2 years 
Use in 
hospitals (n) 
doses Use in 
hospitals (n) 
doses 
Midazolam IV bolus mg kg-1  12  0.05-1.5 12  0.05-1.5 
Midazolam IV mg kg-1 h-1 15  0.06-4 15  0.06-0.5 
Clonidine IV bolus mcg kg-1 3  0.5-2 3  0.5-2 
Clonidine IV mcg-1 kg-1 h-1 7  0.5-2 7  0.5-2 
Lorazepam PO mg kg-1 3  0.05 3  0.05 
Propofol IV bolus mg kg-1 3  1 3  1 
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 Neonates 0-28 days Infants 29 days – 2 years 
Propofol IV mg kg-1 h-1 3  1-6 3  1-6 
Esketamine IV bolus mg kg-1 1  0.5-1 1  0.5-1 
Esketamine IV mg kg-1 h-1 1  0.5-1.5 1  0.5-1.5 
Chloral hydrate IV mg kg-1 3  10-50 3  10-50 
Chloral hydrate NG mg kg-1 1  12.5-25 1  12.5-25 
Promethazine mg kg-1 1  0.5-1.5 1  0.5-1.5 
Chlorpromazine mg kg-1 2  0.5-1.5 2  0.5-1.5 
Hospitals represented in the survey: see table 1. IV: intravenous, mg: milligram, mcg: 
microgram, kg: kilogram, h: hour, PO: per oral, NG: nasogastric 
 
Sedation scores 
All hospitals used a validated pain and sedation score. Table 3 shows the different scores used. 
Pain and sedation was assessed using a total of six different paediatric pain and four different 
sedation scores. Eleven (73%) of the 15 hospitals used the COMFORT-B scale and Numeric 
Rating Scale (NRS) for pain and sedation. Frequency of pain and sedation assessment varies 
between hospitals. Reassessment after an intervention, either medical or non-medical, was 
reported by two respondents.  
Each centre reported the use of a local protocol to guide analgosedation after cardiac surgery.  
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Table 3: PD tools reported in the survey.  
Scale  Validated age 
range 
Number of 
centres 
How often assessed first 
72 hours after surgery?  
(Minimal and maximal) 
Pain assessment     
FLACC[33] 2 months- 7 years 2 n.s. 
CRIES[34] 0-28 days 1 n.s. 
COMFORT-B scale[35-37] 0 - 3 years 1 n.s. 
VAS pain obs 0-3 years 7 8 hourly, after bolus 
NRS pain obs 0-3 years 4 2-4 hourly, after bolus 
LLanto scale   1 n.s. 
Sedation assessment    
NISS[38] 0-18 years 2 8 hourly, after bolus 
COMFORT-B scale[38] 0-18 years  11 4-8 hourly, after bolus 
Brussels Sedation Scale [39] Adults  1 n.s. 
Ashworth scale [40]  1 n.s. 
FLACC: acronym for Face, Legs, Activity, Cry, Consolability, CRIES: acronym for Crying, Requires 
O2 for SaO2 <95%, Increased vital signs (Blood pressure and Heartrate), Expression, Sleepless, 
COMFORT-B: COMFORT-behavioural scale, VASobs: Visual Analogue Scale observation, NRS: 
Numeric Rating Scale pain observation, LLANTO SCALE: acronym for llanto, actitud, 
normorrespiración, tono postural y observación (crying, attitude, respiratory pattern, muscle 
tone and facial), NISS: Nurses’ Interpretation of Sedation Score, N.S.: not specified, Mo: 
month, Y: years. 
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Discussion 
The choice and dosing regimens of analgesics and sedatives after cardiac surgery in children 
varied extensively across the globe. Opioids were the analgesics of choice. Morphine was the 
preferred analgesic drug, with a wide range of doses, both for continuous infusion and bolus 
administration in both the neonatal age group and in older infants and children. Morphine 
was supplemented by a second analgesic drug in 73% of the surveyed hospitals. Differences 
between local protocols were evident in all age groups, however more variation in analgesics 
and sedatives was found in infants and children as compared to neonates. The underlying 
cardiac diagnosis, severity score or type of surgery did not result in different treatment 
algorithms or dosing regimens. Eight hospitals routinely used a sedative in combination with 
pain treatment, all other institutions started sedatives only in response to a clinical need for 
sedation.  
The reported use of drugs are comparable with those described by Wolf in 2011 and reflect in 
part the guidelines from the Royal College of Paediatrics and Child Health (United Kingdom) 
as well as the guidelines from the Association of Paediatric Anaesthetists of Great Britain and 
Ireland (7, 8). The recent consensus statement by Lucas et al., describes the 
pharmacotherapies currently available to manage pain and sedation in paediatric cardiac 
critical care patients and summarizes dosing recommendations from available literature (13). 
Lucas and colleagues conclude that a more individualized analgesic and sedative treatment 
strategy is necessary to provide optimal care without adverse effects resulting from 
pharmacotherapy.  
This need for individualised dosing is possibly reflected in the reported wide range of dosing 
for morphine with the highest morphine infusion rate of 60 mcg kg-1 h-1 and largest bolus of 
500 mcg kg-1in the participating centres as well as the use of adjuvant analgesics and sedatives. 
However, doses mainly differed between hospitals, not within hospitals. Differences in 
morphine dosing could also reflect differences in local practices and preferences between 
hospitals rather than individualised dosing regimens based on clear PD endpoints.  
Ideally we would like to predict individual morphine requirement beforehand and better 
categorise the efficacy of adjuvant or alternative analgesics to minimize adverse effects. 
Advances towards precision medicine have been made for morphine in non-cardiac surgery 
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The reported use of drugs are comparable with those described by Wolf in 2011 and reflect in 
part the guidelines from the Royal College of Paediatrics and Child Health (United Kingdom) 
as well as the guidelines from the Association of Paediatric Anaesthetists of Great Britain and 
Ireland (7, 8). The recent consensus statement by Lucas et al., describes the 
pharmacotherapies currently available to manage pain and sedation in paediatric cardiac 
critical care patients and summarizes dosing recommendations from available literature (13). 
Lucas and colleagues conclude that a more individualized analgesic and sedative treatment 
strategy is necessary to provide optimal care without adverse effects resulting from 
pharmacotherapy.  
This need for individualised dosing is possibly reflected in the reported wide range of dosing 
for morphine with the highest morphine infusion rate of 60 mcg kg-1 h-1 and largest bolus of 
500 mcg kg-1in the participating centres as well as the use of adjuvant analgesics and sedatives. 
However, doses mainly differed between hospitals, not within hospitals. Differences in 
morphine dosing could also reflect differences in local practices and preferences between 
hospitals rather than individualised dosing regimens based on clear PD endpoints.  
Ideally we would like to predict individual morphine requirement beforehand and better 
categorise the efficacy of adjuvant or alternative analgesics to minimize adverse effects. 
Advances towards precision medicine have been made for morphine in non-cardiac surgery 
patients mainly focusing on the patients’ size, maturation and organ function (6, 15, 16). By 
using information from PK/PD studies on morphine consumption after cardiac surgery we aim 
to individualize and assess treatment effect by regular pain and sedation assessment and 
tracking of adverse drug reactions. However, PK parameters of analgesics and sedatives, or 
potential PK alterations in children after cardiac surgery are currently incomplete. Changes of 
clearance and volume of distribution would be expected in this cohort, dependent on the use 
of the CPB, age and underlying pathology. For remifentanil (17, 18), dexmedetomidine (19, 
20), clonidine (21) and ketamine (22), studies have been published within the last 10 years 
with PK parameters in neonates and children after cardiac surgery. However, these studies 
show conflicting results on PK alterations and most lack PD endpoints to assess efficacy, 
making it difficult to implement dose recommendations in clinical practice.  
Due to polypharmacy it is difficult to assess the efficacy and safety of individual drugs. Our 
survey showed that a multimodal drug approach is often used for analgesics and sedatives. 
The challenge is to determine how these drugs interact (23, 24). The combination of sedatives 
and opioids may contribute to oversedation, which is highly undesirable and could lead to 
longer PICU stay, longer ventilation times, drug tolerance and dependence (25).  
PD aspects after cardiac surgery are rarely described in literature, making interpretation of PK 
knowledge clinically limited. Validated PD scoring tools were used in our survey hospitals; 
mainly the Comfort-B scale (73%), VAS (47%) and the Numeric Rating Scale (26%). 
Interpretation of some scores can be problematic, because of poor validation in neonates and 
infants after cardiac surgery. Moreover, items for rises in blood pressure and heart rate are 
less useful in children after cardiac surgery because of the use of inotropic agents.  
This study has several limitations. Clinical practice may deviate from protocol which might not 
be reflected in the survey. Also, the participating hospitals are all based in developed 
countries, mostly in Europe. Although the data from our study seem to reflect the day-to-day 
practice of analgosedation after cardiac surgery in children, we cannot rule out that some 
selection of the hospitals that were approached and that responded may have an effect on 
the diversity of the findings. A larger survey might increase the amount of variability or show 
more consensus within countries.  
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Conclusion 
This survey shows that there is large variability in both dosing and choice of analgosedative 
drugs used in pediatric post cardiothoracic surgery patients especially between hospitals. This 
large variability reflects the complexity of analgosedation in these vulnerable patients and 
highlights the need for clinical studies combining PK with validated PD outcomes. Such studies 
are necessary to understand specific changes in this population and permit evidence-based 
and personalised treatment protocols.  
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Abstract 
Background: Morphine is worldwide the analgesic of first choice after cardiac surgery in 
children. Morphine has unwanted hemodynamic and respiratory side effects. Post cardiac 
surgery patients may therefore potentially benefit from a non-opioid drug for pain relief. A 
previous study has shown that intravenous (IV) paracetamol is effective and opioid sparing in 
children after major non-cardiac surgery. The aim of the study is to test the hypothesis that 
intermittent IV paracetamol administration in children after cardiac surgery will result in a 
reduction of at least 30% of the cumulative morphine requirement.  
Methods: A prospective, multi-center, randomized controlled trial at four level 3 pediatric 
ICUs in the Netherlands and Belgium. Children aged 0-36 months will be randomized to receive 
either intermittent IV paracetamol or continuous IV morphine up to 48 hours postoperatively. 
Morphine will be available as rescue medication for both groups. Validated pain and sedation 
assessment tools will be used to monitor patients. The sample size (n=208, 104 per arm) was 
calculated in order to detect a 30% reduction in morphine dose, with a two-sided significance 
level of 5% and a power of 95%.  
Discussion: This study will focus on the reduction, or replacement, of morphine by IV 
paracetamol in children aged 0-36 months after cardiac surgery. The results of this study will 
form the basis of a new pain management algorithm and will be implemented at the 
participating ICUs, resulting in an evidence-based guideline on postoperative pain after 
cardiac surgery in infants aged 0-36 months.  
 
 
  
Background  
Congenital heart disease (CHD) accounts for almost one-third of all congenital anomalies, with 
a reported total prevalence in Europe of 8.0 in 1000 births (1, 2). Surgical intervention is 
necessary within the first year of life in 55% and in 67% during the first three years of life (3).  
The importance of adequate postsurgical pain relief in neonates and infants became apparent 
after findings that untreated pain results in increased stress hormone levels and prolonged 
behavioral consequences (4). These findings have resulted in an increased use of morphine as 
the world-wide standard for pain relief after major surgery in neonates and children (5-9). 
However, morphine can cause unwanted hemodynamically and respiratory reactions and 
therefore patients could potentially benefit from a non-opioid analgesic.  
In a recent randomized controlled trial iv paracetamol was compared to morphine as a primary 
analgesic drug in non-cardiac postoperative children up to 1 year. IV paracetamol was equally 
effective in pain relief and no difference in rescue analgesics was shown between groups (10). 
The iv paracetamol group had a lower cumulative morphine dose the first 48 hours after 
surgery and less adverse drug reactions. Whether these results also apply to neonates and 
children after cardiac surgery is unclear. Pharmacokinetic (PK) parameters are assumed to be 
different in patients during and after cardiac surgery compared to non-cardiac surgery and 
changes in pharmacodynamics (PD) and pharmacogenetics (PG) concerning pain perception 
need to be taken into account.   
Cardiothoracic Surgery 
Based on the general anesthesia guidelines, opioids are considered standard of care in 
children to prevent and treat postoperative pain after cardiac surgery even though clear PK 
data is lacking (11). There are reasons to assume that children after cardiac surgery have 
different PK and/or PD compared to adults or children after non-cardiac surgery. Valkenburg 
et al. describes a lower clearance of morphine and a higher volume of distribution in 38 
children after cardiac surgery compared to non-cardiac surgery, possibly necessitating a 
different dosing regimen (12).  
The use of cardiopulmonary bypass (CPB) is the main reasons to expect PK changes. CPB has 
a profound effect on the PK parameters because of hemodynamic changes, hemodilution, 
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surgery and less adverse drug reactions. Whether these results also apply to neonates and 
children after cardiac surgery is unclear. Pharmacokinetic (PK) parameters are assumed to be 
different in patients during and after cardiac surgery compared to non-cardiac surgery and 
changes in pharmacodynamics (PD) and pharmacogenetics (PG) concerning pain perception 
need to be taken into account.   
Cardiothoracic Surgery 
Based on the general anesthesia guidelines, opioids are considered standard of care in 
children to prevent and treat postoperative pain after cardiac surgery even though clear PK 
data is lacking (11). There are reasons to assume that children after cardiac surgery have 
different PK and/or PD compared to adults or children after non-cardiac surgery. Valkenburg 
et al. describes a lower clearance of morphine and a higher volume of distribution in 38 
children after cardiac surgery compared to non-cardiac surgery, possibly necessitating a 
different dosing regimen (12).  
The use of cardiopulmonary bypass (CPB) is the main reasons to expect PK changes. CPB has 
a profound effect on the PK parameters because of hemodynamic changes, hemodilution, 
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hypothermia and systemic inflammatory reactions (SIRS). These effects change constantly 
throughout CPB and some continue to exert influence after the patient has been successfully 
weaned from CPB (13).  
Hemodynamic changes affect organ perfusion and ultimately organ function. Hemodynamics 
may also be altered by the need for inotropic support during and after surgery. Children with 
a normal cardiovascular system undergoing surgery seem to clear morphine more efficiently 
than infants undergoing cardiovascular surgery (14). On initiation of CPB, prime fluid causes 
dilution of the patients’ blood. This causes a shift in the bound and unbound fraction of the 
drug and a redistribution from peripheral to central compartments. Decreased renal and 
hepatic perfusion due to hypothermia, hypotension, decreased flow rate and hemodilution 
may result in decreased elimination of drugs (13).  
Surgical correction of more complex congenital cardiac defects has an additionally influence 
on systemic circulation influencing PK of drugs itself, due to longer CPB run times with higher 
risk for severe SIRS and hemodynamic instability (13, 15, 16). However, there is currently no 
literature suggesting a difference in sedative or analgesic requirements based on type of 
congenital defect or surgical procedure.  
Morphine 
The elimination of morphine is mainly through glucuronidation by urine diphosphate 
glucuronosyltransferase (UGT) 2B7. Morphine clearance directly reflects the formation of its 
two major metabolites that are pharmacologically active, morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G). Both metabolites are cleared through renal elimination, and 
a reduced renal function can lead to accumulation. Evidence suggests that clearance of 
morphine is significantly slower in children who need inotropic support after cardiac surgery 
(17).  
The unwanted hemodynamically and respiratory effects of morphine are a particular problem 
in these hemodynamically unstable children and may lead to delayed recovery and prolonged 
PICU stay (18, 19). Other adverse effects of morphine are intestinal obstruction, which mainly 
occurs in younger children, whereas nausea, vomiting and itching mainly occur in older 
children (7).  
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hypothermia and systemic inflammatory reactions (SIRS). These effects change constantly 
throughout CPB and some continue to exert influence after the patient has been successfully 
weaned from CPB (13).  
Hemodynamic changes affect organ perfusion and ultimately organ function. Hemodynamics 
may also be altered by the need for inotropic support during and after surgery. Children with 
a normal cardiovascular system undergoing surgery seem to clear morphine more efficiently 
than infants undergoing cardiovascular surgery (14). On initiation of CPB, prime fluid causes 
dilution of the patients’ blood. This causes a shift in the bound and unbound fraction of the 
drug and a redistribution from peripheral to central compartments. Decreased renal and 
hepatic perfusion due to hypothermia, hypotension, decreased flow rate and hemodilution 
may result in decreased elimination of drugs (13).  
Surgical correction of more complex congenital cardiac defects has an additionally influence 
on systemic circulation influencing PK of drugs itself, due to longer CPB run times with higher 
risk for severe SIRS and hemodynamic instability (13, 15, 16). However, there is currently no 
literature suggesting a difference in sedative or analgesic requirements based on type of 
congenital defect or surgical procedure.  
Morphine 
The elimination of morphine is mainly through glucuronidation by urine diphosphate 
glucuronosyltransferase (UGT) 2B7. Morphine clearance directly reflects the formation of its 
two major metabolites that are pharmacologically active, morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G). Both metabolites are cleared through renal elimination, and 
a reduced renal function can lead to accumulation. Evidence suggests that clearance of 
morphine is significantly slower in children who need inotropic support after cardiac surgery 
(17).  
The unwanted hemodynamically and respiratory effects of morphine are a particular problem 
in these hemodynamically unstable children and may lead to delayed recovery and prolonged 
PICU stay (18, 19). Other adverse effects of morphine are intestinal obstruction, which mainly 
occurs in younger children, whereas nausea, vomiting and itching mainly occur in older 
children (7).  
Paracetamol 
The analgesic effect of paracetamol is not yet fully understood but is likely due to interaction 
with the serotonergic system. Glucuronidation is the major pathway of paracetamol 
metabolism (50-60%), with an contribution of sulfation (25-44%) and oxidation (2-10%). 
Glucuronidation and sulfation result in inactive and non-toxic end products. The hepatic 
oxidation pathway forms NAPQI (N-acetyl-p-benzo-quinone imine) (20). NAPQI is toxic and in 
case of overdose causes mitochondrial dysfunction and centrilobular necrosis in the liver (21). 
Several studies show that, when used in therapeutic doses in children without liver 
dysfunction, the safety profile is excellent (20).  
Enteral or rectal dosing is sufficient for mild to moderate pain. However, after major surgery 
rectal administration of paracetamol was shown to be insufficient to reach a therapeutic level 
for pain relief and does not reduce the morphine consumption (22-24). Potentially, 
intravenous paracetamol performs better in case of severe or acute pain. IV paracetamol 
rapidly penetrates an intact blood brain barrier in children, which contributes to the fast of 
the analgesic effect (25-27). 
Pharmacogenetics 
A large number of candidate gene studies has illustrated associations between genetic 
variants with opioid response (28, 29) and paracetamol efficacy (30). The genetic impact can 
arise from polymorphisms in genes that alter drug levels (PK) such as metabolizing enzymes 
and transporters. PK genes relevant for morphine are UGT2B7, ABCC3 and OCT1 (31-33).  
Hypothesis 
It is our hypothesis that intermittent IV paracetamol is effective as the primary analgesic drug 
in post cardiac surgery patients up to 3 years of age and that the use of IV paracetamol will 
reduce overall morphine requirements.  
This hypothesis is currently being tested at three level 4 PICUs in the Netherlands and Belgium 
(Erasmus MC- Sophia Rotterdam, Wilhelmina Children’s Hospital UMC Utrecht, Beatrix 
Children’s Hospital UMC Groningen, UZ Leuven).  
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Methods 
Trial design 
This study is a multi-center, prospective, randomized, double blind study, with a non-
inferiority design.  
Study setting 
The study will be conducted at 4 level 3 PICUs in the Netherlands and Belgium (Erasmus MC- 
Sophia Rotterdam, Wilhelmina Children’s Hospital UMC Utrecht, Beatrix Children’s Hospital 
UMC Groningen and UZ Leuven). 
Interventions  
All patients will receive a loading dose of morphine 100 mcg/kg at the end of surgery. After 
the loading dose, patients are randomized to receive either a morphine continuous infusion 
or intermittent intravenous paracetamol. A double dummy (intermittent or continuous 
infusion of NaCl0.9%) will be used in each group to ensure blinding. Patients in the 
intervention group receive intermittent iv paracetamol.  
Justification of dosing 
Howard et al. prospectively evaluated effectiveness, morphine requirements and safety of iv 
morphine in over 10,000 pediatric patients, including almost 1000 patients after cardiac 
surgery in a tertiary care hospital (34). Patients after cardiac surgery had the highest morphine 
requirements with an average dose of 23 mcg/kg/h (5-50 mcg/kg/h) but PK data was not 
collected and it is unclear whether morphine dosing was based on validated pain scores. Lynn 
at al. described morphine serum levels of 15-20 ng/ml in infants after cardiac surgery with 
continuous morphine infusions of 10-20 mcg/kg/h without describing analgesic efficacy (9). 
These morphine serum levels are typically associated with adequate pain relief (17). In 2009 
Knibbe et al. proposed a novel morphine dosing regimen for neonates and children based on 
PK studies resulting in a significant dose reduction of morphine in neonates < 10 days post-
natal age (35). This model was further validated with new data sets (36) and ultimately 
resulted in a prospective randomized controlled trial in which the proposed dosing regimen 
for morphine dosing was evaluated (37). This morphine dosing regimen was used in the 
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Methods 
Trial design 
This study is a multi-center, prospective, randomized, double blind study, with a non-
inferiority design.  
Study setting 
The study will be conducted at 4 level 3 PICUs in the Netherlands and Belgium (Erasmus MC- 
Sophia Rotterdam, Wilhelmina Children’s Hospital UMC Utrecht, Beatrix Children’s Hospital 
UMC Groningen and UZ Leuven). 
Interventions  
All patients will receive a loading dose of morphine 100 mcg/kg at the end of surgery. After 
the loading dose, patients are randomized to receive either a morphine continuous infusion 
or intermittent intravenous paracetamol. A double dummy (intermittent or continuous 
infusion of NaCl0.9%) will be used in each group to ensure blinding. Patients in the 
intervention group receive intermittent iv paracetamol.  
Justification of dosing 
Howard et al. prospectively evaluated effectiveness, morphine requirements and safety of iv 
morphine in over 10,000 pediatric patients, including almost 1000 patients after cardiac 
surgery in a tertiary care hospital (34). Patients after cardiac surgery had the highest morphine 
requirements with an average dose of 23 mcg/kg/h (5-50 mcg/kg/h) but PK data was not 
collected and it is unclear whether morphine dosing was based on validated pain scores. Lynn 
at al. described morphine serum levels of 15-20 ng/ml in infants after cardiac surgery with 
continuous morphine infusions of 10-20 mcg/kg/h without describing analgesic efficacy (9). 
These morphine serum levels are typically associated with adequate pain relief (17). In 2009 
Knibbe et al. proposed a novel morphine dosing regimen for neonates and children based on 
PK studies resulting in a significant dose reduction of morphine in neonates < 10 days post-
natal age (35). This model was further validated with new data sets (36) and ultimately 
resulted in a prospective randomized controlled trial in which the proposed dosing regimen 
for morphine dosing was evaluated (37). This morphine dosing regimen was used in the 
previous trial comparing continuous iv morphine with intermittent iv paracetamol after major 
non-cardiac surgery. 
Several studies have determined paracetamol metabolism in children (20, 38). 
Pharmacokinetics of IV paracetamol in children until the age of 16 years have been described, 
however, no children undergoing cardiac surgery were included in this study (39, 40).  
IV paracetamol will be dosed according to the Dutch pediatric formulary with a loading dose 
of 20 mg/kg, and maintenance dose of 10 mg/kg (<1 month of age) or 15 mg/kg (>1 month) 
(41). 
Worldwide iv paracetamol is given in 3-4 dosages daily and not as continuous infusion. Even 
though continuous administration of iv paracetamol is possible, limited evidence in healthy 
adults shows that the analgesic effect of iv paracetamol is better with intermittent 
administration (42). Different delivery schedules for morphine (continuous) and paracetamol 
(intermittent) are therefore selected. 
Control group 
Patients in the control group will receive a continuous morphine infusion after the loading 
dose of morphine 100 mcg/kg. Based on our PK data on morphine in non-cardiac and cardiac 
pediatric patients (35, 37, 40) we developed a new morphine dosing regimen for neonates 
and children aged 0 to 36 months. The dosing algorithm is added in appendix A.  
Use of co-intervention 
Standard postoperative care is given to all patients with analgesic rescue medication. Short 
acting analgesics and sedatives are available during interventions, such as chest drain removal. 
All co-medications used during the first 48 hours after surgery are registered in the database.  
Rescue analgesic medication 
Rescue morphine will be administered with a maximum of three times per hour whenever the 
Numeric Rating Scale (NRS) is equal to or greater than 4. Standard additional dose of morphine 
is 10 mcg/kg for patients aged <10 days postnatal age and 15 mcg/kg for patients aged ≥10 
days.  
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Ten minutes after each extra dose of morphine, pain is re-assessed. If there is no improvement 
in the scores (i.e. NRS ≥ 4) after three additional (rescue) doses, a morphine loading dose of 
100 mcg/kg is given and a continuous morphine infusion is started at 10 mcg/kg/h in a 
separate pump (to ensure blinding). Whenever pain is not responding to the extra morphine 
boluses and the additional continuous morphine infusion in a maximum dose of 30 mcg/kg/h, 
fentanyl is started at 1-2 mcg/kg loading dose and 1-3 mcg/kg/h continuous infusion. At the 
start of fentanyl, morphine will be discontinued. In case of discomfort midazolam is started. 
Discomfort is determined as Comfort-Behavior (COMFORT-B) score >22 or COMFORT-B score 
between 11 and 22 but with the Nurse Interpretation of Sedation Score (NISS) suggesting 
undersedation. Standardized sedation will be part of the treatment protocol. Sedation 
protocols regarding the primary sedatives are already comparable between the participating 
ICUs, This treatment algorithm is similar with the one used in the recent study comparing 
morphine and paracetamol in non-cardiac patients (10). 
In both groups, continuous morphine infusion (if started) will be decreased in the second 24 
hours depending on the NRS and COMFORT-B score. 
If discharge from the ICU occurs within 48 hours after surgery, the study medication will be 
continued on the ward. The arterial catheter will be removed at discharge from the ICU. PK 
sampling on the ward will only be done simultaneously with routine blood examination. At 48 
hours after surgery, the study medication will be changed to open label paracetamol and 
rescue morphine if needed.  
PD outcome measurements 
PD outcomes will be measured using validated instruments. Both pain and under- and over 
sedation need to be assessed. Signs of pain and distress may overlap, making accurate 
assessment difficult. Therefore, the use of concomitant sedative drugs will be standardized in 
the participating ICUs. The COMFORT-B scale is mainly a distress assessment and to lesser 
extent a pain instrument that asks observers to consider the intensity of six behavioral 
manifestations: Alertness, Calmness, Respiratory response (for mechanically ventilated 
children) or Crying (for spontaneously breathing children), Body movements, Facial tension 
and Muscle tone. For each of these items, five descriptions, rated from 1-5, are provided 
reflecting increasing intensity of behavior in question. Summating the ratings of the six 
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in the scores (i.e. NRS ≥ 4) after three additional (rescue) doses, a morphine loading dose of 
100 mcg/kg is given and a continuous morphine infusion is started at 10 mcg/kg/h in a 
separate pump (to ensure blinding). Whenever pain is not responding to the extra morphine 
boluses and the additional continuous morphine infusion in a maximum dose of 30 mcg/kg/h, 
fentanyl is started at 1-2 mcg/kg loading dose and 1-3 mcg/kg/h continuous infusion. At the 
start of fentanyl, morphine will be discontinued. In case of discomfort midazolam is started. 
Discomfort is determined as Comfort-Behavior (COMFORT-B) score >22 or COMFORT-B score 
between 11 and 22 but with the Nurse Interpretation of Sedation Score (NISS) suggesting 
undersedation. Standardized sedation will be part of the treatment protocol. Sedation 
protocols regarding the primary sedatives are already comparable between the participating 
ICUs, This treatment algorithm is similar with the one used in the recent study comparing 
morphine and paracetamol in non-cardiac patients (10). 
In both groups, continuous morphine infusion (if started) will be decreased in the second 24 
hours depending on the NRS and COMFORT-B score. 
If discharge from the ICU occurs within 48 hours after surgery, the study medication will be 
continued on the ward. The arterial catheter will be removed at discharge from the ICU. PK 
sampling on the ward will only be done simultaneously with routine blood examination. At 48 
hours after surgery, the study medication will be changed to open label paracetamol and 
rescue morphine if needed.  
PD outcome measurements 
PD outcomes will be measured using validated instruments. Both pain and under- and over 
sedation need to be assessed. Signs of pain and distress may overlap, making accurate 
assessment difficult. Therefore, the use of concomitant sedative drugs will be standardized in 
the participating ICUs. The COMFORT-B scale is mainly a distress assessment and to lesser 
extent a pain instrument that asks observers to consider the intensity of six behavioral 
manifestations: Alertness, Calmness, Respiratory response (for mechanically ventilated 
children) or Crying (for spontaneously breathing children), Body movements, Facial tension 
and Muscle tone. For each of these items, five descriptions, rated from 1-5, are provided 
reflecting increasing intensity of behavior in question. Summating the ratings of the six 
behavioral manifestations leads to a total score ranging from 6-30. The COMFORT-B scale has 
been extensively validated in postoperative infants with and without Down syndrome and in 
infants after major cardiac surgery (43-46).  
The Numeric Rating Scale pain (NRS) is a scale from 0 (no pain) to 10 (worst possible pain) and 
is used in conjunction with the COMFORT-B scale to represent the rater’s expert opinion (47). 
The NRS focusses on pain, whereas the COMFORT-B mainly assesses discomfort. Any 
additional rescue morphine is given when the NRS score is four or higher. This dose escalation 
schedule is consistent with additional analgesic treatment in the normal clinical setting.  
Parents will be able to participate in rating the pain in their children, using the NRS. This will 
be used alongside the nurses NRS and COMFORT-B scale. Parents will receive a very short 
instruction explaining the different factors that should be take into account when assigning 
the NRS.  
Parents’ participation will be on a voluntary basis. If parents indicate that active participations 
is not wanted anymore, they will be able to stop at any time. Variation in nurse and parent 
evaluation of pain or discomfort will be analyzed as a secondary endpoint.  
The NISS has been validated for this age group and represents the caregiving nurse’s expert 
opinion scored as 1= undersedation, 2= adequate sedation, or 3= oversedation (47). 
Follow-up will consist of the “parents postoperative pain measurement-short form” (PPPM-
SF) to complete after discharge from hospital. This tool includes 10 items asking parents about 
signs of pain and distress at home in children after surgical intervention (48). Parents will be 
called two days after discharge from the hospital to inform after the child’s health and to take 
the questionnaire.  
Patients after major cardiac surgery are also at risk for opioid withdrawal syndrome and 
pediatric delirium. Therefore, these two conditions were assessed as well. (33, 49).  
The Sophia Observation withdrawal Symptoms-scale (SOS) has been validated to detect 
withdrawal syndrome in critically ill children. It contains 15 items that are scored either not 
present (0) or present (1). A score of 4 or higher suggests withdrawal syndrome (50, 51).  
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Pediatric delirium in our study will be assessed with the SOS-PD and Cornell Assessment of 
Pediatric Delirium (CAPD) (52). The SOS-PD consists of 17 items of which the maximum total 
sum score is 17 points. A total score of at least 4 is used as a cut-off for delirium or when the 
item “hallucination” is scored positive. The CAPD consist of 8 items, scoring the interaction of 
the nurse with the patient. The maximum total sum score is 32 points, with a cut-off for 
delirium at 9 points or greater. According to standard local protocol a pediatric psychiatrist 
will be consulted in case of delirium. Treatment of delirium will be done according to local 
protocol (53).  
Severity of illness will be estimated with the validated Pediatric risk of Mortality-lll score (54) 
together with the more specific Risk Adjusted Classification for Congenital Heart Surgery 
(RACHS-1) score (55). All Dutch hospitals use the Aristotle score to classify the congenital 
cardiac surgery patients. This Aristotle score will also be used to estimate the severity of 
surgical procedure and to compare the two groups with respect to the surgical intervention 
(56, 57). The PELOD-2 score will be used to assess the severity of cases of Multiple Organ 
Dysfunction Syndrome in the PICU on day 0 (day of surgery), day 1 and day 2 (58).  
PK analysis and blood sampling 
Blood samples will be drawn for PKPD analysis, using an indwelling arterial catheter. Blood 
samples will be taken after the morphine bolus dose, directly after the start of the trial 
medication, 30-60 minutes after start trial medication, 3-4 hours after start trial medication, 
and at three standard moments during the day. The timing of the standard sampling moments 
is dependent on local clinical practice. Because of small timing differences this will create a 
diverse sampling scheme, which is very applicable for PKPD analysis. Also, samples will be 
taken before and after changes in the dose of analgesic medication. For ethical reasons not 
more than 5% of the total blood volume will be drawn from the patient. PK samples will thus 
be obtained by sparse sampling, with a minimal burden to the individual patients. Using 
population pharmacokinetics analysis, the data points from the individual subjects will be 
combined to form solid pharmacokinetic data on morphine and paracetamol and their 
metabolites, since these metabolites are biologically active. The population PK analysis will be 
done using non-linear mixed effect modelling (NONMEM).  
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Pediatric delirium in our study will be assessed with the SOS-PD and Cornell Assessment of 
Pediatric Delirium (CAPD) (52). The SOS-PD consists of 17 items of which the maximum total 
sum score is 17 points. A total score of at least 4 is used as a cut-off for delirium or when the 
item “hallucination” is scored positive. The CAPD consist of 8 items, scoring the interaction of 
the nurse with the patient. The maximum total sum score is 32 points, with a cut-off for 
delirium at 9 points or greater. According to standard local protocol a pediatric psychiatrist 
will be consulted in case of delirium. Treatment of delirium will be done according to local 
protocol (53).  
Severity of illness will be estimated with the validated Pediatric risk of Mortality-lll score (54) 
together with the more specific Risk Adjusted Classification for Congenital Heart Surgery 
(RACHS-1) score (55). All Dutch hospitals use the Aristotle score to classify the congenital 
cardiac surgery patients. This Aristotle score will also be used to estimate the severity of 
surgical procedure and to compare the two groups with respect to the surgical intervention 
(56, 57). The PELOD-2 score will be used to assess the severity of cases of Multiple Organ 
Dysfunction Syndrome in the PICU on day 0 (day of surgery), day 1 and day 2 (58).  
PK analysis and blood sampling 
Blood samples will be drawn for PKPD analysis, using an indwelling arterial catheter. Blood 
samples will be taken after the morphine bolus dose, directly after the start of the trial 
medication, 30-60 minutes after start trial medication, 3-4 hours after start trial medication, 
and at three standard moments during the day. The timing of the standard sampling moments 
is dependent on local clinical practice. Because of small timing differences this will create a 
diverse sampling scheme, which is very applicable for PKPD analysis. Also, samples will be 
taken before and after changes in the dose of analgesic medication. For ethical reasons not 
more than 5% of the total blood volume will be drawn from the patient. PK samples will thus 
be obtained by sparse sampling, with a minimal burden to the individual patients. Using 
population pharmacokinetics analysis, the data points from the individual subjects will be 
combined to form solid pharmacokinetic data on morphine and paracetamol and their 
metabolites, since these metabolites are biologically active. The population PK analysis will be 
done using non-linear mixed effect modelling (NONMEM).  
DNA analysis will be performed to evaluate interindividual variability drug responses. Genetic 
variability of morphine and paracetamol will be the main focus.  
 Eligibility criteria & parental consent 
Patients eligible to participate in the study will be infants and children aged 0-36 months 
admitted to the ICU after cardiac surgery with the use of the CPB. Information regarding the 
trial will be given to parents, or authorized surrogates, of potential trial participants at the 
out-patient clinic or at the ward. Information will be given by a researcher, either the doctor 
or research nurse. Written informed consent is obtained from all trial participants before 
surgery.  
Inclusion criteria 
• Informed consent, 
• Neonate / infant aged 0-36 months, 
• Cardiac surgery with the use of CPB. 
Exclusion criteria 
• No informed consent  
• Known allergy to or intolerance for paracetamol or morphine, 
• Administration of opioids in the 24 hours prior to surgery. 
• Hepatic dysfunction defined as three times the reference value of ALAT/ASAT. 
• Renal insufficiency defined as Pediatric RIFLE category - injury, defined as estimated 
creatinine clearance reduced by 50% and urine output <0.5 ml/kg/h for 16 hours.  
In case patients develop renal or hepatic insufficiency after randomization they will be 
withdrawn from the trial.  
Primary objectives 
To test the hypothesis that analgesia with intermittent intravenous paracetamol will lead to a 
morphine sparing effect of at least 30% as compared to model-based continuous iv morphine 
infusion during the first 48 hours after cardiac surgery in infants aged 0-36 months.  
Chapter 8
168
The primary outcome measure is the weight-adjusted cumulative morphine consumption 
(mcg/kg) in the first 48 hours postoperatively.  
The reduction of morphine has been chosen as the primary outcome, since this is directly 
related with the decrease of morphine related adverse drug reactions. The previous trial 
comparing iv paracetamol with morphine clearly showed a reduction of morphine related 
adverse drug reactions in the iv paracetamol group. Among these drug reactions are gastro-
intestinal symptoms, which are also described as two out of six endpoints in the recent StEP 
recommendations for patient comfort (59).  
Secondary objectives: 
1. Incidence of adverse drug reactions 
a. hemodynamic: hypotension or bradycardia, with the need for intervention by 
means of medication or a fluid bolus.  
b. Decreased gastro-intestinal motility or intestinal obstruction not directly 
related to the underlying diagnosis and not previously existing, with the need 
for intervention.  
c. Vomiting. 
d. Number of re-intubations. 
e. Pediatric delirium as measured by the SOS-PD-scale or CAP-D score.  
2. Non-inferiority analysis of comparing patients with one or more NRS pain scores ≥4 
between groups 
3. DNA analysis will be performed to evaluate the effect of gene polymorphisms on the 
PK of analgesic medication. 
4. Concomitant use of sedatives. 
5. The number of hours on ventilation.  
6. The length of PICU stay. 
7. Role of alarmins in the systemic inflammatory response (only at Wilhelmina Children’s 
Hospital, UMCUtrecht). To develop a population PKPD-based postoperative pain 
management algorithm based on the results of this trial.  
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for intervention.  
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d. Number of re-intubations. 
e. Pediatric delirium as measured by the SOS-PD-scale or CAP-D score.  
2. Non-inferiority analysis of comparing patients with one or more NRS pain scores ≥4 
between groups 
3. DNA analysis will be performed to evaluate the effect of gene polymorphisms on the 
PK of analgesic medication. 
4. Concomitant use of sedatives. 
5. The number of hours on ventilation.  
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Sample size calculation 
We estimate that the required morphine dose in the paracetamol group can be reduced by at 
least 30% compared to the morphine group in the first 48 hours after surgery. This is in line 
with the outcome of a previous study we conducted in a 0-1 year old patient group after major 
non-cardiac surgery with similar study medication (10). 
The power analysis is based on a comparison of the primary outcome between groups using 
a Mann-Whitney test. A simulation study was done for this power analysis using data on the 
cumulative morphine dose from a previous study with comparable morphine dosing (10). 
Based on this data set, the median cumulative morphine dose was 357 mcg/kg (IQR: 220-605) 
in the control group, and we assumed that this morphine dose will be reduced by 30% in the 
intervention group. The simulation study showed that using a two-sided significance level of 
5%, 86 patients per group will be required to obtain a power of 95%. To account for the effects 
of stratification by center and missing data, we will include 104 patients per study arm, 208 in 
total. We expect this sample size to also be sufficient to assess secondary outcomes.  
As described above, the primary endpoint of the study is the total amount of morphine 
administered in the first 48 hours after surgery. Any additional morphine given will be based 
on NRS scores of 4 and higher. In a secondary, non-inferiority analysis, we will therefore also 
compare the percentage of patients with one or more NRS scores of 4 and higher between 
the two groups, using a non-inferiority margin of 20%, based on the previous trial and clinical 
experience. NRS-pain scores are assessed often per patient and should give a clear indication 
of number of painful moments per treatment group. Since NRS scores are recorded often per 
patient we set the non-inferiority margin on 20%, assuming this will reflect a clinically relevant 
difference. Non-inferiority will be assessed using a one-sided 97.5% confidence interval for 
the difference in the percentage of patients with at least one NRS score of 4 or higher between 
the paracetamol group and the morphine group, and non-inferiority will be proven if the 
upper limit of this confidence interval is lower than 20%. The confidence interval will be 
calculated using the method of Klingenberg , with adjustment for center. Using data from our 
previous study (10) on paracetamol and morphine it is estimated that 60% of all patients will 
have one or more NRS scores >3. Using a simulation study, we calculated that to detect non-
inferiority with a power of 75%, 200 patients (100 per group) are required. Even though the 
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power is 75%, this is considered to be sufficient for this secondary endpoint. This means that 
the sample size of 104 patients per group is sufficient for the non-inferiority analysis.  
Randomization, blinding and treatment allocation 
Blocked randomization with randomly chosen block sized and stratification by center will be 
used. The randomization schedule will be kept in the local pharmacy at every center. The 
pharmacist is the only person to have access to the randomization schedule to ensure 
concealed allocation. The randomization schedules are made by the study’s biostatistician. 
Study medication will be prepared at the participating centers. We will use standard morphine 
and paracetamol formulations.  
In case of a medical emergency the pharmacists can be consulted what medication was 
administered to a patient.  
Statistical methods 
The non-parametric Van Elteren test with stratification by center will be used to compare the 
primary outcome of cumulative age-adjusted morphine between groups.  
Analysis of secondary outcomes will include length of PICU stay, number of hours on 
ventilation and concomitant use of sedatives . These secondary outcomes will be compared 
using linear regression analysis with group and treatment center as categorical independent 
variables. Analysis using linear regression models will be performed with cumulative rescue 
morphine (first 48 hours) as outcome variable and group (morphine vs paracetamol) as 
predictor variable. Center, Down syndrome (yes/no) and cyanotic vs non-cyanotic cardiac 
defects will be added as covariates. Robust regression models will be used when necessary, 
i.e. when the outcome variable is non-normally distributed.  
In a secondary, non-inferiority analysis, we will also compare the number of patients with one 
or more NRS scores of 4 and higher between the two groups, using a non-inferiority margin of 
20%. Non-inferiority will be assessed using a one-sided 97.5% confidence interval for the 
difference in the percentage of patients with at least one NRS score of 4 or higher between 
the paracetamol group and the morphine group, and non-inferiority will be proven if the 
upper limit of this confidence interval is lower than 20%. The confidence interval will be 
calculated using the method of Klingenberg (Stat Med 2014), with adjustment for center.  
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power is 75%, this is considered to be sufficient for this secondary endpoint. This means that 
the sample size of 104 patients per group is sufficient for the non-inferiority analysis.  
Randomization, blinding and treatment allocation 
Blocked randomization with randomly chosen block sized and stratification by center will be 
used. The randomization schedule will be kept in the local pharmacy at every center. The 
pharmacist is the only person to have access to the randomization schedule to ensure 
concealed allocation. The randomization schedules are made by the study’s biostatistician. 
Study medication will be prepared at the participating centers. We will use standard morphine 
and paracetamol formulations.  
In case of a medical emergency the pharmacists can be consulted what medication was 
administered to a patient.  
Statistical methods 
The non-parametric Van Elteren test with stratification by center will be used to compare the 
primary outcome of cumulative age-adjusted morphine between groups.  
Analysis of secondary outcomes will include length of PICU stay, number of hours on 
ventilation and concomitant use of sedatives . These secondary outcomes will be compared 
using linear regression analysis with group and treatment center as categorical independent 
variables. Analysis using linear regression models will be performed with cumulative rescue 
morphine (first 48 hours) as outcome variable and group (morphine vs paracetamol) as 
predictor variable. Center, Down syndrome (yes/no) and cyanotic vs non-cyanotic cardiac 
defects will be added as covariates. Robust regression models will be used when necessary, 
i.e. when the outcome variable is non-normally distributed.  
In a secondary, non-inferiority analysis, we will also compare the number of patients with one 
or more NRS scores of 4 and higher between the two groups, using a non-inferiority margin of 
20%. Non-inferiority will be assessed using a one-sided 97.5% confidence interval for the 
difference in the percentage of patients with at least one NRS score of 4 or higher between 
the paracetamol group and the morphine group, and non-inferiority will be proven if the 
upper limit of this confidence interval is lower than 20%. The confidence interval will be 
calculated using the method of Klingenberg (Stat Med 2014), with adjustment for center.  
Adverse drug reactions will be specified as hemodynamic, gastro-intestinal, respiratory 
reactions or pediatric delirium, as previously described. Adverse effects and other 
dichotomous outcomes, such as re-intubation, will be compared between groups using 
Fisher’s exact tests, and the uncertainty in these estimated proportions will be assessed using 
95% confidence intervals. The level of significance will be set at 5%, and all tests will be two-
sided. Non-linear mixed effect modelling (NONMEM) will be used to perform population 
pharmacokinetic analysis. 
Safety 
Patients can be withdrawn from the study at any time by the investigator or the treating 
physician. The intention-to-treat analysis will include all subjects. The subjects that have been 
withdrawn during the study will be included only for the time period in which they have 
participated. The cumulative morphine requirement will be calculated for the time that the 
patient participated in the study. 
An external data safety monitoring board (DSMB) is established composed of pediatric 
intensivists and cardio-anesthesiologist with extensive clinical and research experience in the 
field of analgosedation on the PICU. The study protocol does not contain an interim analysis. 
The secondary endpoints require more included patients then the primary endpoint. An 
interim analysis could terminate the trial prematurely based on a favorable primary outcome, 
while not having enough power to assess secondary endpoints. However, the DSMB can 
advise to stop the trial if necessary. The DSMB has advised the researchers during the study 
set-up and evaluated study proceedings after inclusion of the first 10 patients. The DSMB 
evaluated inclusion rate and safety of participants (need for rescue morphine in both groups) 
several times during the inclusion period, with the last meeting in October 2017. The DSMB 
advised to continue the study, without changes to the protocol.  
An advisory board is established composed of representatives from two patient and parent 
associations (Stichting Kind en Ziekenhuis, and Patientvereniging Aangeboren 
Hartafwijkingen), a neonatologist and clinical pharmacologist and a pediatric cardiologist. The 
advisory board has been involved in the design of the study and parental participation. 
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Data management and monitoring 
Data is collected through case report forms in OpenClinica, a web-based database 
(OpenClinica, LCC, Waltham, MA, USA), supported by the Erasmus MC. Range checks for data 
values were added in the CRF, if possible, to promote data quality. Data management is 
coordinated by the Erasmus MC researchers and trial support unit. All participants receive a 
trial ID, with the personal details only known to the researchers, pharmacy and attending 
physician. Double data entry and validation is done by all participating centers. Monitoring of 
the data and trial proceedings is coordinated by the Erasmus MC. Monitoring of the data and 
trial proceedings is done per research site before the start of trial, soon after start of the trial, 
and three times a year for the duration of the trial. A close-out visit is done after completion 
of the inclusion period per research site. Trial auditing is done only by invitation from the 
hospital board and its frequency is not specified.  
The Erasmus MC, as the coordinating center and owns intellectual property. The investigators 
have unlimited access to the final dataset. A newsletter with the study results will be made 
available on the website of the patient and parent organizations and will be sent to 
participants upon request. Public access to the data and data sharing is in line with the 
guidelines of ZonMw (data management plan), the main funder of this trial. Data access is 
restricted to authorized use only, and access will be granted by the researchers upon 
reasonable request. 
Discussion  
PK-based dosing of analgesics in children after cardiac surgery is lacking. Intravenous 
paracetamol as primary analgesic after cardiac surgery could have an opioid sparing effect and 
therefore less opioid related adverse drug reactions. This study will also provide the necessary 
PK and PD parameters to establish a PKPD-based dosing regimen for analgesics after cardiac 
surgery. This will lead to a more individualized dosing regimen to guide clinician in providing 
the best analgesic therapy for their patients.  
The results of this trial will by incorporated in an international guideline for pain treatment 
after cardiac surgery in neonates and children aged 0-36 months. This guideline will be 
endorsed by several scientific societies for pediatricians and anesthesiologists.  
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Data management and monitoring 
Data is collected through case report forms in OpenClinica, a web-based database 
(OpenClinica, LCC, Waltham, MA, USA), supported by the Erasmus MC. Range checks for data 
values were added in the CRF, if possible, to promote data quality. Data management is 
coordinated by the Erasmus MC researchers and trial support unit. All participants receive a 
trial ID, with the personal details only known to the researchers, pharmacy and attending 
physician. Double data entry and validation is done by all participating centers. Monitoring of 
the data and trial proceedings is coordinated by the Erasmus MC. Monitoring of the data and 
trial proceedings is done per research site before the start of trial, soon after start of the trial, 
and three times a year for the duration of the trial. A close-out visit is done after completion 
of the inclusion period per research site. Trial auditing is done only by invitation from the 
hospital board and its frequency is not specified.  
The Erasmus MC, as the coordinating center and owns intellectual property. The investigators 
have unlimited access to the final dataset. A newsletter with the study results will be made 
available on the website of the patient and parent organizations and will be sent to 
participants upon request. Public access to the data and data sharing is in line with the 
guidelines of ZonMw (data management plan), the main funder of this trial. Data access is 
restricted to authorized use only, and access will be granted by the researchers upon 
reasonable request. 
Discussion  
PK-based dosing of analgesics in children after cardiac surgery is lacking. Intravenous 
paracetamol as primary analgesic after cardiac surgery could have an opioid sparing effect and 
therefore less opioid related adverse drug reactions. This study will also provide the necessary 
PK and PD parameters to establish a PKPD-based dosing regimen for analgesics after cardiac 
surgery. This will lead to a more individualized dosing regimen to guide clinician in providing 
the best analgesic therapy for their patients.  
The results of this trial will by incorporated in an international guideline for pain treatment 
after cardiac surgery in neonates and children aged 0-36 months. This guideline will be 
endorsed by several scientific societies for pediatricians and anesthesiologists.  
Trial status 
The study was initiated in March 2016. On March 23, 2018, 124 patients had been enrolled in 
the study. Enrolment of all 208 patients is expected to be completed in the fall of 2018. The 
Spirit checklist and figure on the trial proceedings are added as appendices B and C, 
respectively. 
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Appendix A: morphine dosing algorithm (adapted from Wang et al (40)) 
Weight of patient 
  
dosis mcg/kg/h 
  
dosis mcg/day 
  
Continuous infusion (ml/h) 
(solution 100 mcg/ml) 
2.5-2.9 3.9 257.4 0.1 
3-3.4 5.3 413.4 0.2 
3.5-3.9 7.1 639.0 0.3 
4-4.4 9.3 948.6 0.4 
4.5-4.9 11.4 1299.6 0.5 
5-5.4 13.2 1663.2 0.7 
5.5-5.9 14.5 2001.0 0.8 
6-6.4 15.4 2310.0 1.0 
6.5-6.9 16.0 2592.0 1.1 
7-7.4 16.4 2853.6 1.2 
7.5-7.9 16.6 3087.6 1.3 
8-8.9 16.8 3427.2 1.4 
9-9.9 16.9 3853.2 1.6 
10-10.9 16.8 4233.6 1.8 
11-11.9 16.7 4609.2 1.9 
12-12.9 16.6 4980.0 2.1 
13-13.9 16.5 5346.0 2.2 
14-14.9 16.4 5707.2 2.4 
15-15.9 16.0 5952.0 2.5 
16-16.9 16.0 6336.0 2.6 
17-17.9 16.0 6720.0 2.8 
18-18.9 16.0 7104.0 3.0 
19-19.9 16.0 7488.0 3.1 
20-20.9 16.0 7872.0 3.3 
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Congenital cardiac defects are the largest group of congenital defects, with a prevalence of 
7.2 per 1000 live births (1). Surgical correction is often needed in the first year of life, and most 
patients will have undergone surgery in the first three years of life (1, 2). Little is known on 
preferred, evidence-based drug use during surgery and the recovery period during their stay 
in the pediatric intensive care unit (PICU) (3). This knowledge gap has resulted in a large 
variability in drug therapy in children during and after cardiac surgery. 
In pharmacotherapy, the most important aspects are pharmacokinetics (PK) and 
pharmacodynamics (PD). PK follows the general principles of drug absorption, distribution, 
metabolism and elimination (ADME) (4, 5). Knowledge of ADME increases accuracy in drug 
dosing in patients, i.e. obtaining the desired target concentration. PD investigates the 
reactions of the body on drugs, i.e. the desired effect of drugs in the patient. Ideally, both PK 
and PD should be investigated in drug research, determining the optimal dose combined with 
the optimal drug effect in the patient. PK parameters can be determined by measuring drug 
concentrations in patients. To evaluate PD, validated assessment tools need to be used. 
Interpretation of these assessment tools and the effects of drugs on the outcome can be 
difficult to determine, especially in case of polypharmacy (6, 7). Equally important are the 
desired outcome parameters on long term effects, such as abnormal executive functions. 
In the last decade, the different aspect of ADME, were increasingly investigated in children 
under a variety of conditions and patient populations (8, 9). Before these studies became 
available, drug doses from adults were repeatedly downsized to the pediatric population. 
However, children are not small adults when it comes to PK and simply extrapolating adult 
data to children has increasingly been recognized as inappropriate (4, 10-13). Even within the 
pediatric age group, PK is expected to be different between patient populations, warranting 
more accurate information on drug dosing in specific patients and age groups (4, 14-16).In 
particular considering patients with congenital cardiac defects, the various aspects of PK are 
very likely different from children without cardiac defects. Absorption, i.e. the time to reach 
peak plasma drug concentration, is variable and can be influenced by maturational, such as 
weight and age, and non-maturational changes. Non-maturational changes are disease and 
treatment specific and may include differences in systemic and pulmonary circulation due to 
shunt physiology, altered first pass effects in the liver, hemodynamic status and the effects of 
surgery. Distribution is expressed by the Volume of distribution (Vd) of drugs in the body. This 
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Vd consists of a fictional central compartment and sometimes one or more peripheral 
compartments that are in equilibrium with the central compartment. Vd is strongly dependent 
on drug characteristics, with lipophilic drugs having a larger Vd compared to hydrophilic drugs. 
Also, maturational and non-maturational changes affect Vd. An example is the development 
of systemic inflammatory response syndrome (SIRS) during and after surgery, leading to 
decreased clearance and potentially a larger Vd (17). SIRS is very common in children admitted 
to a PICU, and 21% of patients with SIRS do not have an infectious origin of SIRS (18). 
Elimination is influenced by hepatic and renal function and can therefore be affected by 
decreased renal or hepatic blood flow.  
Traditional PK models incorporating all these different variables are based on measured drug 
concentrations in selected patient groups. The measured drug concentrations are combined 
in a time-concentration curve, showing the drug concentration in patients over time. The 
classical approach to determine a time-concentration curve requires frequent blood sampling 
in patients to reconstruct a reliable curve. In some patient groups, such as critically ill children, 
frequent blood sampling is not feasible. These special patients groups can be investigated 
using population PK (4, 19). Population PK combines data from sparse sampling regimens to a 
reliable time-concentration curve. Using population PK analyses, the burden to participate in 
drug research is negligible for individual patients. However, in combining the data from all 
patients, accurate predictions in drug concentration over time can be made.  
This thesis investigates drug dosing in children with congenital cardiac defects undergoing 
cardiac surgery. Several factors related to the surgery influence PK, such as the use of the 
cardiopulmonary bypass (CPB) and subsequent hemodilution and changed organ perfusion. 
Therefore, PK in cardiac surgery patients is expected to differ substantially from non-cardiac 
surgery patients (15). PK parameters investigated in children without cardiac surgery cannot 
simply be extrapolated to cardiac surgery patients. When describing the factors that influence 
PK in children with congenital cardiac defects undergoing cardiac surgery, several phases of 
treatment and recovery need to be discussed. In all of these phases, different aspects of the 
cardiac defect and the treatment are expected to influence drug PK. In this thesis we have 
investigated these different phases and treatments in a systematic approach to gain insight in 
these PK changes. Validated PD assessment tools were used to determine the effects of drug 
therapy. This insight is needed to incorporate potential influences on PK and eventually PD of 
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cardiopulmonary bypass (CPB) and subsequent hemodilution and changed organ perfusion. 
Therefore, PK in cardiac surgery patients is expected to differ substantially from non-cardiac 
surgery patients (15). PK parameters investigated in children without cardiac surgery cannot 
simply be extrapolated to cardiac surgery patients. When describing the factors that influence 
PK in children with congenital cardiac defects undergoing cardiac surgery, several phases of 
treatment and recovery need to be discussed. In all of these phases, different aspects of the 
cardiac defect and the treatment are expected to influence drug PK. In this thesis we have 
investigated these different phases and treatments in a systematic approach to gain insight in 
these PK changes. Validated PD assessment tools were used to determine the effects of drug 
therapy. This insight is needed to incorporate potential influences on PK and eventually PD of 
these treatment phases in dosing regimens to improve clinical care for these children and 
eventually reach personalized- or precision- medicine  
The first phase is the preoperative phase, since children undergoing cardiac surgery have a 
different hemodynamic condition due to the cardiac defect. Also, children can be critically ill 
before surgery and may therefore have different PK and PD responses compared to elective 
surgery in non-critically ill children. Second, the perioperative phase distinguishes itself from 
non-cardiac surgery because of the use of the CPB and an auto-transfusion system. Use of CPB 
increases the Vd and decreases clearance of drugs (20). An increased Vd could lead to sub-
therapeutic plasma concentration of drugs. This has been shown in adult patients undergoing 
cardiac surgery, who had for instance a substantial decrease is plasma cefazolin concentration 
at onset of CPB (21). In contrast, decreased clearance of drugs could lead to overdosing and 
potential toxicity. Other factors, such as hypothermia and changes in the hemodynamic state 
due to surgical correction of the cardiac defect may also influence PK and PD due to changed 
enzyme activity. The final phase is the postoperative phase. Due to the correction of the 
cardiac defects with shifts in volume and pressure load, some children will have a changed 
hemodynamic condition after surgery compared to the preoperative state.  
Preoperative phase 
Even though this thesis mostly examines the peri-and postoperative phase, Chapter 2 
highlights differences in PK in children on the PICU. Additional considerations on PK related 
changes in children with congenital heart defects are also discussed in Chapter 8. Many 
different types of cardiac defects are known, and they can roughly be classified in cyanotic or 
non-cyanotic. Data on the influence of cyanotic or non-cyanotic defects before cardiac surgery 
on PK is extremely scarce. Decreased clearance of alcuronium, a routinely used muscle 
relaxant, has been suggested during surgery, but no other data on this topic could be found 
(22). However, cyanosis in patients before surgery could result in an increased cardiac output, 
resulting in increased renal and hepatic perfusion. For high extraction ratio drugs, i.e. drugs 
that are liver flow dependent, such as morphine, this increased perfusion may lead to an 
increased clearance (23). Patients with cyanotic heart defects are at risk of developing renal 
impairment, leading to a decreased clearance with drug specific effect on the Vd (24-26). 
When considering drug dosing in children with cyanotic cardiac defects, dosing schemes do 
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not take this potentially changed hemodynamic state into account. This may lead to increased 
adverse drug events and patient morbidity. Given the large variability of type; dosing and 
concomitant use of drugs more data from large patient studies are needed to distinguish the 
different effects before, during and after surgery, comparing cyanotic and non-cyanotic 
children. Data from two clinical studies from our institution and partly described in this thesis, 
the CPB-PHARM and the PACS study, are currently being analyzed. These studies did not 
change treatment based on cyanotic or non-cyanotic hemodynamic state. However, PK 
parameters and treatment effects were analyzed comparing patients with cyanotic and non-
cyanotic heart defects.  
All children admitted to the PICU are critically ill, especially after extensive surgery like 
correction of congenital cardiac defects. Most children are not admitted to the PICU before 
cardiac surgery and the procedure is planned electively. However, these children can still have 
a cyanotic cardiac defect and therefore an altered hemodynamic state. Neonates with 
congenital cardiac defects may require drug therapy to maintain an open arterial duct to 
achieve an adequate systemic circulation, for instances in patients with hypoplastic right or 
left ventricles or transposition of the great arteries. These neonates are admitted to the PICU 
before surgery, and are treated according to local protocols that do not incorporate the open 
ductus and subsequent cardiac defects. However, a persistent ductus arteriosus causes a 
larger Vd potentially leading to underdosing of drugs (27).  
Clinical PK studies in critically ill children are difficult to perform due to large inter-patient 
variability (28). However, it is known that critical illness effects PK of routinely used drugs. 
When comparing midazolam clearance between critically ill children admitted to the PICU, 
pediatric oncology patients and healthy children undergoing major craniofacial surgery, 
midazolam clearance was decreased by 86%-93% in PICU patients (29). When investigating 
midazolam in critically ill children in further detail, Vet et al. found that inflammation and 
organ failure strongly reduce midazolam clearance (30). This seems to implicate that 
midazolam is strongly affected by inflammation and thus by SIRS. Even though we suspect 
children with cardiac defects also have SIRS, data on the preoperative phase has not been 
published. SIRS, varying from limited to extensive, is very common in children after correction 
of cardiac defects, most likely due to the use of the CPB (15, 31, 32).  
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ductus and subsequent cardiac defects. However, a persistent ductus arteriosus causes a 
larger Vd potentially leading to underdosing of drugs (27).  
Clinical PK studies in critically ill children are difficult to perform due to large inter-patient 
variability (28). However, it is known that critical illness effects PK of routinely used drugs. 
When comparing midazolam clearance between critically ill children admitted to the PICU, 
pediatric oncology patients and healthy children undergoing major craniofacial surgery, 
midazolam clearance was decreased by 86%-93% in PICU patients (29). When investigating 
midazolam in critically ill children in further detail, Vet et al. found that inflammation and 
organ failure strongly reduce midazolam clearance (30). This seems to implicate that 
midazolam is strongly affected by inflammation and thus by SIRS. Even though we suspect 
children with cardiac defects also have SIRS, data on the preoperative phase has not been 
published. SIRS, varying from limited to extensive, is very common in children after correction 
of cardiac defects, most likely due to the use of the CPB (15, 31, 32).  
Variation in PD in children is even larger then variation in PK. PD parameters are changeable 
and vary over time, per age group, and disease and treatment modalities (33). Altered 
neurological state could be expected to influence PD in patients and may alter a patients 
response to certain drugs, however no clear examples of this could be found in literature. Until 
recently, complications in neurologic state and neurodevelopment in children with congenital 
cardiac defects where believed to be caused by the surgical procedure and concomitant CPB 
use (34). However, even before surgery 50% of patients with mainly complex congenital 
cardiac defects already has neurological injury (35). MRI’s showed preoperative and 
postoperative neurological injury, with mainly new white matter injury after surgery. The 
potential effects that this brain injury may have on administered drugs has not been observed 
and quantified in current literature. Ideally for quantification and observation of PD, validated 
tools and endpoints need to be used. When investigating this in our international survey (see 
Chapter 7), very often validated PD assessment tools were not incorporated in clinical practice 
and an objective observation was unfortunately not reported.  
Considering all the above mentioned factors, children undergoing cardiac surgery most likely 
already have a different PK and PD compared to children undergoing non-cardiac procedures 
even preoperatively. Due to the nature of the surgery these differences only become more 
extensive and reverse gradually after the procedure.  
Key messages: 
• Children with cardiac defects potentially have a different PK and PD already 
preoperatively. 
• Types of cardiac defects, i.e. cyanotic or non-cyanotic, are not incorporated in current 
drug dosing guidelines, even though hemodynamic state and therefore PK could be 
different between patients.  
• Brain injury that is already present before surgery may result in a different response 
of children with cardiac defects to administered drugs.  
Perioperative phase 
The most extensive change in perioperative PK parameters is due to the use of the CPB. The 
changes induced by the CPB have been described in detail in Chapter 2 (4). In summary, 
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hemodilution, sequestration of drugs and decreased organ perfusion are the main reasons for 
changes in PK and PD (15). Sequestration of drugs in pediatric in vitro CPB systems is described 
in Chapters 4 and 5. SIRS can also be induced by the use of CPB, and prolonged CPB use 
increases the SIRS reaction leading to potentially an ever larger Vd and decreased clearance 
(32). However, very little and contradictory data is published on the effects of SIRS on Vd and 
clearance (17, 36). Next to the influence of the CPB, general surgical and anesthesiology 
management such as hypothermia influences drug metabolism. During surgery, an 
autotransfusion system, commonly known as a cell saver, is often used to prevent blood loss 
and to decrease the need for allogenic donor blood. We have investigated the influence of the 
cell saver on drug loss from the operation site and drug administration through 
autotransfused blood in Chapter 3. Finally, the patient himself is a black box when it comes to 
drug PK and PD during cardiac surgery. Very little is known when it comes to hepatic or renal 
function during cardiac surgery, which is important for drug metabolism and clearance.  
Investigating all the above mentioned factors together would require a large in vivo study, 
preferably measuring plasma drug concentrations before, during and after surgery to 
determine the effects of every step of the procedure. The disadvantage of such an approach 
could be that patient, CPB and cell saver influence on drug plasma concentration cannot be 
distinguished from one another. Therefore, we have investigated the different phases of the 
procedure, in an attempt to separate the patient, CPB and cell saver related factors (see 
Chapters 2, 3, 4 and 5).  
Our study of autotransfused blood (Chapter 3) showed that certain drugs could potentially be 
autotransfused to the patient in therapeutic levels (37). The risk of autotransfusion of drugs 
seems to be the greatest for certain lipophilic drugs. Sufentanil, but not midazolam or propofol 
was measurable in clinical relevant concentrations in the autotransfused blood. The 
discrepancy between these lipophilic drugs could not fully be explained by our experiments. 
Propofol could be bound to erythrocytes and therefore not measurable in plasma, but this 
does not account for the low midazolam plasma concentration. Drug concentrations in 
autotransfused blood has not previously been published, and we have therefore no 
comparison for our results or an indication for potential source for loss of midazolam or 
propofol. The drug concentration that we found in the blood removed from the surgical site 
was comparable to concomitant drug concentrations measured in the patients. Therefore, the 
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hemodilution, sequestration of drugs and decreased organ perfusion are the main reasons for 
changes in PK and PD (15). Sequestration of drugs in pediatric in vitro CPB systems is described 
in Chapters 4 and 5. SIRS can also be induced by the use of CPB, and prolonged CPB use 
increases the SIRS reaction leading to potentially an ever larger Vd and decreased clearance 
(32). However, very little and contradictory data is published on the effects of SIRS on Vd and 
clearance (17, 36). Next to the influence of the CPB, general surgical and anesthesiology 
management such as hypothermia influences drug metabolism. During surgery, an 
autotransfusion system, commonly known as a cell saver, is often used to prevent blood loss 
and to decrease the need for allogenic donor blood. We have investigated the influence of the 
cell saver on drug loss from the operation site and drug administration through 
autotransfused blood in Chapter 3. Finally, the patient himself is a black box when it comes to 
drug PK and PD during cardiac surgery. Very little is known when it comes to hepatic or renal 
function during cardiac surgery, which is important for drug metabolism and clearance.  
Investigating all the above mentioned factors together would require a large in vivo study, 
preferably measuring plasma drug concentrations before, during and after surgery to 
determine the effects of every step of the procedure. The disadvantage of such an approach 
could be that patient, CPB and cell saver influence on drug plasma concentration cannot be 
distinguished from one another. Therefore, we have investigated the different phases of the 
procedure, in an attempt to separate the patient, CPB and cell saver related factors (see 
Chapters 2, 3, 4 and 5).  
Our study of autotransfused blood (Chapter 3) showed that certain drugs could potentially be 
autotransfused to the patient in therapeutic levels (37). The risk of autotransfusion of drugs 
seems to be the greatest for certain lipophilic drugs. Sufentanil, but not midazolam or propofol 
was measurable in clinical relevant concentrations in the autotransfused blood. The 
discrepancy between these lipophilic drugs could not fully be explained by our experiments. 
Propofol could be bound to erythrocytes and therefore not measurable in plasma, but this 
does not account for the low midazolam plasma concentration. Drug concentrations in 
autotransfused blood has not previously been published, and we have therefore no 
comparison for our results or an indication for potential source for loss of midazolam or 
propofol. The drug concentration that we found in the blood removed from the surgical site 
was comparable to concomitant drug concentrations measured in the patients. Therefore, the 
cell saver could be a potential source of loss of drugs during surgery. This loss applies to all 
drugs used during surgery. However, the contribution of the cell saver as a source of 
perioperative drug loss is most likely relatively small, except perhaps in small patients 
undergoing extensive repair of congenital cardiac defects. Due to the limited amount of 
circulating volume in these patients, blood and drug loss may influence PK and PD more 
compared to older patients. Even though the drug loss may apply to all drugs, autotransfusion 
of drugs is most likely only relevant for lipophilic drugs. Caution may be necessary when 
administering autotransfused blood to neonates who are no longer mechanically ventilated. 
In neonates still on ventilatory support, the clinical effects on therapeutic sufentanil levels 
may have a negative hemodynamic effect but will most likely not cause serious problems. 
Adjustments of type and dose of drugs based on the use of the cell saver would not be 
recommended based on our findings. Also, in our institution sufentanil and remifentanil are 
the analgesics of first choice and both are lipophilic. Replacing these drugs by a hydrophilic 
analgesic could be most undesirable for optimal analgesic effect.  
Our studies in in vitro CBP systems (Chapters 4 and 5) found that mainly lipophilic drugs 
sequester in the CPB system compared to hydrophilic drugs (38). This sequestration is 
different per type of pediatric CPB system, with higher losses in larger pediatric CPB systems. 
An increased foreign surface to blood ratio is most likely the reason for the decreased drug 
plasma concentration in larger compared to smaller pediatric CPB systems. For adult CPB 
systems, sequestration of lipophilic drugs is not uncommon, however in vitro data is sparse 
(15, 39). One of the main sites of sequestration seems to be the tubing (40). The tubing 
diameter and length is relatively large in pediatric CPB systems compared to adult CPB 
systems. Even though in vitro CPB data in pediatric systems has not been published previously, 
drug sequestration in extracorporeal circulation in children is not new. This topic has been 
investigated in pediatric extracorporeal membrane oxygenators (ECMO) (41-43). Even though 
ECMO experiments are focused on routinely used drugs in the PICU, similarities can be found 
between pediatric CPB and ECMO. In both CPB and ECMO use, patients can be considered 
critically ill with decreased organ perfusion. All children treated with ECMO and CPB have an 
increased Vd and decreased clearance, leading to potential differences in plasma drug 
concentrations compared to other critically ill children. In ECMO systems, drug loss was less 
in hollow fiber membranes compared to silicon-based membranes. All our tested pediatric 
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CPB systems had hollow fiber oxygenators, and we may therefore assume this was not the 
main site of drug sequestration. Different types of surface coating of ECMO tubing have been 
investigated in vitro, since this was previously identified as the primary source of 
sequestration (44). However, regardless of type of surface coating, drug loss in the tubing was 
considerably. So far, no solution seems to be available for decreasing the drug loss in CPB 
systems. To date, almost no data is available on drug regimens compensating for the drug loss 
due to the use of CPB. In adults undergoing cardiac surgery, redosing of cefazolin at the onset 
of CPB restores the plasma concentration to therapeutic range (45). This change in cefazolin 
plasma concentration is probably only due to an increased Vd, since cefazolin is hydrophilic 
and not expected to sequester rapidly in CPB systems. For lipophlic drugs, the increase in Vd 
may be accompanied by a sequestration in the CPB systems. This may potentially cause an 
even greater drop in plasma concentration than we found in vitro. In pediatric in vitro ECMO 
systems, midazolam and sufentanil were lost over 50% after 24 hours (41). Together with our 
results, this implies that longer duration increases the sequestration and a steady decline is 
observed during the entire run time. In part, the decrease in drug concentration may be less 
pronounced with administration by a continuous infusion. Often, analgesic and sedative drugs 
are titrated to effect with an increased heart rate or blood glucose levels indicating stress. 
However, with all confounding factors, such as hypothermia and co-medication, PD cannot be 
measured reliably. Solutions to this dilemma could be to increase drug dosing during surgery, 
but this may increase hemodynamic instability and prolong recovery after surgery. The use of 
a loading dose or an additional dose at the onset of CPB seems to be more adequate based on 
our findings. These assumptions need to be validated in in vivo studies with enough power 
and the use of modern ways of analysis such as popPK modelling (8). 
The changes in Vd and clearance may be less pronounced in new CPB techniques, due to their 
smaller size. These smaller CPB systems need less prime fluid and have a smaller foreign body 
surface area, leading to better hemodynamic stability during surgery (46). As a consequence 
of these alterations, the increase in Vd that occurs at the onset of conventional CPB is likely 
to be less profound. Also, better hemodynamic stability could result in better organ perfusion 
influencing clearance of drugs. Therefore, the use of mini CPB could potentially limit the 
changes in PK parameters during cardiac surgery. The PK parameters in these children would 
then be more similar to the non-cardiac surgery patient. This could have implications for the 
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CPB systems had hollow fiber oxygenators, and we may therefore assume this was not the 
main site of drug sequestration. Different types of surface coating of ECMO tubing have been 
investigated in vitro, since this was previously identified as the primary source of 
sequestration (44). However, regardless of type of surface coating, drug loss in the tubing was 
considerably. So far, no solution seems to be available for decreasing the drug loss in CPB 
systems. To date, almost no data is available on drug regimens compensating for the drug loss 
due to the use of CPB. In adults undergoing cardiac surgery, redosing of cefazolin at the onset 
of CPB restores the plasma concentration to therapeutic range (45). This change in cefazolin 
plasma concentration is probably only due to an increased Vd, since cefazolin is hydrophilic 
and not expected to sequester rapidly in CPB systems. For lipophlic drugs, the increase in Vd 
may be accompanied by a sequestration in the CPB systems. This may potentially cause an 
even greater drop in plasma concentration than we found in vitro. In pediatric in vitro ECMO 
systems, midazolam and sufentanil were lost over 50% after 24 hours (41). Together with our 
results, this implies that longer duration increases the sequestration and a steady decline is 
observed during the entire run time. In part, the decrease in drug concentration may be less 
pronounced with administration by a continuous infusion. Often, analgesic and sedative drugs 
are titrated to effect with an increased heart rate or blood glucose levels indicating stress. 
However, with all confounding factors, such as hypothermia and co-medication, PD cannot be 
measured reliably. Solutions to this dilemma could be to increase drug dosing during surgery, 
but this may increase hemodynamic instability and prolong recovery after surgery. The use of 
a loading dose or an additional dose at the onset of CPB seems to be more adequate based on 
our findings. These assumptions need to be validated in in vivo studies with enough power 
and the use of modern ways of analysis such as popPK modelling (8). 
The changes in Vd and clearance may be less pronounced in new CPB techniques, due to their 
smaller size. These smaller CPB systems need less prime fluid and have a smaller foreign body 
surface area, leading to better hemodynamic stability during surgery (46). As a consequence 
of these alterations, the increase in Vd that occurs at the onset of conventional CPB is likely 
to be less profound. Also, better hemodynamic stability could result in better organ perfusion 
influencing clearance of drugs. Therefore, the use of mini CPB could potentially limit the 
changes in PK parameters during cardiac surgery. The PK parameters in these children would 
then be more similar to the non-cardiac surgery patient. This could have implications for the 
administration and dosing of drugs. However, no published literature could be found on the 
influence of mini CPB on PK of routinely used drugs. A first step towards investigating the 
influence of mini CPB systems on drugs could be performing in vitro experiments. As we have 
shown, sequestration of drugs is influenced by foreign body surface area and therefore 
sequestration should be less in mini CPB systems. The next step should be to investigate drug 
concentration during pediatric cardiac surgery with use of mini CPB systems. Combining this 
data could provide more insight into Vd and Cl of drugs during surgery with mini CPB systems 
and therefore the influence of mini CPB systems on PK parameters. Potentially, a more 
targeted approach in perioperative drug dosing is possible if variation in PK parameters during 
surgery is decreased, leading to less risk of overdosing or underdosing.  
During surgery, hypothermia is often used to protect neurological and organ function. The 
most extreme hypothermia is complete circulatory arrest at a body temperature of 180C. If 
this deep hypothermic circulatory arrest is necessary, isolated cerebral perfusion is used. Due 
to the hypothermia organ function will decrease leading to changes in PK and PD. All aspects 
of ADME are influenced by hypothermia (47). Absorption is decreased, with a later onset of 
effect. Vd is altered with a preferential blood flow towards coronary and cerebral vasculature. 
Vd and clearance of drugs can be increased, decreased or unaltered depending on the drug. 
When investigating the effect of hypothermia on PD, results are highly variable and depend 
on the drug-target interaction and alteration in enzymatic processes. Inflammation does not 
seem to be affected by hypothermia (48). Other alterations in PD may be due to neurological 
injury caused by the underlying cardiac defect; the surgical procedure and CPB use (35). 
As discussed, technical and procedural factors influence PK and PD during surgery. Also, 
patients themselves may be a reason for variation in drug PK and PD. Increasing age is often 
not an issue with children undergoing cardiac surgery for congenital defects. However, obesity 
is a major health problem in both adolescents and children. In Europe childhood obesity 
ranges from 15.3% to 25.6%, depending on the region (49). Considering recent literature, body 
mass index (BMI) may become an interesting patient related factor for PK alterations. 
Alterations in PK in obese patients may be because of more fat tissue and less lean body mass, 
increased blood volume, increased cardiac output and low grade inflammation (50). We 
already know that inflammation occurs in patients preoperatively and SIRS becomes more 
profound during and after the operation. In obese adults, liver abnormalities such as fatty 
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infiltration were present in 90% of patients. Liver abnormalities may result in altered enzyme 
activity in phase 1 and 2 metabolism, decreasing among others, cytochrome P450 subtypes 
(CYPs). A lower CYP3A4 activity is reported in obese compared to non-obese adults, indicating 
a lower CAP3A4 mediated clearance of drugs such as midazolam. A lower clearance could lead 
to accumulation of drugs and thus an increase in drug related adverse events. Our CefCheck 
study (Chapter 6) already stratifies patients depending on BMI, to create more equal 
treatment groups. We found that BMI is not the main predictor for sub-therapeutic plasma 
levels of cefazolin. We did find that during and after surgery many patients have sub-
therapeutic levels of cefazolin. This could potentially lead to deep sternal wound infections, 
with increased morbidity and mortality (51). As discussed previously, a loading dose, or an 
additional dose at onset of CPB could stabilize cefazolin concentrations within the therapeutic 
range. Another option is continuous administration of cefazolin. Recent data has shown that 
continuous administered cefazolin may reduce surgical site infection and provides more stable 
serum levels (52, 53). 
To investigate all the above mentioned changes in PK in vivo research in necessary. When 
considering drug PK and PD parameters of Vd and clearance, the cell saver and CPB cannot be 
seen separately from the patient. The cell saver and CPB systems are both peripheral 
compartments, with the patient as the central compartment. Shifts of plasma and drugs occur 
between those compartments, and the extent of the shifts may vary during surgery. Large 
randomized controlled trials are not feasible given the variation in expected alterations in PK 
and PD of drugs and the sparse clinical patient data, especially in children. A large prospective 
observational cohort study is the best approach to investigate PK and PD in children 
undergoing cardiac surgery. We have conducted this study, called the CPB-PHARM study and 
data will become available on the coming year. We have taken blood samples through an 
indwelling arterial catheter before, during and after surgery. We included 150 patients in the 
CPB-PHARM study, therefore enabling us to investigate various variables in patient, surgery 
and CPB characteristics. Ideally, this should result in a more individualized pharmaco-
therapeutic regimen. Next to the general variables as age and weight, other potential 
covariables for this individualized regimen could be cyanotic or non-cyanotic cardiac defect, 
CPB run time, type of CPB system used; use of hypothermia yes/no and duration of surgery. 
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infiltration were present in 90% of patients. Liver abnormalities may result in altered enzyme 
activity in phase 1 and 2 metabolism, decreasing among others, cytochrome P450 subtypes 
(CYPs). A lower CYP3A4 activity is reported in obese compared to non-obese adults, indicating 
a lower CAP3A4 mediated clearance of drugs such as midazolam. A lower clearance could lead 
to accumulation of drugs and thus an increase in drug related adverse events. Our CefCheck 
study (Chapter 6) already stratifies patients depending on BMI, to create more equal 
treatment groups. We found that BMI is not the main predictor for sub-therapeutic plasma 
levels of cefazolin. We did find that during and after surgery many patients have sub-
therapeutic levels of cefazolin. This could potentially lead to deep sternal wound infections, 
with increased morbidity and mortality (51). As discussed previously, a loading dose, or an 
additional dose at onset of CPB could stabilize cefazolin concentrations within the therapeutic 
range. Another option is continuous administration of cefazolin. Recent data has shown that 
continuous administered cefazolin may reduce surgical site infection and provides more stable 
serum levels (52, 53). 
To investigate all the above mentioned changes in PK in vivo research in necessary. When 
considering drug PK and PD parameters of Vd and clearance, the cell saver and CPB cannot be 
seen separately from the patient. The cell saver and CPB systems are both peripheral 
compartments, with the patient as the central compartment. Shifts of plasma and drugs occur 
between those compartments, and the extent of the shifts may vary during surgery. Large 
randomized controlled trials are not feasible given the variation in expected alterations in PK 
and PD of drugs and the sparse clinical patient data, especially in children. A large prospective 
observational cohort study is the best approach to investigate PK and PD in children 
undergoing cardiac surgery. We have conducted this study, called the CPB-PHARM study and 
data will become available on the coming year. We have taken blood samples through an 
indwelling arterial catheter before, during and after surgery. We included 150 patients in the 
CPB-PHARM study, therefore enabling us to investigate various variables in patient, surgery 
and CPB characteristics. Ideally, this should result in a more individualized pharmaco-
therapeutic regimen. Next to the general variables as age and weight, other potential 
covariables for this individualized regimen could be cyanotic or non-cyanotic cardiac defect, 
CPB run time, type of CPB system used; use of hypothermia yes/no and duration of surgery. 
All these factors have been shown to influence Vd and clearance, but no data is yet available 
at individual patient level. 
Key messages: 
• PK parameters during surgery are altered due to use of CPB, cell saver and patient 
variables.  
• Sequestration in CPB systems is mainly influenced by foreign body surface area and 
changes depending on the size of CPB system. 
• The cell saver system could account for perioperative drug loss, but drug concentration 
in autotransfused blood is only relevant in small children. 
• In adult patients undergoing cardiac surgery, a new cefazolin dosing guideline based 
on non-cardiac surgery data does often not obtain the target concentration, 
emphasizing the need for solid perioperative data in these cardiac patients.  
Postoperative phase 
As discussed in the preoperative and perioperative sections, children after cardiac surgery are 
expected to have different PK and PD parameters compared to children after non-cardiac 
surgery. Most of these changes will reverse to the preoperative state, however this requires 
time. Also SIRS is increased with longer CPB runtime, with elevated C-reactive protein and 
procalcitonine until the third day after surgery and may contribute to a low cardiac output 
syndrome (LCOS) (54-56). LCOS is a clinical condition characterized by decreased systemic 
perfusion due to myocardial dysfunction. LCOS may be observed within 6 to 18 hours after 
cardiac surgery and is associated with increased morbidity and mortality (57). Decreased 
systemic perfusion could lead to decreased clearance of drugs due to impaired renal and 
hepatic blood flow. The kidneys are particularly vulnerable to decreased perfusion. After 
cardiac surgery, renal impairment occurs in approximately 40% of patients (58, 59). This acute 
kidney injury may be due to renal vasoconstriction and hemodilution during surgery (60). 
Considering the percentage of children with impaired kidney function in the postoperative 
phase, renal clearance is expected to be decreased. With the normalization of the Vd to the 
preoperative state, this may lead to accumulation of drugs. We know that midazolam is 
cleared more slowly in critically ill children, but this could also hold true for other drugs.  
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Postoperative drug dosing schemes are similar in children after cardiac surgery, compared to 
children after non-cardiac surgery. However, for the direct postoperative period, this may not 
be the best approach in these children. Ideally, drugs should be titrated to effect to obtain 
optimal drug dosing. To assess the desired effect, validated PD assessment tools should be in 
place. Unfortunately, these assessment tools cannot be used for appropriate interpretation 
of the effects of all drugs. For analgesics and sedatives validated tools are available (61). For 
drugs such as antibiotics, no tools are available and outcome measures like sternal wound 
infections are only detected over a longer period of time. Titrating drug dosing to effect may 
decrease drug related adverse events due to overdosing or underdosing by finding the best 
dosing regimen per individual patient.  
In the postoperative period, this thesis mainly focusses on analgesia in children aged 0-3 years. 
An international survey investigating analgesic type and dose in children after cardiac surgery 
showed large variability per hospital (see Chapter 7) (3). This is mainly due to lack of 
international guidelines on optimal analgesic treatment in this patient group. Analgesic of first 
choice in most hospitals is morphine, but dosing is variable. The first report of morphine as 
primary analgesic in children included dose finding based on respiratory adverse effects (62). 
After this, morphine PK and PD has been investigated, but this has not resulted in dose 
adjustments for children after cardiac surgery (20, 63, 64). In children after major, non-cardiac 
surgery, morphine could be replaced by intravenous (IV) paracetamol as primary analgesic 
(65). Recently, data became available on the PK of paracetamol in children after cardiac 
surgery indicating a decreased clearance and increased Vd compared to children after non-
cardiac surgery (8, 20). We have investigated the replacement of morphine by IV paracetamol 
in children after cardiac surgery. Concomitant use of sedatives was also registered. Since little 
is known about the effects of cardiac surgery on PD postoperatively, we investigated PD with 
validated outcome measures. To date, the study protocol of the PACS study is published, but 
the PACS study has endured some difficult phases in the start-up at several participating 
hospitals. These delays are discussed in Chapter 9.  
The delayed time-path of the PACS study is not new in pediatric drug research. Children 
admitted to the PICU differ from non-critically ill children. The variability in disease, treatment 
and patient and parental burden during PICU admission makes research in these patients 
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Postoperative drug dosing schemes are similar in children after cardiac surgery, compared to 
children after non-cardiac surgery. However, for the direct postoperative period, this may not 
be the best approach in these children. Ideally, drugs should be titrated to effect to obtain 
optimal drug dosing. To assess the desired effect, validated PD assessment tools should be in 
place. Unfortunately, these assessment tools cannot be used for appropriate interpretation 
of the effects of all drugs. For analgesics and sedatives validated tools are available (61). For 
drugs such as antibiotics, no tools are available and outcome measures like sternal wound 
infections are only detected over a longer period of time. Titrating drug dosing to effect may 
decrease drug related adverse events due to overdosing or underdosing by finding the best 
dosing regimen per individual patient.  
In the postoperative period, this thesis mainly focusses on analgesia in children aged 0-3 years. 
An international survey investigating analgesic type and dose in children after cardiac surgery 
showed large variability per hospital (see Chapter 7) (3). This is mainly due to lack of 
international guidelines on optimal analgesic treatment in this patient group. Analgesic of first 
choice in most hospitals is morphine, but dosing is variable. The first report of morphine as 
primary analgesic in children included dose finding based on respiratory adverse effects (62). 
After this, morphine PK and PD has been investigated, but this has not resulted in dose 
adjustments for children after cardiac surgery (20, 63, 64). In children after major, non-cardiac 
surgery, morphine could be replaced by intravenous (IV) paracetamol as primary analgesic 
(65). Recently, data became available on the PK of paracetamol in children after cardiac 
surgery indicating a decreased clearance and increased Vd compared to children after non-
cardiac surgery (8, 20). We have investigated the replacement of morphine by IV paracetamol 
in children after cardiac surgery. Concomitant use of sedatives was also registered. Since little 
is known about the effects of cardiac surgery on PD postoperatively, we investigated PD with 
validated outcome measures. To date, the study protocol of the PACS study is published, but 
the PACS study has endured some difficult phases in the start-up at several participating 
hospitals. These delays are discussed in Chapter 9.  
The delayed time-path of the PACS study is not new in pediatric drug research. Children 
admitted to the PICU differ from non-critically ill children. The variability in disease, treatment 
and patient and parental burden during PICU admission makes research in these patients 
complicated. We will discuss future perspective on research in critically ill patients, with a 
focus on children undergoing cardiac surgery in the following paragraphs.  
Key messages: 
• Current guidelines and local protocols on analgesia do not account for the expected 
differences in PK in children after cardiac surgery compared to non-cardiac surgery 
patients.  
• Multicenter drug research in children is challenging and delays occur both during the 
design and patient inclusion phases. 
Future perspectives 
In this thesis we have investigated changes in PK and some PD aspects in children before, 
during and after cardiac surgery. We have reflected on the effects these PKPD changes 
potentially have on drug plasma concentration and the risk of underdosing and overdosing of 
drugs. Most changes are patient and drug specific. Ideally, based on the results presented in 
this thesis and the future results of the CPB-PHARM and PACS study individualized dosing 
regimen can be made, thus preventing underdosing and overdosing. The data of the CPB-
PHARM study extensively cover the perioperative period and extends to the postoperative 
period. Data from the PACS study, representing the first RCT on analgesics following pediatric 
cardiac surgery, can add information on the postoperative period with a special focus on PK 
and PD of analgesics. Patient safety and optimal treatment is intended by creating an 
individualized dosing regimen before surgery, based on patient characteristics.  
These individualized dosing regimens are based upon population PK models, derived from 
data of the CPB-PHARM and PACS study. These studies have been extensive, including over 
350 children undergoing cardiac surgery. Even though population PK with sparse sampling 
regimens has been used in these patients, the number of covariates and variation in pathology 
remain significant, necessitating this large number of patient enrollment in these studies. With 
potential future changes in drugs, patients or CPB techniques, important covariates in the PK 
models change. Repeating these studies in full to maintain accurate PK prediction models is 
not desirable. Recently, physiologically based pharmacokinetic models are being developed, 
based on previously investigated physiological and biochemical parameters (66). These PBPK 
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models are more predictive compared to the traditional population PK models. A recent study 
showed accurate prediction of paracetamol and it’s metabolites in pregnant and non-
pregnant women (67). In vivo data will be needed to validate and refine the PBPK models, but 
nevertheless an accurate prediction on dosing and toxicity can be made with minimal burden 
to patients. In children after cardiac surgery PBPK models could aid in individualized dosing 
regimens. These models could investigate if dosing or drugs need to be adjusted during 
surgery depending on changes in physiologic parameters, for instance, in case of prolonged 
CPB use. Also, if the use of traditional CPB would change towards mini CPB in children, PBPK 
models could be used to accurately predict the effects on drug concentration. Using PBPK 
models, a limited amount of patients need to be studied to incorporate these new techniques 
into predictable PK models. Another use of PBPK models is to predict shifts in drug 
concentration at specific moments during surgery. Immediately at the onset of CPB is such an 
interesting moment due to the sudden increase of Vd, but due to patient safety usually no 
blood sample can be taken at that time. Acute drops in drug concentration because of this 
hemodilution, as predicted by PBPK models, could necessitate an additional drug dose at 
onset of CPB to maintain the target concentration.  
Ideally, not every drug needs to be studied in these critically ill children. One commonly used 
drug may serve as a proxy for an entire group of drugs, such as midazolam as proxy for CYP3A4 
metabolized drugs. CYP3A4 is the most common subtype of the CYP P450 family and is 
involved in the metabolism of approximately 50% of drugs (29). The age effect of CYP3A4 is 
already well known, with low activity at birth increasing to adult values during infancy. One 
example in which this proxy drug approach has been used is the novel technique of 
radiolabeled drug dosing so called microdosing (68). This new technique does not interfere 
with general patient care and minimalizes the burden to participate in research. In 
radiolabeled drug dosing a radiolabeled drug is administered either concomitantly with a 
therapeutic dose of the same drug (microtracer) or as a sub-therapeutic dose without a 
concomitant therapeutic dose (microdosing). Due to the sub-therapeutic nature of the 
administered drugs, these doses do not interfere with clinical care. Microtracer and 
microdosing studies have been successfully conducted for [14C]paracetamol and 
[14C]midazolam (69, 70). Paracetamol glucuronidation and sulfation was investigated in 50 
children who were administered oral [14C]paracetamol microtracer dosing with concomitant 
intravenous paracetamol. Both in plasma and in urine the [14C]paracetamol 
glucuronide/sulfate ratio increased with age, most likely reflecting a hepatic and intestinal 
maturation (69). A microdosing and microtracer study in [14C]midazolam showed the PK of 
midazolam to be comparable to therapeutic doses, thus supporting these new techniques to 
investigate drug PK in critically ill children (70).  
Recently, it has been suggested that use of the CPB may alter Cytochrome P450 enzyme 
activity. Adiraju et al. describe the general influence of CPB use, with an increased Vd and 
decreased Cl (71). However, an overview of available literature comprised by the authors, 
shows that decreased clearance seems to be more pronounced in hepatic cleared drugs, 
compared to renal cleared drugs. The authors suggest that use of CPB increases pro-
inflammatory cytokines, leading to inhibition of one or more CYPs. It has been shown that also 
C-reactive protein and procalcitonin levels are increased in children after cardiac surgery (55). 
There is no previous connection reported between CPB use and changes in CYP enzyme 
activity. However, influence of inflammation and infection has been known to reduce CYP 
substrate activity by 20-70% (72). 
Another important factor in drug research is the target organ. We routinely measure drugs in 
plasma, however some drugs need an optimal concentration in the brain, such as analgesic 
drugs, or subcutaneous tissue, such as antibiotics. The CefCheck study investigates cefazolin 
PK in adults during and after cardiac surgery. We measured cefazolin concentration in plasma. 
However, the optimal cefazolin concentration is needed most in the subcutaneous tissue to 
prevent sternal wound infections. Subcutaneous tissue concentration of cefazolin has been 
investigated using microdialysis (73, 74). In morbidly obese patients tissue distribution of 
cefazolin was lower compared to non-obese patients (73). In children during cardiac surgery, 
mainly the use of deep hypothermia was essential in skeletal muscle cefazolin concentration 
(74). This stresses the importance of drug measurements in the target organ, but also the 
feasibility of these measurements. Potentially the same results could be obtained when 
obtaining a small tissue biopsy during wound closure to measure cefazolin tissue 
concentration, considering the costs and infrastructure needed for the implementation of the 
microdialysis technique. 
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models are more predictive compared to the traditional population PK models. A recent study 
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Key messages: 
• Proxy drugs need to be incorporated in studies, reducing the number of investigated 
drugs, but building the knowledge on groups of drugs.  
• The influence of the CPB on CYP P450 and thus drug metabolism should be further 
explored and should be incorporated in future studies. 
• Ideally, drug concentration should be measured in the target organ when this is easily 
accessible, or PBPK models could be used to accurately predict the target organ 
concentration guiding evidence-based dosing in the future  
Conclusion 
This thesis investigates the knowledge gap of drug PK and partly PD in children with cardiac 
defects undergoing cardiac surgery. Changes in drug PK parameters, largely induced by CPB 
and cell saver use, are shown to change in vitro and in vivo drug concentrations. These changes 
could lead to sub-therapeutic doses or toxicity and should be incorporated in individualized 
dosing regimens to enhance patient care of this vulnerable group of children. 
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Summary 
Use of the cardiopulmonary bypass (CPB) is often necessary during pediatric cardiac surgery 
to replace the function of the heart and lungs. However, CPB may influence the concentration 
of drugs that are administered during and after surgery. There are several causes for these 
changes in drug concentration, such as hemodilution and absorption of drugs in the CPB 
system. Hemodilution occurs at the onset of CPB, when the total circulating volume increases 
to sometimes double of the patients own blood volume. Absorption of drugs in the CPB system 
is most likely dependent on type of CPB and type of drug. Both these changes could cause a 
decrease in drug concentration, leading to subtherapeutic and thus ineffective drug doses. 
Opposite to this, unexpected accumulation of drugs could lead to toxicity. In children, 
influence of CPB on plasma drug concentration has not been investigated.  
The first part of this thesis investigates the influence of CPB on pharmacokinetic (PK) 
parameters of routinely used drugs. A clearer insight into the PK of drugs during and after 
cardiac surgery with the use of CPB could lead to more precise dosing in pediatric patients, 
preferably based on patient and procedure specific factors.  
PK in children during the first days after cardiac surgery may continue to be different 
compared to children after non-cardiac surgery. Optimal pain treatment after cardiac surgery 
may therefore also be different in these children. There are no clear international guidelines 
on optimal pain treatment in children after cardiac surgery. Because of this, considerable 
variation in type and dose of analgesia remains in worldwide practice. Morphine is the drug 
of first choice in many hospitals even though morphine has several adverse drug effects, such 
as hypotension and respiratory depression. Moreover, the use of validated pharmacodynamic 
(PD) assessment tools to assess clinical efficacy of pain treatment is often not implemented in 
clinical practice. Several years ago it was shown that intravenous (IV) paracetamol was equally 
effective to morphine as primary analgesic in children after major abdominal surgery. Also, 
children who received IV paracetamol had less drug related adverse events. In children after 
cardiac surgery, who are often hemodynamically unstable and may be more prone to 
morphine related drug reactions, use of IV paracetamol may be preferable.  
The second part of this thesis investigates the pain treatment in children after cardiac surgery 
with the use of the CPB. We aim to achieve a more uniform and evidence based approach 
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towards pain treatment after pediatric cardiac surgery and to reduce morphine related 
adverse effects by decreasing the postoperative morphine consumption.  
Chapter 2 gives an overview of PK in relation to pain treatment in several patient groups on 
the pediatric intensive care unit (PICU). General aspects of PK are described and PK changes 
in patients after cardiac surgery compared to patients after non-cardiac surgery are discussed. 
The CPB-PHARM study and its sub studies are described in Chapter 3 to 5. Chapter 3 
investigates the potential drug loss and recovery due to use of the cell saver system. The cell 
saver system is a autotransfusion system that is used to reduce blood loss during surgery. 
Drugs could be lost during surgery because of removal by the cell saver system. However, 
drugs could also be returned to the patient through the autotransfused blood. We describe 
the proceedings of the cell saver system and the measurements of drugs at different stages 
during the procedure and in the autotransfused blood. We measured cefazolin, a hydrophilic 
drug, and sufentanil, propofol and midazolam, lipophilic drugs. Cefazolin was washed out 
during the cell saver procedure and was not measurable in the autotransfused blood. Of the 
three lipophilic drugs we tested, only sufentanil reached a potentially clinically relevant 
concentration in the autotransfused blood. The discrepancy between sufentanil and the other 
lipophilic drugs, propofol and midazolam, is not well understood. Propofol binds to 
erythrocytes and measurements of drugs in plasma may therefore not be representative of 
the actual total bound concentration of propofol.  
The in vitro experiments of the CPB-PHARM study are discussed in the Chapters 4 and 5. We 
have divided the measured drugs in antibiotics in Chapter 4 and anesthetic drugs and 
methylprednisolone in Chapter 5. Neonatal, infant and pediatric CPB systems, similar to the 
ones we use in clinical practice, were spiked with routinely used drugs. Blood samples were 
taken at several time points and after six hours the experiments were stopped. Propofol and 
sufentanil decreased substantially during the CPB runtime. Concentrations of midazolam and 
cefazolin remained relatively stable during the experiments. The measured concentrations of 
clindamycine and methylprednisolone remained stable as well, however, the first measured 
concentration showed great discrepancy with the theoretical starting concentration. This 
means that either, both drugs sequestered very rapidly in the CPB systems, or both drugs were 
not mixed with the priming fluid enough to reach an observed concentration similar to the 
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the pediatric intensive care unit (PICU). General aspects of PK are described and PK changes 
in patients after cardiac surgery compared to patients after non-cardiac surgery are discussed. 
The CPB-PHARM study and its sub studies are described in Chapter 3 to 5. Chapter 3 
investigates the potential drug loss and recovery due to use of the cell saver system. The cell 
saver system is a autotransfusion system that is used to reduce blood loss during surgery. 
Drugs could be lost during surgery because of removal by the cell saver system. However, 
drugs could also be returned to the patient through the autotransfused blood. We describe 
the proceedings of the cell saver system and the measurements of drugs at different stages 
during the procedure and in the autotransfused blood. We measured cefazolin, a hydrophilic 
drug, and sufentanil, propofol and midazolam, lipophilic drugs. Cefazolin was washed out 
during the cell saver procedure and was not measurable in the autotransfused blood. Of the 
three lipophilic drugs we tested, only sufentanil reached a potentially clinically relevant 
concentration in the autotransfused blood. The discrepancy between sufentanil and the other 
lipophilic drugs, propofol and midazolam, is not well understood. Propofol binds to 
erythrocytes and measurements of drugs in plasma may therefore not be representative of 
the actual total bound concentration of propofol.  
The in vitro experiments of the CPB-PHARM study are discussed in the Chapters 4 and 5. We 
have divided the measured drugs in antibiotics in Chapter 4 and anesthetic drugs and 
methylprednisolone in Chapter 5. Neonatal, infant and pediatric CPB systems, similar to the 
ones we use in clinical practice, were spiked with routinely used drugs. Blood samples were 
taken at several time points and after six hours the experiments were stopped. Propofol and 
sufentanil decreased substantially during the CPB runtime. Concentrations of midazolam and 
cefazolin remained relatively stable during the experiments. The measured concentrations of 
clindamycine and methylprednisolone remained stable as well, however, the first measured 
concentration showed great discrepancy with the theoretical starting concentration. This 
means that either, both drugs sequestered very rapidly in the CPB systems, or both drugs were 
not mixed with the priming fluid enough to reach an observed concentration similar to the 
theoretical concentration. Type of CPB system was of significant influence in drug recovery, 
possibly due to surface to volume ratio.   
Chapter 6 discusses the only adult data in this thesis. The CefCheck study was designed 
because of the new Dutch guideline on peri-operative antibiotic prophylaxis in adults 
undergoing cardiac surgery, introducing a decrease in cefazolin dosing. Evidence for this 
change was driven by non-cardiac surgery. However, during cardiac surgery, use of the CPB 
system may lead to a decrease in plasma levels of cefazolin and sub-optimal antibiotic 
prophylaxis. Our data show that the plasma cefazolin concentration gradually drops at onset 
of CPB. We also found that the protein bound fraction of cefazolin is much more variable than 
previously described in literature.  
In Chapter 7 the focus is shifted from routinely used drugs during the peri-operative period to 
pain treatment in the postoperative period. Our international survey showed a multitude of 
types and doses of analgesics used in children after cardiac surgery. Morphine is the drug of 
first choice, but dosing regimens differ substantially between hospitals. Validated assessment 
tools to determine and assess pharmacodynamics (PD) endpoints are often not used in the 
clinic. Without these tools, efficacy of pain treatment, and potential underdosing or 
overdosing are difficult to assess and correct.  
In neonates and infants after major abdominal, non-cardiac surgery, pain treatment with IV 
(intravenous) paracetamol proved equally effective as morphine. Considering the 
hemodynamic undesirable effects of morphine, such as hypotension, IV paracetamol may also 
be preferable in children after cardiac surgery. We have designed the PACS (Pediatric 
Analgesia after Cardiac Surgery) study, a multi-center randomized controlled trial, to 
investigate this. Chapter 8 describes the PACS study protocol. 208 children, aged 0-3 years, 
were randomized to receive IV morphine or IV paracetamol after cardiac surgery with the use 
of CPB. The primary endpoint was a 30% reduction in cumulative morphine consumption 
during the first 48 hours after surgery.  
Much time and effort of conducting a randomized controlled trial is in the design, preparation 
and logistics. However, this is rarely presented in literature and fellow researchers cannot use 
previous experience to their own advantage when designing a randomized controlled drug 
trial. We describe our experiences from the PACS study in Chapter 9. The main delay in our 
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study timeline was due to pharmacy regulations, late withdrawal of a trial site, and 
negotiations with the judicial departments of the participating hospitals.  
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Samenvatting  
Het gebruik van de hartlong machine (HLM) is vaak nodig tijdens cardiochirurgie om de functie 
van het hart en de longen over te nemen. Het gebruik van de HLM heeft invloed op de 
plasmaconcentratie van medicijnen die tijdens én na de operatie worden toegediend. Er zijn 
verschillende redenen voor deze beïnvloeding, zoals toename van het circulerend volume, 
verminderde uitscheiding van medicijnen en opname van medicatie in de HLM. Het starten 
van de HLM geeft een toename van het totale circulerend volume, tot soms een verdubbeling 
van het eigen circulerend volume van de patiënt. Opname van medicijnen in de HLM is 
waarschijnlijk afhankelijk van het type HLM en de eigenschappen van het medicijn. Deze 
veranderingen kunnen leiden tot een verminderde plasmaconcentratie van medicijnen en 
daarmee een subtherapeutische en ineffectieve dosering. Echter, een onverwachte 
opstapeling van medicijnen kan leiden tot toxiciteit. Bij kinderen zijn de effecten van de HLM 
op medicijn concentraties niet onderzocht.  
Het eerste deel van deze thesis gaat over de invloed van de HLM op de farmacokinetiek (PK) 
van medicijnen die zeer vaak worden gebruikt tijdens cardiochirurgie. Een beter inzicht in de 
PK van medicatie tijdens en na de operatie kan leiden tot een preciezer doseringsadvies in 
kinderen, bij voorkeur gebaseerd op specifieke eigenschappen van de patiënt en de operatie.  
Bij kinderen na cardiochirurgie blijft de PK gedurende de eerste dagen na de operatie anders 
dan bij kinderen na grote, niet-cardiochirurgische operaties. Optimale post-operatieve 
pijnbestrijding is in kinderen na cardiochirurgie dus mogelijk ook anders. Er zijn geen duidelijke 
wereldwijde richtlijnen voor pijnbestrijding bij kinderen na cardiochirurgie. Mede om deze 
reden is er wereldwijd grote variatie in het type en de dosering van de gebruikte pijnstillers. 
In veel ziekenhuizen is morfine de pijnstiller van eerste keus, terwijl morfine veel ongewenste 
bijwerkingen kan hebben zoals hypotensie en ademhalingsdepressie. Het gebruik van 
gevalideerde meetinstrumenten om de effectiviteit van de pijnstilling te meten worden vaak 
niet gebruikt in de kliniek. Enkele jaren geleden werd aangetoond dat pijnstilling met 
paracetamol intraveneus (i.v.) even effectief was als pijnstilling met morfine bij kinderen na 
grote niet-cardiochirurgische operaties. Kinderen die paracetamol i.v. kregen hadden ook 
minder medicatie gerelateerde bijwerkingen. Kinderen na cardiochirurgie hebben mogelijk 
meer last van morfine gerelateerde bijwerkingen door de hemodynamisch instabiele situatie 
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na de operatie. Deze kinderen hebben dus potentieel baat bij het gebruik van paracetamol i.v. 
als eerste keus pijnstiller.  
Het tweede deel van deze thesis onderzoekt de pijnstilling in kinderen na cardiochirurgie. Het 
doel van het onderzoek is het vaststellen van een meer evidence-based benadering van 
pijnstilling in kinderen na cardiochirurgie en het verminderen van de morfine gerelateerde 
bijwerkingen door het verminderen van de totale morfine consumptie na de operatie.  
Hoofdstuk 2 geeft een overzicht van verschillende patiënten groepen op de intensive care 
kinderen (ICK) in relatie tot de verschillen in PK en pijnstilling. Algemene aspecten van PK 
worden beschreven en de verschillen tussen patiënten na cardiochirurgie in vergelijking tot 
andere patiënt groepen wordt besproken.  
De CPB-PHARM studie en verschillende substudies worden besproken in Hoofdstukken 3 tot 
en met 5. Hoofdstuk 3 onderzoekt het potentiele medicatie verlies en terugwinning door 
gebruik van het cell saver systeem. Het cellsaver systeem is een auto-transfusie systeem wat 
wordt gebruikt tijdens cardiochirurgie om het peri-operatieve bloedverlies te verminderen. 
Tijdens de operatie kan medicatie samen met bloed worden weggezogen van het operatie 
gebied door het cell saver systeem. Via het autotransfusie bloed kan vervolgens medicatie aan 
de patiënt worden toegediend. In dit hoofdstuk wordt de werking van het cell saver systeem 
beschreven. Tevens zijn plasmaconcentraties van medicijnen gemeten op verschillende 
momenten tijdens de cell saver procedure en in het autotransfusie bloed. Tijdens de 
experimenten werden cefazoline, een hydrofiel medicament, en sufentanil, propofol en 
midazolam, lipofiele medicamenten, gemeten. Cefazoline werd uitgescheiden tijdens de cell 
saver procedure en werd niet teruggevonden in het autotransfusie bloed. Van de lipofiele 
medicamenten die zijn getest, werd alleen voor sufentanil een potentieel klinisch relevante 
concentratie in het autotransfusie bloed gemeten.  Het verschil in plasmaconcentraties tussen 
de lipofiele medicamenten in het autotransfusie bloed is onduidelijk. Propofol bind aan 
erytrocyten en het meten van propofol in plasma geeft daarom mogelijk een foutieve 
weergave van de werkelijke concentratie.  
De in vitro experimenten van de CPB-PHARM studie worden beschreven in Hoofdstukken 4 
en 5. In drie verschillende typen HLM werd de plasmaconcentratie van verschillende 
medicijnen gemeten en een tijd-concentratie curve per systeem en per medicijn 
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kinderen (ICK) in relatie tot de verschillen in PK en pijnstilling. Algemene aspecten van PK 
worden beschreven en de verschillen tussen patiënten na cardiochirurgie in vergelijking tot 
andere patiënt groepen wordt besproken.  
De CPB-PHARM studie en verschillende substudies worden besproken in Hoofdstukken 3 tot 
en met 5. Hoofdstuk 3 onderzoekt het potentiele medicatie verlies en terugwinning door 
gebruik van het cell saver systeem. Het cellsaver systeem is een auto-transfusie systeem wat 
wordt gebruikt tijdens cardiochirurgie om het peri-operatieve bloedverlies te verminderen. 
Tijdens de operatie kan medicatie samen met bloed worden weggezogen van het operatie 
gebied door het cell saver systeem. Via het autotransfusie bloed kan vervolgens medicatie aan 
de patiënt worden toegediend. In dit hoofdstuk wordt de werking van het cell saver systeem 
beschreven. Tevens zijn plasmaconcentraties van medicijnen gemeten op verschillende 
momenten tijdens de cell saver procedure en in het autotransfusie bloed. Tijdens de 
experimenten werden cefazoline, een hydrofiel medicament, en sufentanil, propofol en 
midazolam, lipofiele medicamenten, gemeten. Cefazoline werd uitgescheiden tijdens de cell 
saver procedure en werd niet teruggevonden in het autotransfusie bloed. Van de lipofiele 
medicamenten die zijn getest, werd alleen voor sufentanil een potentieel klinisch relevante 
concentratie in het autotransfusie bloed gemeten.  Het verschil in plasmaconcentraties tussen 
de lipofiele medicamenten in het autotransfusie bloed is onduidelijk. Propofol bind aan 
erytrocyten en het meten van propofol in plasma geeft daarom mogelijk een foutieve 
weergave van de werkelijke concentratie.  
De in vitro experimenten van de CPB-PHARM studie worden beschreven in Hoofdstukken 4 
en 5. In drie verschillende typen HLM werd de plasmaconcentratie van verschillende 
medicijnen gemeten en een tijd-concentratie curve per systeem en per medicijn 
samengesteld. De medicamenten werden onderverdeeld in antibiotica in Hoofdstuk 4 en 
anesthetica en methylprednisolon in Hoofdstuk 5. Medicatie werd toegediend in neonatale, 
infant en pediatrische HLM. Bloedsamples werden afgenomen op verschillende tijdspunten 
en na zes uur werden de experimenten gestopt. Concentraties van propofol en sufentanil 
verminderden aanzienlijk tijdens het experiment, terwijl concentraties van midazolam en 
cefazoline relatief stabiel bleven. Concentraties van clindamycine en methylprednisolon 
bleven relatief stabiel, echter, de eerst gemeten concentratie van beide medicamenten was 
substantieel anders dan de theoretische start concentratie. Dit betekent dat beide 
medicamenten zeer snel werden opgenomen door de HLM, of beiden onvoldoende mengden 
met de priming vloeistof in het systeem om tot vergelijkbare geobserveerde en theoretische 
concentraties te komen. Het type HLM had een significante invloed op de afname van de 
plasmaconcentraties van medicijnen, mogelijk door een verandering in de 
oppervlakte/volume ratio.  
In Hoofdstuk 6 wordt de enige data van volwassen patiënten besproken. De CecfCheck studie 
werd opgezet vanwege de invoering van de nieuwe Nederlandse peri-operatieve richtlijn voor 
antibiotica profylaxe bij volwassen cardiochirurgische patienten. Gebaseerd op data van niet-
cardiochirurgische patiënten, wordt in deze nieuwe richtlijn de cefazoline dosering tijdens 
cardiochirurgische operaties verminderd. Echter, het gebruik van de HLM zou kunnen leiden 
tot een lagere cefazoline concentratie en suboptimale antibiotica profylaxe. Onze data laat 
zien dat de cefazoline concentratie daalt na het starten van de HLM. De eiwit binding van 
cefazoline is veel variabeler in onze studie, vergeleken met de beschikbare literatuur.  
In Hoofdstuk 7 wordt de focus van de thesis verschoven van peri-operatieve gebruikte 
medicatie naar post-operatieve pijnbestrijding. Onze internationale survey toont een grote 
variatie in type en dosering van analgetica in kinderen na cardiochirurgie. Morfine is bijna 
altijd de eerste keus analgetica, maar de dosering verschilt sterk tussen ziekenhuizen. 
Gevalideerde methoden om de effectiviteit van de pijnstilling te meten worden vaak niet 
gebruikt in de kliniek. Bij gebrek aan methoden om de effectiviteit van de pijnstilling te meten, 
kunnen onder- of overdosering moeilijk worden opgemerkt en gecorrigeerd.  
In neonaten en jonge kinderen na grote niet-cardiochirurgische operaties, werkt pijnstilling 
met paracetamol i.v. even goed als pijnstilling met morfine. Vanwege de negatieve 
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bijwerkingen van morfine op onder andere de bloeddruk, zou pijnstilling met paracetamol i.v. 
ook in kinderen na cardiochirurgie de voorkeur kunnen hebben. We hebben de PACS 
(Pediatric Analgesia after Cardiac Surgery) studie ontworpen om deze hypothese te testen. De 
PACS studie is een multi-center, gerandomizeerde, dubbel-blinde studie. In Hoofdstuk 8 
wordt het PACS studie protocol beschreven. In de PACS studie kregen 208 kinderen, in de 
leeftijd van nul tot drie jaar, gerandomiseerd paracetamol i.v. of morfine i.v. na cardiochirurgie 
toegediend. Het primaire doel van de studie was een 30% vermindering van de morfine 
consumptie in de eerste 48 uur na de operatie.  
De opzet, voorbereiding en logistiek vergen een groot deel van de tijd en energie bij het 
uitvoeren van een multi-center, gerandomiseerde studie. Deze facetten worden bijna nooit in 
de literatuur besproken, waardoor collega onderzoekers geen gebruik kunnen maken van 
eerder opgedane ervaring. Wij beschrijven onze ervaringen met de PACS studie in Hoofdstuk 
9. De grootste vertraging tijdens de PACS studie werd veroorzaakt door regelgeving van de 
trialapotheken, de late terugtrekking van een deelnemend centrum en langdurige 
onderhandelingen met de juridische afdelingen van deelnemende ziekenhuizen.   
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Dankwoord 
De afgelopen jaren heb ik met heel veel plezier aan mijn proefschrift gewerkt. Toch is het 
inmiddels tijd om dit laatste hoofdstuk op papier te zetten. Ik had dit proefschrift niet kunnen 
schrijven zonder de hulp van collega’s, vrienden en familie. Ook heb ik de afgelopen jaren veel 
patiënten en ouders bereid gevonden om deel te nemen aan medisch wetenschappelijk 
onderzoek. Veel van dit onderzoek is nog niet opgenomen in dit proefschrift, maar dat maakt 
mijn dank aan hen niet minder groot. Dit betekent alleen maar dat er nog veel mooie 
publicaties zullen volgen.  
Mijn promotor, geachte prof. dr. Tibboel, beste Dick. Mijn carrière als onderzoeker startte met 
ons kennismakingsgesprek. Aan het einde van het gesprek ‘moest ik ook maar eens met prof. 
Bogers gaan praten’ want er lag een interessant project te wachten op een onderzoeker. Zo 
gezegd, zo gedaan, en er werd gestart met de CPB-PHARM studie. Al snel hierna werd 
gesproken over de postoperatieve pijnstilling en werden de voorbereidingen voor PACS 
getroffen. Ik kreeg van jou veel vrijheid om deze studie op te zetten, met hulp van Enno en 
Joke. Het was heel fijn dat je altijd bereikbaar was voor vragen en ik altijd op jou terug kon 
vallen voor de helaas soms onontkoombare trouble shooting.  
Beste prof. dr. Bogers, mijn tweede promotor, bij wie ik altijd aan kon kloppen. De informele 
overlegmomenten, waarvan sommige plaatsvonden op de operatie kamer of op de IC, hebben 
mij geholpen om de studies en de daaruit volgende publicaties gaandeweg te verbeteren. Het 
actief vragen naar het vorderen van portfolio maakte mij duidelijk dat een promotie traject 
niet alleen draait om de studies an sich en bijbehorende publicaties, maar ook om 
professionele en persoonlijke ontwikkeling.  
Beste Enno, de eerste keer dat je een co-promotor bent! Dat was vast even wennen. Een 
veelzijdig project als PACS was misschien ook voor jou een sprong in het diepe. Heel veel dank 
voor de altijd kritische blik en de scherpe beschrijvingen van problemen en oplossingen. Dit 
heeft mij veel geleerd over zowel de klinische kant van deze studies, maar ook in de discussie 
over de toekomstige implicaties van dit proefschrift. Ik heb geleerd om zaken niet zomaar aan 
te nemen, ook al wordt het ‘altijd’ zo gedaan. Alsnog excuses voor het soms spammen via 
email en WhatsApp, het eindresultaat maakt het wat mij betreft de moeite waard.  
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te nemen, ook al wordt het ‘altijd’ zo gedaan. Alsnog excuses voor het soms spammen via 
email en WhatsApp, het eindresultaat maakt het wat mij betreft de moeite waard.  
De leden van de kleine commissie, prof. dr. Van den Anker, prof. dr. De Hoog en prof. dr. mr. 
dr. De Mol, hartelijk dank voor het beoordelen van mijn proefschrift. Daarnaast bedank ik de 
overige leden van de promotiecommissie voor het zitting nemen in de grote commissie.  
Lieve Paola, ondanks alle plannen die zijn gemaakt voor de PACS studie is deze niet in onze 
proefschriften gekomen! Desondanks heb ik veel prettige en leerzame uren besteed aan onze 
discussies. Onze samenwerking heeft PACS absoluut een betere studie gemaakt. De avonturen 
in Praag, het schrijven van de K3 paper, het waren allemaal waardevolle toevoegingen aan 
mijn promotie traject.  
Lieve Annewil, ik heb met veel plezier meegeholpen om ‘jouw kindje’ de CPB-PHARM af te 
ronden. De hoeveelheid data uit dit onderzoek is overweldigend, waardoor publicatie helaas 
nog op zich laat wachten. Ik kijk uit naar jouw proefschrift waarin dit allemaal beschreven gaat 
worden. Dank voor de leerzame samenwerking en jouw, enigszins ironische, 
relativeringsvermogen.  
Lieve Joke, de spin in het ICK onderzoek web. Het was ontzettend waardevol om ter zijde te 
worden gestaan door zo’n goede, vriendelijke en geïnteresseerde research coördinator. 
Zonder jou was de uitvoering van de studies in dit proefschrift ontzettend veel moeilijker 
geweest. Heel hartelijk dank voor jouw praktische toevoegingen om de studies tot een succes 
te maken en de vele uren monitoring die daarbij hoorden. De dagtochten naar Groningen, 
Utrecht en Leuven waren een stuk leuker met jou in de auto. Dank voor de koffie voor 
onderweg! 
Lieve Harma, als doorgewinterde ICK verpleegkundige was jij een onmisbare toevoeging voor 
de PACS studie. Jouw kunde en gedetailleerde manier van werken hebben enorm geholpen 
bij het opbouwen van de database. Jouw kennis van de afdeling en motivering van de collega’s 
hebben de uitvoeding van de studie en de dataverzameling erg geholpen.  
Lieve Christine, ik had me geen betere opvolgster voor de PACS studie kunnen wensen. Ik heb 
de studie met een gerust hart aan jou overgedragen door jouw enthousiasme en toewijding 
om dit project tot een goed einde te brengen.  
Heel hartelijk dank aan alle ICK verpleegkundigen die zo ontzettend goed hebben geholpen 
om alle data voor de CPB-PHARM en PACS studies te verzamelen. Zonder jullie waren deze 
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studies nooit gelukt! Ook hartelijk dank aan de IC staf voor het vertrouwen in IV paracetamol 
als adequate pijnstilling en het tot een succes maken van de PACS studie. Christine, Karen, 
Jan-Piet en alle vrijwilligers; dank voor de moeite die jullie elke week namen zodat ik ouders 
op de poli kon informeren over PACS.  
Een speciaal dankwoord voor de researchteams in de deelnemende centra; 
researchverpleegkundigen Sandra (UMCG), Maaike en Pauline (UMCU) en Liese en Pieter (UZ 
Leuven). Allen hartelijk dank voor jullie inzet voor de PACS studie. Het was een hele prettige 
samenwerking en een voorrecht om in jullie ‘keukens’ te mogen kijken. De lokale 
hoofdonderzoekers van de PACS studie; dr. Koos Jansen en Erik Koomen (UMCU), dr. Martin 
Kneyber (UMCG) en dr. Sofie Maebe, dr. Renata Haghedooren en prof. dr. Greet van den 
Berghe (UZ Leuven); dank voor de prettige samenwerking. 
Als promovendi werk je vaak op een eigen ‘eilandje’. Mijn eilandje werd een stuk aangenamer 
door de samenwerking met de collega’s van de ICK poule. Shelly, Manuel, Özge, Paola, Bianca, 
Nienke en Renate; ontzettend bedankt voor de gezelligheid, koffie momentjes, poule uitjes en 
jullie inzet voor PACS in de weekenddiensten. Ik heb het erg leuk gevonden om aan jullie 
studies te werken en zo af en toe even van mijn eilandje af te komen.  
Ik heb veel geleerd van al de collega’s van de pediatric pharmacology groep, onder de leiding 
van prof. dr. Karel Allegaert, prof. Dr. Saskia de Wildt en dr. Lidwien Hanff. Annet, Maja, Sanne, 
Mirjam, Nina, en alle anderen (door mijn langdurige promotie traject zijn jullie met teveel om 
op te noemen); bedankt!  
Een onderzoek uitvoeren kan je niet alleen. Gelukkig werd op het thorax centrum niet meer 
raar opgekeken als ik weer eens ergens samples van wilde afnemen. Alle medewerkers van 
het thoraxcentrum; chirurgen, anesthesiologen, anesthesie assistenten, perfusionisten en 
operatie assistenten wil ik danken voor hun medewerking aan en hun belangstelling voor het 
onderzoek. Jos, Caroline en Maureen, dank voor het plannen van mijn week, en mij up-to-date 
houden van alle wijzigingen in de operatie planning. Een bijzonder dankjewel voor een 
prettige samenwerking en waardevolle feedback aan alle kindercardioanesthesiologen: Inge 
de Liefde, Anke de Bruijn, Marielle Buitenhuis, Erik Maas, Maarten ter Horst en Jenny Kissler. 
Ook heel veel dank aan de perfusionisten van het thorax centrum voor de hulp met het 
afnemen van ontelbare samples tijdens operaties en de in vitro experimenten. Antony, 
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operatie assistenten wil ik danken voor hun medewerking aan en hun belangstelling voor het 
onderzoek. Jos, Caroline en Maureen, dank voor het plannen van mijn week, en mij up-to-date 
houden van alle wijzigingen in de operatie planning. Een bijzonder dankjewel voor een 
prettige samenwerking en waardevolle feedback aan alle kindercardioanesthesiologen: Inge 
de Liefde, Anke de Bruijn, Marielle Buitenhuis, Erik Maas, Maarten ter Horst en Jenny Kissler. 
Ook heel veel dank aan de perfusionisten van het thorax centrum voor de hulp met het 
afnemen van ontelbare samples tijdens operaties en de in vitro experimenten. Antony, 
Marloes en Emma, de in vitro experimenten en de CefCheck studie waren zonder jullie niet 
gelukt! 
Alle collega onderzoekers van de thoraxchirurgie; Jonathan, Kevin, Simone, Isabel, Rahat, 
Stan, Jamie, Pepijn, Andras, Milan, Jamila, Arjan, Nelleke, Sahar, Bardia. Ontzettend bedankt 
voor de lunches, journal clubs, (antwoorden op) statistische vraagstukken en nog veel meer.  
Lieve vrienden, dank voor jullie geduld als ik weg werd gebeld tijdens een etentje (gelukkig na 
het hoofdgerecht) of in de bioscoop zat met mijn telefoon op schoot tijdens een oproepdienst. 
Een speciaal dankjewel voor Belle voor het ontwerpen van de kunstzinnige kaft van dit 
proefschrift! 
Lieve ouders en Mirjam, het is eindelijk zover. Dank voor jullie steun door de jaren heen.  
Mijn man Gert-Jan, zonder jouw steun was dit proefschrift nu nog niet klaar geweest. 
Gedurende het hele traject heb jij mij gemotiveerd gehouden als het even tegen zat. Na de 
start van mijn opleiding heb je je ontpopt tot een ware huisman, zodat ik in de avonduren en 
weekenden tijd had om te schrijven. Gelukkig is nu de eindstreep in zicht en rest alleen nog 
de verdediging. Daarna zijn de weekenden om te ontspannen en met jou te genieten van onze 
lieve dochter Lizzy.  
 


